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4. Abstract 
4.1.1 Introduction 
Carotid endarterectomy (CEA) remains the standard of care for patients with greater 
than 50% symptomatic carotid artery stenosis to prevent recurrent stroke. The 
International Carotid Stenting Study (ICSS) compared the safety and efficacy of carotid 
angioplasty and stenting (CAS), with CEA. This thesis aims to determine which 
baseline patient characteristics, processes of care or vascular anatomical variants are 
associated with risk of stroke, myocardial infarction (MI) or death within 30 days of 
either procedure, and whether existing models to predict the risk of these complications 
performed well in ICSS patients. 
4.1.2 Methods 
ICSS was a multicentre international randomized controlled open trial. Medically stable 
patients with >50% symptomatic carotid artery stenosis due to atherosclerosis were 
randomized to either CAS or CEA. Procedures were carried out by accredited 
operators according to trial protocol. 
4.1.3 Results 
Women in ICSS experienced a higher risk of stroke, (MI) or death within 30 days of 
CEA, although sex was not an independent risk factor for this endpoint. They also 
experienced a significantly higher risk of haematoma and cranial nerve palsy after 
surgery. The risk of surgery was not significantly influenced by type of anaesthesia, 
surgical reconstruction or shunt use. 
The risk of stroke, MI or death following CAS rose with increasing age and was higher 
with open-cell design stents. The risk of CAS was not influenced by vascular 
anatomical variation seen on pre-stenting catheter angiography. Cerebral protection 
devices (CPDs), designed to prevent debris causing stroke, did not protect against 
periprocedural stroke. 
Existing risk scores for CEA and CAS tested in ICSS had insufficient power to 
discriminate between low- and high-risk groups. 
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4.1.4 Conclusions 
New methods of predicting the risk of carotid revascularization are needed to allow 
patients and clinicians to make informed choices about treatment for symptomatic 
carotid artery stenosis. 
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12. Introduction and literature review 
 Stroke and vascular disease 12.1
12.1.1 Background 
Stroke is one of the leading causes of death and disability throughout the world [1]. 
Most commonly-defined as “rapidly-developed clinical signs of focal or global 
disturbance of cerebral function, lasting more than 24 hours or until earlier death, with 
no apparent non-vascular cause” [2], the term “stroke” therefore describes the 
presentation of the patient rather than the underlying pathophysiology, and is distinct 
from a Transient Ischaemic Attack (TIA) in which the signs and symptoms of focal 
cerebral dysfunction resolve within 24 hours. As brain imaging becomes more 
accessible, TIA has more recently been defined as “a transient episode of neurological 
dysfunction caused by focal brain, spinal cord, or retinal ischaemia without acute 
infarction” [3]. Stroke syndromes affect all age groups, becoming increasingly prevalent 
in later life. Data from the United States suggest that nearly 800,000 residents in that 
country alone suffered a new or recurrent stroke each year [4]. In the United Kingdom 
the equivalent figure is estimated to be 152,000 new patients experiencing a stroke 
each year [5].  
Early treatment and identification of risk factors for recurrent disease is important – 
mortality following a stroke may be as high as 41% after 5 years [6]. However, rapid 
assessment and organized treatment in a stroke unit, including a multi-disciplinary 
approach to rehabilitation, investigation of the underlying cause, attention to secondary 
prevention medications and avoidance of complications can improve outcome [7]. 
There are many causes of stroke or TIA, and identification of the aetiology in each 
patient will be guided by the patient’s demographics, the results of clinical examination, 
the pattern of infarction or ischaemia in the brain and the results of investigations such 
as ECG, cardiac echo, vascular studies and blood tests. 
This thesis focuses on patients with ischaemic stroke. In broad categories, ischaemic 
stroke may be caused by embolism (from arterial atheroma, from the heart or 
paradoxical embolism from the venous system in patients with atrial septal defect), 
thrombosis of an intracranial artery, haemodynamic disturbance (particularly in the 
setting of carotid or vertebral artery occlusion), or cerebral venous thrombosis [8]. 
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12.1.2 Stroke and large-vessel vascular disease 
Increasing age is a major risk factor for stroke [9]. A major cause of ischaemic stroke in 
the elderly, along with atrial fibrillation, is atherosclerosis affecting the carotid arteries, 
the aorta or small penetrating vessels in the brain. The estimate of the proportion of 
stroke due to underlying large-vessel disease (largely atheromatous carotid stenosis) 
ranges from 13% to 68% in heterogeneous populations [10].  
Atheroma is formed wherever there is turbulent blood flow – frequently at sites of 
arterial branching such as the carotid arteries, at the origins of the supra-aortic vessels, 
in the coronary arteries, the intracranial arteries and the arterial supply to the leg where 
there is injury to the vascular endothelium as a result of haemodynamic shear stress 
[11]. The response to chronic injury at these sites is infiltration of inflammatory cells 
laden with fat (“foam cells”), followed by proliferation of smooth muscle cells. Some 
lesions will form a fibrous cap over the top. Reduction in the calibre of the vessel, 
stenosis, occurs over time and may give rise to a clinically-audible bruit. Lesions that 
are large in volume are more likely to be “unstable” with a high degree of inflammatory 
infiltration and a large lipid core [12], leading to rupture of any fibrous cap, exposure of 
the circulating blood components to underlying tissue antigens, platelet aggregation 
and thrombus formation. Both the thickness of the plaque [13] and irregularity of the 
plaque surface [14] have been demonstrated to predict the risk of subsequent stroke in 
asymptomatic patients. Progressive occlusion of the artery itself will not usually cause 
stroke because of the collateral supply to the brain through the circle of Willis, but if the 
circle is incompetent or there is reduction in perfusion due to atherosclerosis of the 
other carotid or vertebral arteries then ischaemia may result. However, if thrombus on 
the atherosclerotic plaque dislodges following plaque rupture and embolizes distally to 
the intracranial arteries then an embolic stroke may result. 
Carotid atherosclerosis is relatively common, and can be found in over 2% of European 
populations [15]. It is particularly prevalent in patient populations with vascular disease 
in the coronary or peripheral arteries, with as many as one in four having co-existent 
carotid disease [16] [17]. As expected, therefore, the risk factors for developing carotid 
atheroma are similar to those for atheroma in other vessels – older age, smoking, high 
blood pressure and high cholesterol [18]. 
The value of screening patients for carotid disease with a view to primary stroke 
prevention is brought into question when the risk of subsequent stroke may be less 
than 1% per year in patients using modern secondary prevention medications [19]. 
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However, amongst patients who have already had TIA or stroke, those with carotid 
atherosclerosis are at highest risk of early recurrence [20]. Targeted secondary 
prevention therapy, therefore, consists of aspirin [21] and dipyridamole [22] or 
clopidogrel monotherapy [23], antihypertensive medication [24], a statin where 
appropriate [25] and control of diabetes. Patients are also encouraged to modify their 
lifestyle risk factors for stroke by eating healthily, taking part in moderate-intensity 
exercise, smoking cessation and reducing alcohol intake [26]. 
 Investigating carotid artery disease 12.2
Carotid stenosis is difficult to detect clinically. Turbulent flow across a stenosis may 
produce a bruit clinically-detectable using a stethoscope, although high degrees of 
stenosis may reduce flow to a degree that no bruit is audible. Additionally, less-relevant 
external carotid artery (ECA) stenosis may also produce a bruit, as may transmitted 
sounds from an ejection systolic heart murmur. As such it is an unreliable sign and 
further radiological investigations are required to confidently make the diagnosis. 
12.2.1 Catheter angiography 
Digital subtraction catheter angiography (DSA or “XA”) is often regarded as the “gold 
standard” investigation for the diagnosis of carotid atheroma, and was the primary 
method of determining the degree of stenosis in most of the early clinical trials of 
carotid surgery versus medical therapy for symptomatic carotid stenosis. A catheter is 
advanced from a peripheral artery, usually the femoral, around the aortic arch. The 
common carotid is then cannulated and the carotid arteries imaged by means of 
radiopaque dye. A “mask” image obtained before the administration of intra-arterial 
contrast is then digitally subtracted from the contrast image to remove other radio-
opaque structures such as bone from the final image. However, this invasive technique 
carries with it a risk of stroke or TIA of up to 4% in those with even lower-risk 
asymptomatic plaques [27] due to dislodgement of either atheroma in the vascular tree 
or thrombus on a complicated plaque. Figure 1 illustrates a stenosis of the left internal 
carotid artery just above the level of the carotid bifurcation (arrowed) as viewed on 
magnetic resonance angiography. 
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Figure 1. Magnetic resonance angiogram of internal carotid artery stenosis 
An atheromatous plaque causing stenosis of the internal carotid artery just above the 
level of the carotid bifurcation is arrowed 
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12.2.2 Ultrasound 
Because of their proximity to the surface of the neck, it is usually possible to examine 
the internal and external carotid arteries as they branch from the common carotid artery 
using ultrasound. Ultrasound may be used to visualize the internal carotid artery (ICA) 
itself, and although features such as plaque thickness can be measured, the degree of 
stenosis is usually is most closely correlated to the velocity of blood flowing through the 
artery. As the systolic blood pulse flows through a stenosis there is a corresponding 
increase in the velocity of the blood which is measured using Doppler-mode 
ultrasound. The degree of stenosis is derived from measurement of the peak systolic 
velocity (PSV) and end-diastolic velocity (EDV) of blood flow in the common carotid 
and internal carotid arteries and the ratio between the two measurements, although 
technical limitations to determining the degree of stenosis include acoustic shadowing 
from calcification in the plaque and difficulties interpreting velocity measurements in 
tortuous vessels or arteries without normal runoff [28]. 
12.2.3 CT and MR angiography 
Computed tomography (CT) angiography is a less-invasive alternative to DSA. Risks 
associated with CT angiography include contrast nephropathy and allergic reaction to 
contrast media, and the ability to visualize the degree of stenosis may be limited in 
lesions with heavy calcification that can cause artefact on the scan image. 
Magnetic resonance angiography (MRA) has a number of advantages over CT, 
including the avoidance of ionising radiation. However, patients do not tolerate the 
investigation as well, mostly because of the confined nature of the scanning tunnel. 
Contrast-enhanced MR has been reported to be more accurate investigation than CTA 
or DUS for the detection of high-grade (70-99%) stenosis than other non-invasive 
methods (>90% sensitivity and specificity) [29], although it is not clear whether 
combinations of non-invasive tests are as reliable for detecting carotid stenosis 
compared with catheter angiography as the results of different investigations do not 
always agree on the degree of stenosis. As MR angiography without contrast (“time of 
flight” sequences) can lead to over-estimation of the degree of stenosis [30] contrast-
enhanced MRA is usually preferred. Because of the risk of complications associated 
with catheter angiography, non-invasive tests, sometimes in combination, are currently 
preferred for the initial investigation of carotid stenosis, with catheter angiogram being 
reserved for those cases where doubt over the diagnosis or degree of stenosis 
remains. 
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 Carotid endarterectomy 12.3
That carotid artery stenosis could be a cause of focal neurological symptoms has long 
been recognized. Early forms of surgical intervention were focussed on attempts to 
improve blood flow through techniques such as cervical sympathectomy, based on the 
assumption that a lack of blood supply to the ipsilateral cerebral hemisphere produced 
symptoms (“brain claudication”) similar to critical reduction of blood flow in the coronary 
arteries causing symptoms of angina through myocardial ischaemia. The first published 
descriptions of carotid endarterectomy – surgical removal of the atheromatous lesion – 
were from the surgeons DeBakey in the United States and Eastcott in the United 
Kingdom. In 1975 DeBakey reported having operating on a patient in 1953 with 
recurrent left hemisphere ischaemic symptoms due to carotid atheroma with good 
results [31]. Eastcott in 1954 reported endarterectomy and repair of the carotid artery 
on a 66-year-old housewife with similar ischaemic symptoms [32]. 
Endarterectomy for carotid stenosis was widely adopted before large-scale clinical 
trials could provide definitive evidence for its efficacy in the prevention of recurrent 
stroke, and by the early 1980s had become the third-most performed operation in the 
United States [33]. Surgery for carotid stenosis carries a risk of complications, including 
death, stroke, myocardial infarction, wound haematoma, cranial nerve palsy and 
pulmonary problems [34], and so to justify performing the procedure these short-term 
risks must be outweighed by the long-term benefit of the operation in terms of stroke 
prevention. 
12.3.1 Trials of carotid endarterectomy versus medical therapy – symptomatic 
patients 
In the 1980s and 1990s two large clinical trials were performed which provide the 
foundation for evidence-based intervention in recently-symptomatic patients since – the 
North American Symptomatic Carotid Endarterectomy Trial (NASCET) [35] and the 
European Carotid Surgery Trial (ECST) [36]. 
NASCET grouped patients into those with “low moderate” (<50%), “high moderate” (50-
69%) and “severe” (70-99%) carotid stenosis. Patients were randomized to either CEA 
or medical treatment. Interim analysis of 659 patients with 70-99% stenosis revealed a 
statistically significant reduction in the risk of any stroke or death over 2 years in the 
surgery group (15.8%) as compared to the medical group (32.3%) [37]. The 
subsequent observation that the benefit of surgery in terms of stroke prevention was 
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reduced in groups with lower degrees of stenosis (and, indeed, absent in those with 
<50% stenosis) led the authors to conclude that “the degree of benefit individual 
patients received from carotid endarterectomy was directly proportional to the risk they 
faced without surgery” [35], with lesser degrees of stenosis conferring lower risk of 
recurrent stroke. 
ECST, a trial that enrolled 3204 patients, reached a similar conclusion, but used a 
different method of measuring stenosis [36]. This trial showed a significant reduction in 
the risk of stroke or surgical death over 5 years in those undergoing CEA vs those on 
medical therapy of 21.2% (95% CI 12.9% to 29.4%) in patients with 70-99% stenosis 
and 5.7% (95% CI 0% to 11.6%) in those with 50-69% stenosis [38]. Like NASCET, 
there was no evidence of a benefit of surgery in patients with less than 50% carotid 
stenosis. 
Meta-analysis of the results of NASCET, ECST and the smaller 189-patient trial from 
the Veterans Affairs Cooperative Studies Program 309 Trialist Group [39], using only 
the NASCET method of measuring stenosis [40], clarifies the extent of this risk 
reduction in patients with varying degrees of stenosis. Overall, the absolute risk of 
ipsilateral stroke was 16.0% lower (p<0.01) in those with more than 70% stenosis 
undergoing CEA as compared with those in the medical treatment group, and 4.6% 
lower (p=0.04) in patients with 50-69% stenosis undergoing surgery [38]. Patients with 
less than 50% stenosis did not benefit. A specific subgroup of patients with greater 
than 99% stenosis and vessel collapse due to poor runoff distal to the stenosis also did 
not benefit from surgery, perhaps because these lesions progressed to complete 
occlusion [41]. The relationship between the reduction in the main outcomes of these 
trials with CEA and the degree of stenosis is illustrated in Figure 2. 
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Figure 2. The effect of surgery on the absolute risk reduction in NASCET and 
ECST at 3, 5 and 8 years’ follow-up stratified by the degree of carotid stenosis 
at baseline for a) any stroke or operative death, b) ipsilateral ischaemic or 
operative stroke and operative death and c) disabling or fatal ipsilateral or 
operative stroke and operative death 
Adapted from [38] and reproduced from [42] with kind permission of Elsevier and of the 
Annual Review of Medicine, Volume 63 © 2012 by Annual Reviews
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There is evidence that some subgroups of patients in whom surgery is recommended 
will benefit more than others. The risk/benefit ratio most favours surgery over medical 
treatment in men and the elderly. In addition, the overall benefit of surgery diminishes 
as the time between symptoms and surgery increases, strongly favouring intervention 
within 2 weeks of symptoms in stable patients [43]. 
The results of these trials, taken together, demonstrated a strong link between 
increasing degrees of carotid stenosis and increasing risk of recurrent stroke or TIA on 
medical treatment alone. This was matched by a corresponding decrease in risk for 
patients with high degrees of stenosis who undergo CEA. The most recent guidelines 
from the American Heart Association [44], the Society for Vascular Surgery [45] and 
the European Society for Vascular Surgery [46] continue to recommend carotid 
endarterectomy for the long-term prevention of stroke in patients with recently-
symptomatic carotid artery stenosis >50% and in selected asymptomatic patients with 
60-99% stenosis. However, stroke, myocardial infarction and death are not the only 
risks associated with CEA, and both cranial nerve palsy [47] [48] [49] [50] and neck 
haematoma [51] [52] are well-recognized “minor” complications which may have a 
major impact on the patient but have been less-extensively studied in clinical trials. 
These extra hazards of a neck incision have led to the consideration of carotid stenting 
as a less-invasive alternative to CEA, and as an alternative in patients with difficult 
surgical access owing to previous neck surgery or carotid stenosis secondary to 
radiotherapy [53]. 
12.3.2 Trials of carotid endarterectomy versus medical therapy – asymptomatic 
patients 
The rate of ipsilateral stroke in patients with asymptomatic carotid disease is much 
lower than that of patients with symptomatic stenosis – possibly as low as 0.34% per 
year when optimal medical therapy is prescribed [19]. Two large randomized trials 
provide much of the data addressing the question of whether prophylactic CEA in 
asymptomatic patients prevents long-term stroke.  
The North American Asymptomatic Carotid Atherosclerosis Study (ACAS) randomized 
1662 patients with ≥60% stenosis to either daily aspirin treatment or daily aspirin plus 
carotid endarterectomy. In addition, patients in both groups received “medical risk 
factor management” targeting vascular risk factors. The primary comparison was 
between the rate of ipsilateral stroke or any perioperative stroke or death. CEA reduced 
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the risk of this outcome from 11.0% to 5.1% (relative risk reduction 53%, 95% CI 22% 
to 72%) [54]. 
The Asymptomatic Carotid Surgery Trial (ACST) randomized 3120 patients with 60-
99% carotid stenosis to either “immediate” endarterectomy or deferral of CEA until a 
clinician considered there to be a clear indication for proceeding with surgery. Half of 
the patients in the “immediate” CEA group were operated on within one month of 
randomization. The combined risk of perioperative and subsequent stroke over a five-
year period was 11.8% in the deferred group and 6.4% in the immediate surgery group 
(p<0.01) [55]. Long-term results have since confirmed an extended benefit of CEA 
stroke prevention for patients under the age of 75 years [56] up to 10 years after 
surgery. 
 Carotid angioplasty and stenting 12.4
Carotid angioplasty and stenting evolved as a less-invasive alternative to CEA in part 
to avoid the hazards of a surgical incision. One of the first descriptions of the use of 
endovascular intervention for atheroma in a peripheral artery by balloon angioplasty 
was by Dotter in 1964, who recanalized the femoral artery of an elderly patient with 
peripheral vascular disease who had critically-reduced perfusion to the foot. The 
procedure was a clinical and radiological success [57]. (He would later develop the 
technique further by introducing the first stents (“coilspring grafts”) into the femoral or 
popliteal arteries of dogs, demonstrating that the stents remained patent after insertion 
[58]). 
The first descriptions of using this technique to treat atheromatous disease of the 
carotid artery in humans emerged in the 1980s, although only small numbers of 
patients were included in published case series. Early results were promising, although 
the problem of transient neurological and cardiac symptoms due to balloon inflation 
and the hazards of carotid artery dissection were recognized [59] [60]. A significant 
restenosis rate was also reported [61], although early restenosis after angioplasty often 
represents smooth muscle growth rather than enlargement of the atheromatous plaque 
and therefore was thought to confer a lower risk of subsequent ischaemic stroke. 
However, much like endarterectomy, CAS was widely adopted before good-quality 
evidence from large randomized trials was available to support its routine use. By 2003 
an estimated 10,000 patients worldwide had been recorded as having undergone CAS 
with a reported rate of recanalization over 99% [62]. Figure 3, below, shows a 3D 
reconstruction of a carotid stent in situ in the internal carotid artery (arrowed).  
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Figure 3. 3D reconstruction of CT angioram of head and neck of patient 
illustrating a carotid stent in situ in the left internal carotid artery (arrowed) 
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One of the major developments in CAS followed the observation that particulate debris 
generated during the procedure itself was a cause of periprocedural stroke. “Cerebral 
protection devices” (CPDs) were developed to catch this debris before entering the 
cerebral circulation, and employed either a mesh-type filter to trap particles or used 
proximal and/or distal balloons to obstruct flow. There is some conflicting evidence as 
to the efficacy of CPDs in preventing procedural cerebral ischaemia, and while one 
clinical trial found poor results in patients who did not receive a CPD [63], the 
International Carotid Stenting Study demonstrated a significantly higher rate of new 
ischaemic brain lesions after CAS versus CEA in patients recruited in centres with a 
policy of routine CPD use (OR 12.20, 95% CI 4.53 to 32.84) compared with CAS 
versus CEA in centres using unprotected stenting (OR 2.70, 95% CI 1.12 to 6.24, 
interaction p=0.02) [64]. Flow reversal systems, first described by Parodi [65], are a 
newer alternative to filter-type CPDs that use a system of inflatable balloons to create 
reversal of flow in the ICA into an arteriovenous shunt created by the operator. This 
technique has been less extensively studied, but is currently undergoing evaluation 
[66]. Figure 4, below, illustrates three cerebral protection devices used in ICSS. 
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Figure 4. Three cerebral protection devices used in the International Carotid 
Stenting Study – Anioguard (top), NeuroShield (middle) and FilterWire EX 
(bottom) 
 
 
 
From [67] with kind permission from Lippincott Williams & Wilkins / Wolters Kluwer 
Health 
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Stenting carries hazards because of the endovascular nature of the procedure. 
Atheromatous lesions around the level of the carotid bifurcation are likely to contain 
friable material [68] which can be dislodged by catheterization or the passage of 
endovascular devices across the lesion causing TIA or stroke. Although avoiding an 
incision in the neck, there is still a risk of groin haematoma of around 2-3% which may 
necessitate repair of the femoral artery used for vascular access [69]. Patients who 
may have renal impairment should have their renal function checked prior to 
angiography and/or stenting as the procedure involves the administration of iodinated 
intravascular contrast. 
12.4.1 Trials of CAS vs CEA – symptomatic stenosis 
Early randomized trials comparing CAS and CEA yielded mixed results and generated 
some concern about the safety of CAS. In Leicester in the UK, Naylor and colleagues 
randomized 23 patients (of whom 17 received treatment) to CEA or angioplasty before 
the study was stopped owing to a periprocedural stroke risk of 71% (5/7 patients) in the 
stenting arm [70]. In contrast to this risk, Brooks and colleagues in Lexington, 
Kentucky, recorded only one death out of 51 patients randomized to CEA and one TIA 
in 53 patients randomized to CAS in their trial [71]. They noted the shorter length of 
hospital stay in CAS patients and concluded that CAS “challenged” CEA as the 
preferred treatment for patients with symptomatic carotid stenosis. The BACASS trial in 
Basel, Switzerland, reported similar results – none of the 10 patients randomized to 
CAS in this study suffered stroke, myocardial infarction or death before the trial was 
stopped when the centre decided to participate in the International Carotid Stenting 
Study [72]. The results of the WALLSTENT study [73] have only been published in 
abstract form, but it is known that after enrolling 219 patients the risk of any stroke or 
death within 30 days in the CAS arm was 12.1% vs 4.5% for CEA (p=0.05). The study 
was stopped on the grounds of futility. 
Two larger multicentre trials more firmly established the basis for offering angioplasty 
as an alternative to CEA – the Stenting and Angioplasty with Protection in Patients at 
High Risk for Endarterectomy (SAPPHIRE) trial [74] and the Carotid and Vertebral 
Artery Transluminal Angioplasty Study (CAVATAS) [75]. 
CAVATAS included patients with anterior circulation symptoms due to carotid stenosis 
as well as those with posterior circulation symptoms due to vertebral stenosis. Patients 
were randomized to either angioplasty or endarterectomy. The 30-day rate of stroke 
with symptoms persisting more than 7 days or death was almost identical between the 
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two groups [75], but during extended follow-up there was a non-significant increase in 
the 8-year incidence of ipsilateral non-perioperative stroke risk to 11.3% in the 
endovascular group versus 8.6% in the CEA group [76]. This study of 504 patients was 
therefore considered underpowered to detect a difference in treatment effect, and 
interpretation of the result was complicated by the introduction of stenting as a routine 
addition to angioplasty during the course of the trial. 
SAPPHIRE enrolled symptomatic patients considered at “high risk” for CEA – those 
with cardiac or respiratory disease, contralateral carotid occlusion, recurrent stenosis, 
previous neck surgery or radiotherapy, age over 80 years or contralateral recurrent 
laryngeal nerve palsy – who had stenosis of at least 50%. Asymptomatic patients fitting 
the above criteria were enrolled if they presented with carotid stenosis greater than 
80%. Patients were randomized between CAS and CEA, and CAS patients were 
treated using a CPD.  At one year, the specified endpoint of death, stroke or MI was 
reached by 12.2% of CAS and 20.1% of CEA patients, but confidence intervals for this 
difference included equality of the two treatments [74]. At three years follow-up there 
was also no difference in the risk of the combined endpoint. 
The results of the long-term follow-up in these and one other early trial of CAS vs CEA 
is presented in Table 1 below. 
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Table 1. Results of follow-up in the early randomized controlled trials of CA(S) vs CEA 
 
  
Trial Region N Inclusion 
Criteria 
Comparison Primary Outcome Follow-up Risk of Primary Outcome 
Naylor et al. 
[70] 
UK 23 >70% 
symptomatic 
ICA stenosis 
Angioplasty 
vs 
CEA 
Death or disabling or non-disabling 
stroke 
30 days 71% vs 0% (p<0.01) 
Brooks et al. 
[71] 
USA 104 >70% 
symptomatic 
ICA stenosis 
CAS 
vs 
CEA 
Death or cerebral ischemia 2 years 1.9% vs 2.0% 
Alberts et al. 
(WALLSTENT) 
[73] 
USA 219 60 – 99% 
symptomatic 
ICA stenosis 
CAS 
vs 
CEA 
Ipsilateral stroke, procedure-related 
death, or vascular death within 1 year 
1 year 12.1% vs 3.6% (p=0.02) 
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Table 1 continued 
  
Trial Region N Inclusion Criteria Comparison Primary Outcome Follow-up Risk of Primary Outcome 
Hoffman et al. 
(BACASS) [72] 
Switzerland 20 ≥70% symptomatic 
ICA stenosis 
CAS 
vs 
CEA 
Periprocedural stroke, death or MI 4 years 0.0% vs 10.0% 
Ederle et al. 
(CAVATAS) [75] 
International 504 Carotid stenosis 
requiring treatment 
(90% 
symptomatic) 
Angioplasty ± 
stenting 
vs 
CEA 
Ipsilateral non-perioperative stroke 8 years 11.3% vs 8.6% (HR 1.22, 
95% CI 0.59-2.54) by 
intention to treat 
Yadav et al. 
(SAPPHIRE) 
[74] 
 
North 
America 
334 ≥50% symptomatic 
stenosis / ≥80% 
asymptomatic ICA 
stenosis 
CAS 
vs 
CEA 
Death, stroke or MI within 30 days 
or death or ipsilateral stroke 
between 31 and 1080 days 
3 years 24.6% vs 26.9% (absolute 
difference -2.3%, 95% CI –
11.8% to 7.0%) by 
intention to treat 
 38 
Four large randomized controlled open trials of CAS versus CEA that enrolled 
symptomatic patients have been carried out more recently, and all have formally 
reported results. 
The Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) trial was 
carried out in Central Europe. Of non-inferiority design, it enrolled 1200 patients with 
symptomatic “severe” stenosis (≥50% by NASCET method [40]) before analysis 
determined that it has failed to conclusively demonstrate non-inferiority. The trial was 
thus stopped early when its initial funding source expired and it was thought unlikely to 
reach a conclusive sample size. Analysis of 1183 patients showed a 30-day risk of 
death or ipsilateral stroke of 6.84% of the CAS group and 6.34% of the CEA group 
(absolute risk difference 0.51%, 90% CI -1.89% to 2.91%) [77]. At 2-year follow-up 
there was a similar rate of recurrent ipsilateral stroke in both groups, although it was 
noted that recurrent carotid stenosis was more common in the CAS group [78].  
The French Endarterectomy versus Angioplasty in Patients with Symptomatic Severe 
Carotid Stenosis (EVA-3S) trial was also of non-inferiority design. After randomization 
of 527 patients recruitment was stopped on the advice of the safety committee – the 
primary combined endpoint of periprocedural stroke or death occurred in 9.6% of the 
CAS group (95% CI 6.4% to 14.0%) compared with 3.9% of the CEA group (95% CI 
2.0% to 7.2%) [79]. Follow-up was continued out to four years, and showed that the 
subsequent long-term risk of recurrent ipsilateral stroke, excluding procedural risk, was 
low and “similar in both treatment groups” [80]. 
The International Carotid Stenting Study (ICSS) was funded mainly by the UK Medical 
Research Council, the Stroke Association and the European Union, and it recruited 
internationally. It randomized 1713 patients with greater-than 50% carotid stenosis 
using the NASCET method of measurement or non-invasive equivalent [81]. The trial 
protocol is described in brief in Chapter 13 and presented in full in Appendix IV. In an 
intention-to-treat analysis of results up to 120 days after randomization the risk of 
stroke, myocardial infarction or death in the CAS group was 8.5% versus 5.2% in the 
endarterectomy group (HR 1.92, 95% CI 1.27 to 2.89) [82]. Recruitment finished in 
2008 and the results of long-term follow-up have been presented. The long-term risk of 
fatal or disabling stroke was no different between the two groups during a median 
follow-up duration of 4.2 years (HR 1.08, 95% CI 0.73 to 1.60, p=0.69), but the risk of 
any stroke was greater in the CAS group (HR 1.73, 95% CI 1.29 to 2.32, p<0.01) 
reflecting an excess of minor perioperative stroke in patients undergoing CAS [83]. 
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Finally, the North American Carotid Revascularization: Endarterectomy versus Stent 
Trial (CREST) began recruiting symptomatic patients, but later amended its protocol to 
allow randomization of asymptomatic patients. CREST enrolled 2502 patients in total. 
Symptomatic patients were required to have ≥50% stenosis on angiography, ≥70% 
stenosis on Doppler ultrasound or ≥70% stenosis on MRA or CTA if ultrasound 
indicated 50-69% stenosis. Asymptomatic patients were required to have ≥60% 
stenosis on angiography, ≥70% on ultrasound, or ≥80% on MRA or CTA if ultrasound 
indicated 50-69% stenosis. CREST also differed from the European trials in mandating 
the use of a single manufacturer’s devices for CAS – the Acculink stent and the 
Accunet CPD. No significant difference was found between CAS and CEA for the 
primary outcome measure of any periprocedural stroke, MI or death or postprocedural 
ipsilateral stroke at four years follow-up (7.2% vs 6.8%, HR 1.11, 95% CI 0.81 to 1.51), 
but there was a higher risk of periprocedural stroke in the CAS group (4.1% vs 2.3%, 
p=0.01) in keeping with the results of EVA-3S, SPACE and ICSS [84]. This analysis 
included both asymptomatic and symptomatic patients. 
The short-term results of symptomatic patients only from these trials are summarized in 
Table 2.     
  
 
 
4
0
 
Table 2. Results of the recent large randomized controlled trials of CAS vs CEA in symptomatic patients 
Trial Region Sample 
Size (n) 
Comparison Outcome  Risk of outcome at 30 days post-procedure 
EVA-3S 
[79] 
France 527 CAS + CPD vs 
CEA 
Any periprocedural stroke or 
death 
9.6% vs 3.9% (p=0.01) by intention to treat 
SPACE 
[77] 
Germany, 
Austria, 
Switzerland 
1183 CAS +/- CPD vs 
CEA 
Any periprocedural ipsilateral 
ischemic stroke or death 
6.8% vs 6.3% (p=0.09 for non-inferiority) by 
intention to treat 
ICSS 
[82] 
International 1713 CAS +/- CPD 
vs 
CEA 
Any periprocedural stroke, MI or 
death 
7.4% vs 4.0% (p<0.01) per protocol 
CREST 
(symptomatic 
patients only) 
[85] 
USA, 
Canada 
1321 CAS + CPD vs 
CEA 
Any periprocedural stroke, MI or 
death 
6.7% vs 5.4% (p=0.30) by intention to treat 
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12.4.2 Trials of CAS vs CEA – asymptomatic stenosis 
The safety and efficacy of CAS against CEA has also been tested in asymptomatic 
patients. Three large trials have reported results. The largest cohort of asymptomatic 
patients is found in the CREST study, which enrolled 1181 patients with carotid 
stenosis >50% but without symptoms. The combined risk of stroke, myocardial 
infarction (MI) or periprocedural death within 30 days of the procedure in these 
asymptomatic patients was 2.5% in the CAS group and 1.4% in the CEA group (HR 
1.88, 95% CI 0.79 to 4.42, p=0.15) [85] suggesting that stenting was more risky than 
endarterectomy although the difference was not statistically significant. The results of 
long-term follow-up are awaited. In the older Stenting and Angioplasty with Protection 
in Patients at High Risk for Endarterectomy (SAPPHIRE) study, 7 out of 117 
asymptomatic patients in the CAS group and 5 out of 120 asymptomatic patients in the 
CEA group suffered stroke or periprocedural death [86]. Brooks et al. also enrolled 85 
asymptomatic patients with carotid stenosis >80% in their trial of CAS vs CEA, but 
none suffered stroke or death following the procedure [71]. 
Another study conducted in China, the Trial of Endarterectomy versus Stenting for the 
treatment of Carotid Atherosclerotic Stenosis (TESCAS-C) [87], enrolled a mixture of 
symptomatic and asymptomatic patients, but to date has not reported these results 
separately. And one further trial, the North American Asymptomatic Carotid Trial (ACT-
1), was designed to compare CAS with CEA by randomizing patients in a 3:1 ratio to 
these treatments. Its protocol specified exclusive use of the Xact carotid stent and 
Emboshield protection device in the CAS arm, but has now stopped recruitment as a 
result of a decision by the sponsor to discontinue funding [88]. 
Meta-analysis of these trials suggests a trend towards worse outcome with CAS in 
asymptomatic patients in the short-term with a higher risk of periprocedural death or 
stroke, and in the long-term with a higher risk of periprocedural death or stroke or 
ipsilateral stroke thereafter. However, the total number of patients enrolled in 
asymptomatic trials is low, and this excess risk does not reach statistical significance 
[86]. 
12.4.3 Cost considerations 
Limited research exists on the potential health economic benefits of carotid stenting 
versus endarterectomy. In theory, stenting may offer a reduced hospital stay, 
avoidance of a general anaesthetic and, at least in younger patients, a similar 
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complication rate to that of CEA while avoiding cranial nerve palsy or haematoma from 
a neck incision. 
The data on the cost of the procedure itself is mixed – some studies find CAS to be 
more expensive [89], while other analyses attribute a higher cost to CEA [90]. Of 
interest, data from the USA showed that the net revenue for hospitals was 29% higher 
when patients were treated with CEA rather than CAS [91]. In order to be as cost-
effective as surgery, CAS operators and device manufacturers will need to consistently 
demonstrate a similar complication rate to that of CEA in low-risk patients, reduce the 
cost of the procedure, or perhaps restrict the procedure to patients at higher surgical 
risk [92]. A cost-effectiveness analysis in the International Carotid Stenting Study is 
ongoing. 
 From trial data to individual patients: predicting procedural risk 12.5
Complications following any surgical procedure remain common, and occur in up to 7% 
of all patients even when specific interventions are applied to reduce their risk [93]. 
Examples of postoperative problems include cardiac arrest, myocardial infarction, 
pulmonary embolism, bleeding, pneumonia, wound problems including infection, sepsis 
and death. Data suggest that up to half of these events are potentially avoidable [94] 
[95]. Complication rates in carotid artery surgery and stenting remain significant [96] 
[97], and excluding those patients who would suffer stroke, myocardial infarction or 
other serious complications would prevent much perioperative morbidity and mortality. 
Studies identifying subgroups of patients at risk of complications following CEA and 
CAS are reviewed in detail in Chapters 14, 15 and 17. However, an overview of 
important risk factors that appear to have a strong influence on outcome and that have 
been reported in multiple studies or meta-analysis is presented here. 
12.5.1 Predicting the risk of CEA 
Patient factors 
Risk modelling drawing on patient data from ECST suggests that there are specific 
subgroups of patients at increased risk of stroke or death following CEA. These include 
female patients, those with peripheral vascular disease, and those with a high systolic 
blood pressure before surgery [98]. 
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Some anatomical factors – previous surgery, radiotherapy, restenosis of a vessel, a 
high stenosis or inflexible neck – are thought to confer high risk for carotid 
endarterectomy because of limited surgical access to the carotid plaque or a 
technically difficult procedure, but there is some evidence from small case series to 
suggest that patients with some of these factors may not actually suffer more 
complications [99] [100]. In addition, the patient with heart or lung disease is often 
thought to be at increased risk from surgery [101], but again this is not always borne 
out in case series [100] [102].  
Technical variables 
CEA can be performed under local or general anaesthesia with seemingly little 
difference in outcome [103] [104], but with the advantage of clinical monitoring of the 
patient for signs of focal neurological dysfunction during the procedure if local 
anaesthetic is used. Contralateral ICA stenosis appears to increase the perioperative 
risk of stroke [105], and the use of shunts during surgery to bypass arterial clamping on 
the ipsilateral side and maintain distal flow to the brain has become widespread despite 
limited evidence of efficacy [106]. After resection of the atherosclerotic plaque the 
vessel may be repaired by primary closure, by patch or by vein graft. The safety of 
differing surgical techniques appears similar, although there is some evidence that 
patch closure may reduce late restenosis [107]. Figure 5 illustrates the process of 
exposing the atheromatous plaque in eversion carotid endarterectomy – one surgical 
technique for performing arteriotomy and removal of the plaque. 
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Figure 5. Surgical technique for eversion carotid endarterectomy 
a. Haemostatic control is achieved by clamps on common, internal and external 
carotid arteries 
 
b. Arteriotomy is made, extending toward the fork of the carotid bifurcation 
 
c. Complete transection of the internal carotid artery is followed by resection of the 
plaque then surgical repair of the artery 
 
From [108] with kind permission from Springer Science and Business Media
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Centre and operator experience 
Technical errors made during surgery may contribute to perioperative stroke [109]. 
Several studies address the influence of operator experience or volume in carotid 
endarterectomy. Surgeons performing a high volume of operations appear to have 
lower mortality and postoperative stroke rates [110] [111] [112]. There is also a 
relationship between the annual hospital volume of endarterectomies and adverse 
neurological outcome [113], and UK professional bodies are moving to support 
centralization of vascular surgical services in high-volume centres [114].  
12.5.2 Predicting the risk of CAS 
Patient factors 
There appears to be a strong and consistent effect of the patient’s age on the outcome 
of stenting, with a doubling of the risk of any stroke or death up to 120 days after CAS 
compared with CEA in patients over the age of 70 years (RR 2.04, 95% CI 1.48 to 
2.82) in meta-analysis of the results of the European trials of CAS versus CEA [115]. 
CREST separately reported a strikingly similar finding – the efficacy of CAS and CEA 
was approximately equal at age 70, but the risk of CAS rose with increasing age while 
there was no corresponding increase in risk in the CEA group [84] [116]. There is also 
recent evidence that the patient with a higher burden of white matter brain disease at 
baseline has an increased risk of stroke following CAS [117], independent of the 
patient’s age. 
CREST reported a worse outcome after CAS in women – the 30-day risk of stroke, MI 
or death was 6.8% in women randomized to CAS versus 3.8% in women randomized 
to CEA (HR 1.84, 95% CI 1.01 to 3.37), whereas there was no significant difference 
between CAS and CEA complications in men. However, there was no difference in 
long-term outcome in CREST between the sexes and the Carotid Stenting Trialists’ 
Collaboration did not report a difference in short-term outcomes between men and 
women in the European trials of CAS versus CEA [118] [84]. 
Technical variables 
A variety of endovascular devices from different manufacturers are available to 
interventionists. While some clinical trials such as the International Carotid Stenting 
Study approved a wide range of devices [81], others including CREST mandated 
specific devices [84]. Thus evidence comparing devices to each other is sparse. 
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However, by grouping devices by their characteristics some distinction can be made 
between the performance of closed-cell and open-cell stents. Closed-cell stents offer 
enhanced coverage of the atheromatous lesion with a smaller area between metallic 
struts, and there is a suggestion that they offer better protection against stroke and TIA 
by containing debris at the site of the lesion [119]. 
Anatomical features 
Several vascular anatomical features are thought to confer increased risk of stroke 
following CAS. Among those that have been shown to be associated with an increased 
risk are ICA angulation ≥60o [120] [121], lesion length >15mm, type III or “bovine” aortic 
arch [122], aortic calcification [122], a calcified or ulcerated lesion [122] or an ostial 
lesion [122] [121]. In addition to these features, an angulated distal ICA and “pinhole” 
tight stenosis are described as technically challenging [123]. If some vascular 
anatomical variants are indeed more difficult to navigate and stent than others, it 
follows that more experienced operators could be able to avoid dislodging thrombus or 
fragmenting atheroma and therefore avoid perioperative stroke. 
Centre and operator experience 
While there appears to be remarkable consistency across the results of these 
randomized trials, the design of the European trials (ICSS, EVA-3S and SPACE) in 
particular have been criticized. As CAS is the newer procedure, the number of 
interventionists able to demonstrate substantial volumes of stenting procedures is 
smaller, and this was reflected in the criteria for centre enrolment in ICSS, for example. 
Surgeons performing endarterectomy in ICSS were required to have performed a 
minimum of 50 prior CEA procedures with a minimum volume of 10 cases per year and 
demonstrate acceptable patient outcome data. In contrast, interventionists could 
perform CAS procedures in the trial having placed only 10 carotid stents (albeit with a 
minimum of 50 stenting procedures in total including those in other vascular territories). 
Assessing the risk of complications with any individual operator is difficult, and larger 
numbers of patients are required to report a risk with narrow confidence intervals [124]. 
This has led to the suggestion that inexperience in these trials is responsible for the 
higher rate of stroke in CAS patients, and that perhaps “CAS performed by 
inexperienced interventionists has higher peri-procedural complication rates than CEA 
done by experienced surgeons” [125] is the most valid conclusion to be drawn from the 
data from these trials. Recent pooled analysis of the 1546 patients undergoing CAS in 
the three European trials suggests that the patients of interventionists who performed a 
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low number of procedures each year within the trials were at double the risk of stroke 
or death within 30 days of CAS compared with the patients of interventionists who 
performed more than 5 stenting procedures within the trial each year (RR 2.30, 95% CI 
1.36 to 3.87) [126]. 
 The current status of CAS & CEA for symptomatic patients 12.6
Carotid revascularization is recommended in UK, US and European guidelines for 
patients with symptomatic stenosis ≥50% where the operative morbidity is estimated to 
be low. 2014 AHA guidelines note the reduced benefit of CEA in patients with 50-69% 
stenosis, and suggest that the intervention in these patients should be “performed by a 
surgeon with excellent operative skills” [127]. In these guidelines, CAS is deemed to be 
indicated as an alternative to CEA in patients at average or low risk of complications, 
taking age into account, or in those with contraindications to CEA. In the UK the 
National Institute for Clinical Excellence (NICE) guidelines from 2008 do not specify a 
recommendation for the use of CAS other than in cases of symptomatic carotid 
stenosis ≥50% where endarterectomy might be high risk or contraindicated [128] [129]. 
Similarly, the European Vascular Society guidelines continue to recommend CEA over 
CAS for the majority of symptomatic patients [46] [130]. 
Are these guidelines reflected in clinical practice? Data from hospitals in England 
reveals that the overwhelming majority of revascularization procedures carried out on 
the carotid artery are endarterectomies, with only 5% of patients receiving stenting 
[131]. The results of the major randomized trials that overall favour CEA as the safer 
procedure – SPACE, EVA-3S, ICSS and CREST – appear not to have affected the 
number of CAS procedures being carried out between 2006 and 2012, but interestingly 
the patients undergoing CAS were younger in age, perhaps reflecting the 
recommendation that CAS be considered more carefully in older patients because of 
the higher risk of peri-procedural complications. In the United States, there has been a 
significant increase in the number of CAS procedures performed since the publication 
of the main results of these trials predominantly, again, in younger patients and those 
who were asymptomatic [132]. The debate as to which procedure is superior seems far 
from settled in clinicians’ minds. 
 This thesis 12.7
This thesis will examine the risk of, and impact of, complications arising from carotid 
revascularization in symptomatic patients in the International Carotid Stenting Study – 
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stroke, myocardial infarction, death, cranial nerve palsy and neck haematoma. It will 
determine whether there are subgroups of patients at particular risk of these 
complications following CEA or CAS based on their demographic characteristics, the 
type of procedure they have undergone or their individual vascular anatomy. Finally it 
will examine the performance of existing risk-scoring systems for predicting 
complications of CEA and CAS when applied to the patients in ICSS who were 
randomized to those procedures. The thesis concludes with a summary and discussion 
of its main findings, and places the work in the context of recent and ongoing studies of 
CEA and CAS.  
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13. Methods – ICSS and the ICSS-MRI Substudy 
 The International Carotid Stenting Study 13.1
13.1.1 Introduction 
The full protocol for ICSS is presented in Appendix IV, and is published elsewhere [81]. 
The ICSS-MRI Substudy protocol is presented in full in Appendix V. The International 
Carotid Stenting Study was conceived after the conclusion of CAVATAS [75], which 
found no statistically significant difference in outcome between CAS and CEA 
immediately following treatment or in the long term. However, carotid angioplasty 
continued to evolve during the trial, and the use of stents in the procedure developed 
while CAVATAS was still recruiting. CAS still promised the advantages of reduced 
hospital stay, potential avoidance of a general anaesthetic, and a reduced rate of 
surgery-specific complications such as neck haematoma and cranial nerve palsy. ICSS 
was therefore designed as an international, multicentre, randomized, controlled open 
clinical trial to test the difference between the long-term risk of fatal or disabling stroke 
in patients with symptomatic carotid artery stenosis greater than 50% after 
randomization to either CEA or CAS. 
13.1.2 Selection and enrolment of trial centres & interventionists 
50 academic centres in Europe, North America and Oceania enrolled patients in ICSS. 
Each was required to provide a principal investigator qualified in neurology or internal 
medicine to see patients prior to randomization and then again in follow-up. Surgeons 
performing trial procedures were required to have carried out 50 CEA operations with 
an annual rate of at least 10 cases per year, while CAS interventionists were required 
to have performed 50 stenting procedures, at least 10 in the carotid artery territory. All 
were expected to provide audit data to an ICSS accreditation committee showing a 
satisfactory complication rate similar to that of ECST (7.0% risk stroke or death within 
30 days of the procedure, 95% CI 5.8% to 8.3%) [36]. 
Centres unable to fulfil the above requirements for CAS competency were allowed to 
join the trial and enrol patients as a “probationary centre”. CAS procedures carried out 
at these centres were supervised by an experienced interventionist until 10 more 
successful procedures were completed within the trial and the proctor was satisfied that 
the interventionist in question could carry out the procedure independently. 
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13.1.3 Selection of patients and randomization 
Patients randomized in ICSS had symptomatic extracranial stenosis of the carotid 
artery attributable to atherosclerotic disease. Stenosis had to be greater than 50% as 
measured by the NASCET method [40] or an equivalent non-invasive method such as 
carotid ultrasound, and symptoms were required to have occurred within the last 12 
months. 
Patients were excluded if they were thought unsuitable for either treatment due to 
 Tortuous carotid vascular anatomy 
 Proximal common carotid artery disease or the presence of thrombus 
 Pseudo-occlusion (>99% stenosis with normal distal runoff on angiography) 
 Distal stenosis or rigid neck rendering surgery hazardous or impossible 
 Previous CAS or CEA in the artery to be randomized 
 Clinical instability or serious co-morbid illness (“not fit for surgery”) 
 A life expectancy of less than 2 years due to a pre-existing condition 
 Planned coronary artery bypass grafting within 1 month of CAS or CEA 
 Refusal or inability to give written informed consent to trial participation or 
refusal to be randomized to either treatment 
 Major stroke with no useful recovery of function within the territory of the artery 
to be randomized 
Prior to randomization patients were given written information about the trial and 
informed consent to participate was given by the patient. 
13.1.4 Baseline visit and investigations 
At baseline visit, investigators recorded demographic information about the patient and 
details of past medical history including vascular risk factors. Brain imaging, in the form 
of CT or MRI, was required to identify previous areas of infarction or haemorrhage and 
to provide a comparison with any post-procedure scans. 
To confirm the presence and extent of carotid stenosis, imaging from at least one of the 
following modalities was required 
 Catheter angiogram showing the carotid bifurcation 
 Bilateral MRI angiograms with a concordant Doppler ultrasound scan 
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 Bilateral CT angiograms with a concordant Doppler ultrasound scan  
 Bilateral Doppler ultrasound scan only, if the centre was able to provide 
documented evidence of the reliability of their results through clinical audit and 
if it was standard practise to treat on the basis of ultrasound alone at that centre 
Pre-randomization clinical and imaging data were returned to the trial office in London. 
13.1.5 Randomization procedure 
Randomization was carried out by the Oxford Clinical Trials Service Unit, stratified by 
centre with risk factors balanced between the two arms. Minimization was used to 
balance patient characteristics between the two arms. Patients with stenosis in both 
carotid arteries could only be randomized once, for the symptomatic artery to be 
treated first. The allocated procedure was then required to be carried out as soon as 
safely and practically possible after randomization. The possibility of a patient 
becoming ineligible for revascularization after randomization in the trial or crossing over 
to the other treatment was anticipated, and these patients were included in intention-to-
treat analyses. 
13.1.6 Carotid endarterectomy 
Carotid endarterectomy was carried out according to the operating surgeon and the 
trial centre’s usual protocol. The type of anaesthesia to be used was not specified nor 
was the choice of arterial reconstruction. The use of a patch to close the arteriotomy 
was optional. All patients undergoing surgery were required to receive “best medical 
care” including management of vascular risk factors and appropriate antiplatelet, 
antihypertensive or cholesterol-lowering drugs. 
13.1.7 Carotid stenting 
Devices used in the carotid stenting procedure were required to be CE-marked and 
were approved by the trial steering committee. The use of a cerebral protection device 
was optional, but recommended “whenever the operator [thought] one could be safely 
deployed”. Aspirin and clopidogrel prescription prior to the procedure and for a 
minimum of 4 weeks after was recommended. The use of intra-procedural heparin to 
prevent acute thrombosis secondary to instrumentation of the carotid was mandatory, 
as was the administration of atropine or equivalent drugs to prevent haemodynamic 
disturbance secondary to manipulation of the carotid baroreceptors. Finally, it was 
anticipated that most patients would require balloon dilation (“pre-dilation”) of the 
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stenotic lesion to facilitate the passage of equipment through the stenosis. Patients 
undergoing CAS otherwise received the same “best medical care” as the surgical 
group. Technical details of either CAS or CEA were returned to the trial office. 
13.1.8 Post-procedure follow-up 
Patients were monitored in hospital, and events occurring between the procedure and 
discharge were reported on the technical data form. Patients were then followed-up by 
a trial investigator at one month after the procedure. 
13.1.9 Outcome events and adjudication 
The main outcome events examined in the primary outcome of the trial and 
subsequently in this thesis are defined below 
 Stroke – “an acute disturbance of focal neurological function with symptoms 
lasting more than 24 hours resulting from intracranial vascular disturbance” 
 This diagnosis included retinal stroke causing loss of vision in one eye for more 
than 24 hours 
 Myocardial infarction – recorded if the patient experienced two out of 
o Cardiac enzyme rise more than twice the upper limit of normal range 
o The development of specific ECG abnormalities 
o A history of chest discomfort for at least 30 minutes 
 Cranial nerve palsy (within 30 days of the procedure) – reported by the 
investigator in individual patients who experienced motor or sensory 
disturbance, attributed to the procedure, in one of the cranial nerves. 
 Haematoma – defined by the investigator in patients who experienced bleeding 
in the neck as a result of revascularization. “Severe haematoma” was defined 
as haematoma requiring blood transfusion, re-operation or one that prolonged 
hospital stay 
 Death 
A clinical diagnosis of stroke was confirmed by brain CT or MRI carried out as soon as 
possible after the clinical event. The cause of death was confirmed through clinical 
reports from the treating centre and death certificate or post-mortem results where 
available. 
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Potential stroke or MI outcome events were reported in detail to the trial office as 
above. An adjudication process was carried out to decide if the reported event met the 
criteria of one of the trial outcome events. Adjudication was carried out by two 
investigators at the trial office blinded to allocated treatment. A third, independent, 
adjudicator then reviewed the event. If a disagreement occurred between adjudicators 
the difference was resolved with the opinion of a second independent adjudicator and 
consensus. Additional information on the clinical consequences of cranial nerve palsy 
occurring within 30 days of CEA was sought by means of a questionnaire, detailed in 
Appendix II.  
Stroke or cranial nerve palsy was flagged as “disabling” if the patient experienced an 
increase in their modified Rankin Scale (mRS) score to 3 or more where that increase 
was attributable to the event at a specified time-point during follow-up. 
13.1.10 Sample size and statistical analysis 
Sample size in ICSS was planned as 1500 patients in fully-enrolled centres, with a 
calculated 95% confidence interval for a difference in risk between CAS and CEA of 
±3% for the composite outcome of stroke, myocardial infarction or death within 30 days 
of treatment. Additional patients were enrolled in probationary centres. 
13.1.11 Ethical approval and safety monitoring 
ICSS was approved by a Multicentre Research Ethics Committee (MREC) in the United 
Kingdom. In addition, individual centres obtained their own local ethics committee 
approval before starting randomization in the trial. 
The safety of the patients enrolled in ICSS was overseen by a Data Monitoring 
Committee comprising a neurologist, medical statistician, surgeon and interventionist. 
Interim analyses were carried out during the trial to ensure that morbidity and mortality 
remained within acceptable limits. Individual centres’ results were monitored by the trial 
manager, with two consecutive deaths or three consecutive major events at an 
individual centre within 30 days of treatment in one arm of the study prompting a review 
of outcome events at this centre. Similarly, a cumulative stroke, MI or death risk of 
>10% over 20 cases would prompt a review. 
During the course of the trial concern was raised, by the above mechanism, about the 
results of two investigators performing CAS procedures at two separate supervised 
centres. Both centres suspended recruitment while outcome events were reviewed, 
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although one centre subsequently re-started enrolment into ICSS with a different 
interventionist performing trial procedures [82]. The results presented in this thesis 
include patients treated by these investigators where the patients received their 
allocated treatment. 
 The ICSS-MRI Substudy 13.2
13.2.1 Introduction 
Complementary to the International Carotid Stenting Study was the ICSS-MRI 
Substudy. The aim of this substudy was to compare the risk of ischaemic (and possibly 
sub-clinical) brain injury as assessed by MRI in patients undergoing stenting in ICSS 
compared to those undergoing surgery. 
13.2.2 Substudy design 
Patients enrolled in the ICSS-MRI Substudy received standard treatment as specified 
in the ICSS protocol above. They additionally underwent brain MRI 1-3 days before 
treatment, 1-3 days after treatment and approximately 30 days after revascularization. 
Patients with a contraindication to MRI (e.g. metallic implant or claustrophobia) were 
excluded from participation in the study. The following MRI sequences were specified 
in the trial protocol 
 Diffusion-weighted imaging (DWI) to detect acute brain ischaemia or infarction 
 Gradient echo T2*-weighted to detect brain haemorrhage 
 T1-weighted and fluid-attenuated inversion recovery (FLAIR) to assess whether 
acute brain lesions on DWI persisted to become permanent FLAIR lesions at 30 
days after the revascularization 
13.2.3 Sample size, data and statistical analyses 
A sample size of 200 patients was planned assuming a risk of new DWI lesions after 
endarterectomy of 25%, giving a 90% power to detect a doubling of the risk of a new 
DWI lesion in the stenting group.  
The analysis of brain imaging in the ICSS-MRI Substudy is described in more detail in 
Chapter 18. Two investigators independently recorded the presence, volume and 
location of ischaemic and haemorrhagic lesions on each scan, and a third investigator 
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reviewed in cases of disagreement. Scans were reported blind to allocated treatment or 
the nature of the scan (e.g. pre- or post-procedural). 
 CONSORT flow diagram 13.3
The progress of patients through the International Carotid Stenting Study is outlined in 
the CONSORT flow diagram in Figure 6 below. 
 Trial funding 13.4
ICSS was funded by the UK Medical Research Council, the Stroke Association, Sanofi-
Synthélabo, and the European Union. ICSS is a registered clinical trial: ISRCTN 
25337470. 
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Figure 6. ICSS CONSORT trial diagram 
  
855 assigned to Stenting  858 assigned to Endarterectomy 
853 analysed by intention to treat from 
randomisation until end of follow-up 
857 analysed by intention to treat from 
randomisation until end of follow-up 
2 withdrew all consent 
immediately after randomisation 
1 withdrew all consent immediately 
after randomisation 
9 crossed over to endarterectomy 
   2 anatomy unsuitable 
   3 medical contraindications 
   1 refused treatment 
   3 other reasons 
16 underwent no procedure 
   1 disabling stroke before  
      intended procedure 
   5 artery occluded 
   3 artery less than 50% stenosed 
   1 anatomy unsuitable 
   2 other medical contraindications 
   3 other reasons 
 
15 crossed over to stenting 
   1 anatomy unsuitable 
   6 medical contraindications 
   4 refused treatment 
   4 other reasons 
   21 underwent no procedure 
   2 died before intended procedure 
   3 disabling stroke before intended  
      procedure 
   9 artery occluded 
   1 artery less than 50% stenosed 
   3 medical contraindications 
   1 refused treatment 
   2 other reasons 
 
 
828 stenting procedures initiated 821 endarterectomy procedures initiated 
64 stenting aborted 
752 per-protocol patients 
reached 30-day follow-up in 
ICSS 
12 follow-up <30 days 
    10 fatal events 
    2 had no further follow-up 
2 endarterectomy aborted 
811 per-protocol patients 
reached 30-day follow-up in 
ICSS 
8 follow-up <30 days 
   4 fatal events 
   4 had no further follow-up 
1713 patients randomised 
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14. Risk factors for stroke, myocardial infarction or death 
following carotid endarterectomy 
 Introduction 14.1
The North American Symptomatic Carotid Endarterectomy Trial (NASCET) [35], the 
European Carotid Surgery Trial (ECST) [36] and the smaller Veteran’s Affairs Trial [39] 
demonstrated a reduction in the long-term rate of recurrent stroke in patients with 
>50% symptomatic carotid artery stenosis undergoing carotid endarterectomy 
compared with those on medical therapy. Meta-analysis of the results of these three 
trials, and two smaller studies, suggests that for every 11 symptomatic patients 
undergoing CEA one outcome event is prevented for the combined endpoint of any 
stroke or perioperative death [133]. 
However, CEA in these trials carried a risk of perioperative stroke or death of 7.0% 
(95% CI 6.2 to 8.0) [133] and subsequent studies, focussing on these short-term 
measures of safety, continue to demonstrate a significant risk of major complications 
following revascularization [134] [96]. Perioperative stroke and MI have been shown to 
have a significant adverse impact on long-term survival, and stroke in particular may 
halve survival in the first year after surgery [135]. The choice of anaesthesia and 
surgical technique during CEA varies [136] [137], and despite CEA being a long-
established technique for revascularization there remains debate about the optimal 
processes of care for surgery including perioperative medical therapy, type of arterial 
reconstruction and mode of anaesthesia to prevent complications. 
This analysis aimed to determine whether there were groups of patients at higher risk 
of stroke, MI or death within 30 days of CEA in the International Carotid Stenting Study 
and whether there are surgical practices associated with higher risk. 
 Methods 14.2
14.2.1 Study design & CEA procedure 
This chapter presents a per-protocol analysis of patients enrolled in ICSS who were 
randomized to CEA and in whom the allocated procedure was initiated. The inclusion 
and exclusion criteria for ICSS are outlined in Chapter 13.1 and the trial protocol is 
detailed in full in Appendix IV. Patients over the age of 40 years old could be enrolled in 
ICSS if they presented with recently-symptomatic carotid artery stenosis >50% due to 
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atheroma. Patients were excluded from randomization in ICSS if they were unsuitable 
for surgery due to a surgically-inaccessibly high level of stenosis, if they had a rigid 
neck making positioning difficult for surgery, or if there was previous revascularization 
of the artery to be randomized. 
CEA in ICSS was performed according to the surgeon’s usual practice – the type of 
arterial reconstruction was not specified, nor was the mode of anaesthesia. Medical 
therapy for control of vascular risk factors was required in both groups in the trial, but 
the prescription of one or more antiplatelet agents prior to or after surgery was at the 
operator’s discretion. Surgeons in ICSS were required to provide audited complication 
rates within acceptable limits and to have performed a minimum of 50 CEA procedures 
prior to joining the trial with a minimum volume of 10 procedures per year. In addition to 
this technical information, centres provided demographic information about patients 
and specified whether their general policy was to send patients to a specialized post-
procedure ward such as a high-dependency or intensive care unit, or whether patients 
were admitted to a general surgical or medical ward post-operatively. 
14.2.2 Outcome events 
The combined endpoint of stroke, MI or death within 30 days of the procedure was 
analysed. Events were reported in detail to investigators at the central trial office. 
Confirmatory evidence was required where available: CT or MRI brain after stroke, 
cardiac enzymes and / or ECG after MI, death certificate and autopsy report if available 
following death. Stroke was defined as “an acute disturbance of focal neurological 
function lasting more than 24 hours resulting from intracranial vascular disturbance”. A 
diagnosis of MI required two out of three features – a clinical history of chest discomfort 
lasting at least 30 minutes, cardiac enzyme rise more than twice the upper limit of 
normal or the development of specific ECG abnormalities. Outcome events were 
submitted to an external, independent, adjudicator who was masked to treatment 
allocation. If their assessment differed from the trial office’s initial assessment a second 
external adjudicator reviewed the event. Differences in adjudication were resolved by 
consensus. 
14.2.3 Statistical methods 
Only patients in ICSS in whom the allocated procedure was initiated were included in 
this analysis. Trial patients who crossed-over to medical therapy or received CEA after 
a prior stenting procedure (attempted or completed) were excluded from this analysis. 
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CEA was considered “initiated” if the patient underwent either local or general 
anaesthesia prior to surgical incision. Risk factors for stroke, MI or death were 
examined sequentially in a univariable binomial regression analysis using maximum 
likelihood estimation. Second events within 30 days of the procedure were not counted. 
Patients with missing data were excluded from each relevant analysis. The risk ratio for 
each baseline or technical variable was estimated with a 95% confidence interval. Wald 
tests were used for continuous and binary predictors, with an overall likelihood test for 
categorical predictors of more than two levels. No correction was applied for multiple 
comparisons. p<0.05 was accepted as conferring statistical significance in all analyses. 
A multivariable model was developed using a forward stepwise approach. Analyses 
were performed with Stata (StataCorp, 2011. Stata Statistical Software: Release 12. 
College Station, TX: StataCorp LP). 
 Results 14.3
14.3.1 Outcome events 
14.3.2 Patient and procedure characteristics 
CEA was initiated in 821/855 patients allocated to the procedure in ICSS. Patient and 
procedural characteristics for this group are presented in detail in Figure 7 along with 
the results of univariable analysis. 70.4% of patients were male and 52% of patients 
were aged 70 years or more (the median age in the CEA arm of ICSS at the date of 
enrolment). Vascular risk factors were common. 21.2% of patients were diabetic, 
66.2% were receiving treatment for hyperlipidaemia and 69.7% were receiving 
treatment for hypertension. 
Arterial reconstruction was by patch closure in 55.9%, “standard” closure without patch 
in 22.1% and by eversion endarterectomy in 6.0%. Vein interposition was used in only 
0.4%. General anaesthesia or combined local-general anaesthesia was administered 
to 79.2% of patients. A shunt was used during the procedure in 39.5%. An antiplatelet 
drug was prescribed to 88.4% of patients prior to the procedure, of whom 30.1% were 
taking two or more antiplatelet medications. 
14.3.3 Characteristics and timing of outcome events 
27/821 patients (3.3%) suffered a stroke of any severity within 30 days of the 
procedure, 5 suffered MI, and one patient died of another cause giving a combined risk 
of stroke, death or MI within 30 days of the procedure of 4.0%. 13/33 (39.4%) of these 
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events occurred on day 0 – the day of the procedure, the remainder occurring between 
days 1 and 30. 7/33 (21.2%) events occurred on or after the date of discharge. The 
median length of stay was 4 days before discharge. 
14.3.4 Patient and procedural risk factors for stroke, MI or death within 30 days 
of the procedure 
The results of univariable analyses of patient and procedural factors on the risk of 
stroke, MI or death within 30 days of CEA are presented in Figure 7. The risk of the 
combined outcome was significantly higher in female patients (RR 1.98, 95% CI 1.02 to 
3.87, p=0.05) and with each increasing 10mmHg of baseline diastolic blood pressure 
(RR 1.31 for each +10mmHg, 95% CI 1.20 to 1.66, p=0.04). The time from the index 
event that prompted randomization in the trial (stroke or TIA) to the date of surgery was 
also a significant predictor, but this this result was influenced by one outlying patient. 
Removing this patient from the per-protocol population in a sensitivity analysis resulted 
in a non-significant p-value (RR 1.01 per 7 days, 95% CI 0.97 to 1.06, p=0.48). The 
age of the patient, the side of surgery, the level of disability and the degree of ipsilateral 
or contralateral carotid artery stenosis were not predictors of the risk of stroke, MI or 
death within 30 days of surgery. 
Shunt use (RR 0.99, 95% CI 0.50 to 1.96, p=0.98), local anaesthesia only vs general or 
combined local-general anaesthesia (RR 0.48, 95% CI 0.15 to 1.57, p=0.23) and the 
type of surgical reconstruction (i.e. primary closure vs patch vs vein interposition) did 
not statistically significantly influence risk despite one out of three patients in whom 
vein interposition was used experiencing an event. 
Centres with a policy of sending patients to a specialized ward (such as a high 
dependency or intensive care unit) following CEA reported a lower risk of stroke, MI or 
death within 30 days of surgery (RR 0.57, 95% CI 0.29 to 1.13, p=0.11), but this result 
was not statistically significant. 
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Figure 7. Univariable predictors of the risk of stroke, myocardial infarction or death 
in 821 patients undergoing CEA in whom the procedure was initiated 
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Figure 7 continued 
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In a multivariable model, only diastolic blood pressure remained a significant predictor 
of the risk of stroke, MI or death within 30 days of the procedure in the presence of any 
other included variables (RR 1.30 for each +10mmHg, 95% CI 1.02 to 1.66, p=0.04). 
This model included only 785 patients for whom complete predictor data were 
available. 
 Discussion and conclusion 14.4
14.4.1 Summary 
The overall risk of stroke, MI or death within 30 days of CEA in ICSS was 4.0%. The 
majority of these events were strokes, and the majority of events occurred before 
discharge. Of the baseline demographic and vascular risk factors examined, only sex 
and increasing diastolic blood pressure at baseline significantly predicted the risk of 
stroke, MI or death. Female patients experienced roughly double the risk of male 
patients of reaching the composite endpoint. In a multivariable model, only baseline 
diastolic blood pressure remained a significant predictor of risk after adjustment for all 
other included variables.  
None of the surgical technical variables examined – type of anaesthesia, type of 
arterial reconstruction, variation in medical therapy or shunt use – significantly 
predicted risk. 
14.4.2 Discussion 
The finding that women undergoing CEA in ICSS experienced a higher risk of stroke, 
MI or death than men is broadly consistent with findings from other randomized trials 
and audits of carotid endarterectomy outcomes [138] [133] [139] [140], although recent 
data from the Society for Vascular Surgery Vascular Registry suggest a similar 
complication rate (around 4% risk of stroke, MI or death within 30 days of CEA) for both 
men and women outside a clinical trial setting [141]. Although a statistically significant 
difference was observed in ICSS this result was not confirmed in multivariable analysis. 
This suggests that differences in baseline patient characteristics between male and 
female patients might explain this difference in risk [118], although this analysis had 
limited power to detect predictors because of the relative paucity of outcome events. 
An alternative explanation for a higher observed risk of complications in women may be 
that the smaller carotid artery diameter in women is associated with procedural stroke 
due to in-situ thrombosis following more technically-demanding surgery [142] [143] 
[139]. Or perhaps women, with an older age of onset of cerebrovascular disease than 
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men, might have more medical comorbidities that increase procedural risk [144]. In 
addition, many of the post-procedural strokes experienced by ICSS patients 
undergoing CEA occurred some days after the procedure, and it has been suggested 
that women are at a higher risk of post-procedural embolism [145] [146]. 
Notably, women with symptomatic carotid stenosis may also experience less benefit in 
terms of stroke prevention from CEA, particularly where the procedure is delayed [147]. 
Thus any risk-benefit discussion with female patients should highlight both a potential 
increased risk of minor complications as well as a reduced overall benefit as compared 
with men. 
Time from the index event prompting randomization in ICSS to the date of surgery did 
not appear to influence risk, but the majority of patients in ICSS waited more than 14 
days after randomization for surgery [82] which exceeds the maximum recommended 
delay in current guidelines [128]. In 2012, 33% of UK patients undergoing CEA were 
operated on within 14 days of their symptoms. However, there is some evidence that 
very early CEA, within 48 hours of symptoms, is associated with increased risk [148]. 
In ICSS surgical technique and mode of anaesthesia had less influence on short-term 
outcome than patient characteristics. The largest randomized trial of general vs local 
anaesthesia for CEA, the General Anaesthesia versus Local Anaesthesia for carotid 
surgery trial (GALA), found no difference in the risk of stroke, MI or death within 30 
days of surgery between the two groups [104] [103]. There is currently insufficient 
evidence to suggest that routine shunt use reduces perioperative stroke or death [106], 
by maintaining cerebral perfusion pressure in the presence of a tight contralateral 
carotid stenosis, although there is some suggestion that patch closure of the artery, as 
opposed to primary closure, is associated with a lower risk of perioperative ipsilateral 
stroke [107]. 
The association between baseline blood pressure and outcome of surgery has also 
been demonstrated previously in a systematic review including patients from the 
European Carotid Surgery Trial [149]. Despite detailed baseline and follow-up 
measurements, ICSS investigators did not collect perioperative blood pressures and 
therefore it was not possible to assess the influence of perioperative haemodynamic 
control on outcome. Patients who are transferred to Intensive Care or a similar 
specialized unit after the procedure might be expected to have better optimization of 
their blood pressures and medications. In ICSS 8.3% of patients undergoing CEA 
experienced post-procedural hypertension which was associated with higher baseline 
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blood pressure [150] and in other studies has been shown to be associated with stroke 
or death [151] [152]. What is not known is whether closer control of blood pressure 
after stroke or TIA could reduce the risks of subsequent CEA. Although not statistically 
significant, ICSS patients treated in centres with a policy of sending the patient to 
intensive care afterwards experienced a much-reduced rate of complications, which 
could in turn be due to closer monitoring of haemodynamic parameters and treatment 
of excessively high or low blood pressures. Current guidelines for CEA have focussed 
on patient selection, procedural technique and medication use [153]. Therefore given 
our findings on diastolic blood pressure, and that more events occurred on the days 
following the procedure than the day of the procedure itself, future work on the safety of 
CEA should additionally address overall perioperative care and management of 
physiological parameters.    
14.4.3 Limitations 
The risk of stroke, MI or death associated with carotid endarterectomy was acceptably 
low in ICSS. However, a low number of outcome events limited the power to detect a 
significant difference between subgroups of patients and limited the number of factors 
supported in a multivariable model. Multiple statistical comparisons are made in this 
analysis without correction, raising the possibility of a Type 1 (false positive) error. 
Associations between baseline characteristics or processes of care and the outcome 
do not necessarily imply causation, and this was not a randomized comparison 
between surgical techniques. 
Other factors or more generalized measures of health not recorded in ICSS, such as 
the patient’s American Society of Anaesthesiology (ASA) grade, may be more useful 
predictors of adverse outcome [154]. 
14.4.4 Conclusions 
The relative safety of CEA in ICSS limited power to detect predictors of risk. 
Nonetheless, diastolic blood pressure at baseline was a significant independent 
predictor of the risk of stroke, MI or death within 30 days of carotid endarterectomy. It is 
possible that careful attention to blood pressure control following stroke or TIA may 
reduce the risks associated with subsequent CEA in patients with underlying carotid 
stenosis, although concern exists about acute lowering of blood pressure following 
stroke or TIA in the presence of carotid stenosis. The finding that around 20% of events 
occurred on or after the day of discharge underlines the importance of post-discharge 
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follow-up to ensure that patients receive treatment for any late complications and to 
ensure that surgical audit data include all late events. Surgical results should also be 
carefully audited in female patients to ensure that the risk of complications remains 
acceptably low. 
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15. Validation of existing risk scores for carotid 
endarterectomy 
 Introduction 15.1
CEA remains the standard of care for patients with 50-99% symptomatic carotid 
stenosis, as measured by the NASCET method [40]. However, despite improvements 
in the care of surgical patients, and despite innovations in surgical and anaesthetic 
technique for carotid endarterectomy, data from a systematic review of studies 
published between 1994 and 2001 suggest that risk of stroke or death within 30 days of 
surgery remained clinically significant at 6.5% (95% CI 4.3% to 8.7%) in studies 
involving assessment of study endpoints by neurologists [96]. These studies are 
comparable with ICSS in which 4.7% of patients randomized to CEA suffered stroke or 
death [82] within 30 days of surgery. 
Research since the landmark NASCET and ECST trials has attempted to define the 
patient at high risk of complications following surgery. Complications of specific 
concern in CEA include stroke, myocardial infarction, death, neck haematoma and 
cranial nerve palsy. However, few risk factors or scoring systems found to be 
significant predictors in one group of patients have been validated in other cohorts and 
the usefulness of their application in everyday clinical decision-making remains 
unclear. Risk scores may give patients and clinicians an individualized estimate of the 
risk of suffering stroke or death within 30 days of endarterectomy, and could allow 
calculation of the net benefit of surgery in long-term stroke prevention. 
The performance of three risk scores in patients allocated to surgery the International 
Carotid Stenting Study is assessed in this chapter. The patient populations from which 
these scores derived most closely match the inclusion criteria for ICSS and comprise 
clinical characteristics that are apparent at baseline visit. 
Rothwell et al. [98] developed a prognostic model using data from patients undergoing 
CEA in the European Carotid Surgery Trial (ECST) in the 1990s. ECST enrolled 
patients with symptomatic carotid stenosis and randomized them to either carotid 
endarterectomy or medical treatment [36]. A model to predict the risk of stroke or death 
within 30 days of the procedure was calculated in patients with 0-69% stenosis of the 
symptomatic artery and later validated in patients with 70-99% stenosis. Predictors of 
risk were female sex, peripheral vascular disease, and high systolic blood pressure.  
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Tu et al. [155] developed a score to predict the risk of stroke or death within 30 days of 
CEA in 6038 patients undergoing surgery in Ontario, Canada. 69% of those patients 
were symptomatic, and 95% had ICA stenosis between 50-100%. The average age 
was 68 years. Significant predictors of stroke were TIA or stroke in the 6 months prior 
to surgery, atrial fibrillation, heart failure, diabetes and contralateral carotid occlusion. 
Finally, the prediction model developed by Kuhan et al. [156] examined the patient and 
procedural characteristics of 839 patients undergoing CEA in 2 vascular units in the 
United Kingdom between 1992 and 1999. 87% of these patients were symptomatic, 
60% were male and the median age was 68. Significant risk factors for stroke or death 
within 30 days of CEA were “heart disease” (comprising angina, myocardial infarction, 
heart failure or arrhythmia), diabetes and stroke as the index event prompting 
intervention. None of the surgical variables included in the study (shunt use, patch use, 
operating surgeon, vascular unit or the side of operation) significantly predicted risk. 
A number of other publications address risk factors for complications of CEA, but were 
not validated in this patient cohort as they included factors not measured at baseline in 
ICSS patients [157] [158] [159] [160], included a large proportion of asymptomatic 
patients [158] [161] [162] or focus on operator, hospital or process of care factors that 
are modifiable and therefore of limited use in predicting the risk in individual patients 
[163] [164] [165]. 
 Methods 15.2
The performance of the three risk scores predicting the risk of stroke or death within 30 
days of CEA was evaluated [98] [155] [156]. To test the performance of each risk 
score, patients were assigned “risk points” according to their baseline characteristics. 
The characteristics predicting risk in each risk score are outlined in Tables 3 to 5 
below. Baseline patient characteristics were collected by investigators in ICSS at the 
time of the patient’s enrolment into the trial and sent to the central trial office in London. 
The occurrence of stroke or death within 30 days of the procedure was examined in a 
per-protocol population of patients in ICSS in whom the allocated procedure was 
initiated. CEA was deemed to have been initiated if local or general anaesthesia was 
administered prior to the planned commencement of surgery. The adjudication of 
events is described in more detail in Chapters 13 and 14. In brief, stroke was defined 
as “an acute disturbance of focal neurological function lasting more than 24 hours 
resulting from intracranial vascular disturbance”, and confirmatory evidence was 
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required where available in the form of CT or MR brain imaging. Centres reporting 
death within 30 days of the procedure provided either a death certificate or autopsy 
report if available. 
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Table 3. Allocation of risk points in the Rothwell risk score 
Study Risk factors Risk points 
Rothwell et al. 
(1999) [98] 
Female sex 
 
1 
Peripheral vascular disease 
 
1 
Systolic BP > 180mmHg 1 
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Table 4. Allocation of risk points in the Tu risk score 
Study Risk factors Risk points 
Tu et al. 
(2003) [155] 
TIA or stroke in the 6 months prior to surgery 1 
Atrial fibrillation 1 
Heart failure 1 
Diabetes 1 
Contralateral carotid occlusion 1 
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Table 5. Allocation of risk points in the Kuhan risk score 
Study Risk factors Risk points 
Kuhan et al. 
(2001) 
[156] 
Heart disease (any of angina, MI, heart failure, arrhythmia) 1 
Stroke as the index event prompting surgery 1 
Diabetes (any type) 1 
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A 95% confidence interval for the risk of stroke or death within 30 days of the 
procedure was generated, and the performance of the risk score across groups with 
increasing score was tested by means of a chi-squared (χ2) test for trend. The 
“predicted” risk of stroke or death within 30 days of surgery represents the result of 
applying the risk score to the population in which it was originally developed. Groups in 
which no events occurred were combined with lower-risk groups to enable the 
statistical comparison to be carried out. Receiver operator curves (ROC) were plotted 
to assess the performance of each risk score, and the area under the curve (AUC) was 
calculated with 95% confidence intervals and significance test. Statistical analyses 
were performed using GraphPad (GraphPad Software, 2013. GraphPad Instat version 
3.00 for Windows 95. San Diego, California: www.graphpad.com). 
 Results 15.3
The baseline characteristics of patients included in this analysis, and how many 
patients possessed characteristics which feature in each of the three risk scores, are 
presented in detail in Chapter 14.3.2 and Figure 7. 70.4% of patients were male, and 
52% were aged 70 years or more. 59/821 (7.2%) patients had systolic blood pressure 
>180mmHg, and 236 patients (28.7%) had “heart disease” as defined in the Kuhan risk 
score (any of angina, MI, heart failure or arrhythmia). 174 patients (21.2%) were 
diabetic, and 131 (16.0%) had a diagnosis of peripheral vascular disease. 
28/821 (3.4%) patients allocated to CEA in ICSS, in whom the procedure was initiated, 
suffered stroke or death within 30 days of the procedure. 
15.3.1 Rothwell (1999) risk score 
The results of applying the Rothwell score to ICSS patients allocated to CEA are 
detailed in Table 6. The risk of stroke or death within 30 days of surgery was 2.5% 
(95% CI 1.3% to 4.4%) in those with a score of 0, 4.4% (95% CI 2.6% to 7.4%) in those 
with a score of 1 and 5.4% (95% CI 1.3% to 15.2%) in those with a score of 2. 2 
patients had a score of 3 but neither suffered an event. There was an increase in the 
observed risk of an outcome event with increasing score that was not statistically 
significant (p=0.10). 25/28 (89.2%) events occurred in the lowest risk groups (score 0 
to 1). 
A receiver operator curve (ROC) was plotted for the results of applying the Rothwell 
score to the ICSS dataset and is presented in Figure 8. The area under the curve was 
0.58 (95% CI 0.48 to 0.69, p=0.14), indicating poor performance. 
  
 
7
4
 
 
Table 6. Results of application of the Rothwell (1999) risk score to 821 patients undergoing CEA in ICSS 
Score Number at risk Number of events Predicted event rate % (95% CI) Observed event rate % 95% CI for observed event rate 
0 448 11 4.7 (2.6 to 7.6) 2.5 (1.3 to 4.4) 
1 315 14 7.3 (4.3 to 11.0) 4.4 (2.6 to 7.4) 
2 56 3 12.1 (5.0 to 23.0) 5.4 (1.3 to 15.2) 
3 2 0 16.7 (4.2 to 64.0) 0.0  
Totals 821 28  
 
χ2 test for trend p=0.10 
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Figure 8. Receiver operator curve for application of the Rothwell (1999) risk score 
to 821 patients undergoing CEA in ICSS 
 
 
 
Darker line represents receiver operator curve 
Straight line represents area under curve =0.5  
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15.3.2 Tu (2003) risk score 
The results of applying the Tu score to the ICSS dataset are detailed in Table 7. The 
risk of stroke or death within 30 days of the procedure was 2.6% (95% CI 0.6% to 
7.6%) in those with a score of 0, 3.4% (95% CI 2.0% to 5.4%) in those with a score of 1 
and 4.7% (95% CI 2.4% to 8.9%) in those with a score of 2. Patients with higher scores 
did not experience an event. The increase in the risk of an event with increasing score 
did not reach statistical significance (p=0.49). All events occurred in lower risk groups 
(score 0 to 2). 
In a receiver operator curve plot of these results, presented in Figure 9, the AUC was 
0.526 (95% CI 0.42 to 0.63, p=0.64) indicating poor performance. 
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Table 7. Results of application of the Tu (2003) risk score to 821 patients undergoing CEA in ICSS 
Score Number at risk Number of events Predicted event rate % (95% CI) Observed event rate % 95% CI for observed event rate 
0 117 3 3.3 2.6 (0.6 to 7.6) 
1 477 16 6.1 3.4 (2.0 to 5.4) 
2 190 9 9.5 4.7 (2.4 to 8.9) 
3 33 0 9.8 0.0  N/A 
4 4 0 15.8 0.0  N/A 
5 0 0  N/A  N/A N/A 
Totals 821 28  
 
χ2 test for trend p=0.49 
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Figure 9. Receiver operator curve for application of the Tu (2003) risk score to 
821 patients undergoing CEA in ICSS 
 
 
 
Darker line represents receiver operator curve 
Straight line represents area under curve =0.5 
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15.3.3 Kuhan (2001) risk score 
The results of applying the Kuhan score to the ICSS dataset are outlined in Table 8 
below. The risk of stroke or death within 30 days of CEA was 2.2% (95% CI 0.9% to 
4.8%) in patients with a score of 0, 3.7% (95% CI 2.1% to 6.3%) in those with a score 
of 1, 4.2% (95% CI 1.9% to 8.6%) in those with a score of 2 and 5.9% (95% CI 0.7% to 
20.0%) in those with a score of 3. 19/28 (67.9%) events occurred in lower risk groups 
(scores 0 to 1). 
The area under the receiver operator curve, illustrated in Figure 10, was 0.58 (95% CI 
0.47 to 0.68, p=0.18), indicating poor performance. 
  
8
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Table 8. Results of application of the Kuhan (2001) risk score to 821 patients undergoing CEA in ICSS 
Score Number at risk Number of events Predicted event rate % (95% CI) Observed event rate % 95% CI for observed event rate 
0 272 6 1.4 (0.9 to 2.1) 2.2 (0.9 to 4.8) 
1 349 13 3.2 (2.1 to 4.8) 3.7 (2.1 to 6.3) 
2 166 7 7.2 (2.5 to 19.0) 4.2 (1.9 to 8.6) 
3 34 2 15.3 (2.8 to 53.1) 5.9 (0.7 to 20.0) 
Totals 821 28  
 
χ2 test for trend p=0.15 
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Figure 10. Receiver operator curve for application of the Kuhan (2001) risk score to 
821 patients undergoing CEA in ICSS 
 
 
 
Darker line represents receiver operator curve 
Straight line represents area under curve =0.5 
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 Discussion and conclusion 15.4
15.4.1 Summary 
Each of the three risk scores tested in this analysis demonstrated a similar pattern of 
results: a small increase in the risk of stroke or death within 30 days of the procedure 
as the score increased, a lower observed risk of an event in ICSS than predicted, and 
the majority of events occurring in those groups of patients predicted to be at lower 
risk. None of the scores tested were sufficiently discriminating to be able to 
demonstrate a statistically significant difference in risk between groups of patients with 
different scores and all showed poor sensitivity and specificity. 
15.4.2 Limitations 
The ability to accurately test many existing published risk scores was limited by the 
data collected at baseline in ICSS, and the type of patients enrolled in the study. The 
ability to detect significant differences in risk between groups predicted to be at low or 
high risk was limited by the relative safety of CEA in ICSS and therefore the low 
number of outcome events. 
15.4.3 Discussion 
“Complications” following any surgical procedure are common throughout the world, 
occurring in up to 7% of those undergoing surgery even after specific interventions 
designed to reduce the risk of adverse outcome [93]. CEA may be different to some 
other types of major surgery due to the higher risk of stroke. Therefore there is a need 
for unique risk scores to identify the patient at high risk during revascularization. To be 
useful to clinicians, clinical risk scores should be effective, accurate and generalizable 
to other patient populations [166] [167]. 
The risk models analysed in this chapter did not satisfactorily discriminate between 
high- and low-risk groups of patients, and indeed excluding patients in higher risk 
groups for undergoing surgery would not have prevented the majority of periprocedural 
events. 
Other reasons that these models may not have performed so well include differences 
between the inclusion and exclusion criteria in the studies from which they are derived 
as compared to the criteria in ICSS, the influence of unmeasured factors such as 
operator experience or case volume [168], the type of hospital the surgery is carried 
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out in [165], and the influence of vascular features not routinely recorded at baseline in 
ICSS, such as ulcerated plaque or fresh thrombus in the carotid artery, which may 
double the risk of stroke after CEA [158]. There is also a need to update risk models as 
the higher risks observed in original trials as compared with new trials means that the 
models tested all over-estimate risk, a common finding in prediction models [169]. 
Other authors have examined the implications of applying the Rothwell score to a 
population of patients with symptomatic carotid stenosis in a single unit. Their results 
show a similar distribution of risk scores, with patients at lower predicted surgical risk 
(score 0 or 1) making up the majority of those undergoing surgery [170]. However, the 
rate of major stroke or death within 31 days of surgery in this study was only 0.75%, 
and the authors conclude that excluding high-risk patients from surgery in this series 
would have exposed the patients to a high risk of stroke on medical therapy alone with 
no reduction in the risk of a major event in the group undergoing surgery.  
As demonstrated in the European Carotid Surgery Trial, the factors that determine of 
the risk of surgery may well be different from those that determine the risk of stroke 
without treatment [98], and therefore patients should not be excluded from surgery 
because of a high predicted risk of CEA without taking into consideration the risk of 
stroke on secondary prevention medications alone [169]. In addition, the decision to 
operate or not is made more complex by the availability of CAS, which may in turn 
have different risk factors for periprocedural stroke or death as discussed in Chapter 
17. Authors drawing on data from the European trials of stenting vs surgery for 
symptomatic carotid stenosis have developed a clinical rule based on the patient’s sex, 
age, contralateral carotid occlusion and the presence of restenosis (the “SCAR” rule 
[171]) to address this issue and enable practitioners to choose between the two 
revascularization procedures in patients where revascularization is the preferred 
treatment option. 
15.4.4 Conclusions 
The observed risk of CEA in ICSS was acceptably low, and only 3.4% of patients 
suffered stroke or death within 30 days of the procedure. In each of the three risk 
scores evaluated, increasing score was associated with an increasing observed risk of 
the outcome, although this association did not reach statistical significance in any of 
the scores tested. The ability of the scores to discriminate between patients at low and 
high risk was poor as demonstrated by the area under the receiver operator curve 
measurements. Most events in ICSS occurred in groups of patients predicted to be at 
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low risk, and thus the overall performance of these scores was unsatisfactory, and 
routine use of the scores to predict operative risk is not supported. 
Patient risk factor profiles and the nature of surgical care for endarterectomy have 
changed since the landmark NASCET and ECST trials, and influence of risk factors for 
surgical complications from older studies may have diminished. The availability of non-
invasive detailed plaque imaging raises the possibility of developing modern and 
better-performing risk scores for the procedural risk of CEA or the risk of stroke on 
medical therapy alone, drawing on data from large-scale studies or ongoing trials 
randomizing patients to CEA such as ECST-2 [172], SPACE-2 [173] and ACST-2 [174]. 
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16. Risk factors for, and impact of, cranial nerve palsy and 
haematoma following carotid endarterectomy 
 Introduction 16.1
The results of landmark trials of carotid surgery versus medical therapy, NASCET 
[175], ECST [36] and the Veterans’ Affairs Trial [39] provided evidence that carotid 
endarterectomy for symptomatic atherosclerotic carotid stenosis greater than 50% 
provided a better long-term reduction in the risk of recurrent ipsilateral stroke than 
medical therapy. Subsequent trials of CEA vs carotid stenting have suggested that, in 
the short-term at least, surgery remains the safest treatment for carotid stenosis, with 
CAS carrying a higher risk of any stroke, myocardial infarction or death within 30 days 
of the procedure in meta-analysis (OR 1.44, 95% CI 1.15 to 1.80) [176]. However, the 
primary endpoints of these trials and analyses do not contain outcomes that specifically 
relate to the additional hazards of a surgical incision in the neck – namely cranial nerve 
palsy (CNP) and haematoma. 
Carotid stenting developed as an alternative to CEA in part to avoid these hazards of a 
surgical incision. The higher procedural risk associated with CAS in ICSS was mainly 
due to an excess of non-disabling stroke [82], and this disadvantage could be balanced 
by an increased incidence of cranial nerve palsy in the surgical group.  
CNP and haematoma are less extensively studied, but have long been recognised as 
complications of surgery [47], and these “minor outcomes” have been associated with 
an increased risk of major outcomes following surgery such as stroke or death [177]. 
Haematoma has been associated with an increased time spent in critical care following 
surgery [178]. Published case series have highlighted frequently-affected cranial 
nerves which include facial, vagal, hypoglossal and accessory [47] [48] [49] [50], and 
there is a potential for these injuries to cause significant postoperative disability. 
In this chapter the incidence and severity of CNP and haematoma in ICSS are 
examined to determine whether these complications merit consideration in the 
selection of revascularization procedure. Risk factors for their development are 
analysed. 
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 Methods 16.2
The ICSS trial protocol is summarized in Chapter 13 and presented in full in Appendix 
IV. As reported in Chapter 14, the type of anaesthetic or surgical technique for CEA 
were not specified in the trial protocol, but all patients were required to receive medical 
therapy for secondary prevention of stroke as appropriate. A technical case report form 
was completed for each endarterectomy procedure in ICSS and the occurrence of CNP 
or haematoma was reported by investigators. CNP was defined as “weakness or 
sensory impairment in the distribution of one of the cranial nerves attributed to 
treatment”. Each patient was re-assessed at their one-month follow-up appointment by 
a neurologist or investigator with an interest in stroke. CNPs were adjudicated at the 
trial office based on the best available clinical evidence, and deemed “disabling” if the 
patient’s modified Rankin Score (mRS) increased to 3 or more at 30 days post-
procedure where that increase was thought due to CNP. A questionnaire requesting 
additional information about the clinical impact of an event and whether or not 
symptoms eventually resolved (Appendix II) was sent to centres reporting CNP. 
Haematoma was defined as “bleeding attributed to the treatment of carotid narrowing”. 
Severe haematoma was defined as a haematoma “requiring new surgery, transfusion 
or prolonging hospital stay”.  
16.2.1 Statistical methods 
The data were analysed per-protocol, including only those patients in ICSS in whom 
the allocated CEA procedure was initiated. A procedure was deemed to have been 
initiated if local or general anaesthesia was administered prior to commencement of 
surgery. Patients who crossed-over to CAS or medical treatment were excluded. Risk 
factors for CNP and haematoma were examined sequentially in a univariable binomial 
regression analysis using maximum likelihood estimation. The risk ratio for each factor 
is given with corresponding 95% confidence interval. Wald tests were used for 
continuous and binary predictors, with an overall likelihood ratio test for categorical 
predictors of more than two levels. A multivariable model was developed using a 
forward stepwise-based approach with a significance level of 0.1 for predictors in 
univariable analysis accepted for inclusion in the multivariable model. Patients with 
missing data were excluded from each relevant analysis. Analyses were performed 
using Stata (Stata Corp. 2011. Stata Statistical Software: Release 12. College Station, 
TX, USA: Stata Corp LP). 
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 Results – cranial nerve palsy 16.3
858 patients in ICSS were randomized to CEA, of whom 821 had their allocated 
procedure initiated (95.7%). 4/821 patients (0.5%) died after initiation of the procedure 
but before 30-day follow-up. 45/821 (5.5%) patients were reported to have developed 
CNP between initiation of the procedure and 30-day follow-up. The results of an 
adjudication of which cranial nerves are affected are presented in Table 9. The facial 
nerve was involved in 23 patients, vagus nerve in 6, hypoglossal in 13, 
glossopharyngeal in 4, accessory in 1 and trigeminal in 1. The nerve affected was 
undetermined in two patients. In five patients more than one cranial nerve was 
affected. It was not possible to determine the nerve affected in two patients. 
One patient was judged to have disabling CNP at 30-day follow-up due to 
glossopharyngeal nerve palsy. This caused impairment of swallowing with subsequent 
need for naso-gastric feeding. 
In those patients in whom CNP resolution was confirmed (n=20), the median estimated 
duration of symptoms was 30 days (minimum 2 days, maximum 520 days). Permanent 
injury (i.e. without resolution of symptoms by the end of their follow-up in the trial) was 
reported in two patients who were followed-up over 6.4 and 3.1 years respectively.
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Table 9. Summary of cranial nerve palsies following endarterectomy in ICSS 
Cranial nerve Number of 
postoperative 
CNPs (n=50 in 45 
patients) 
Number of 
disabling 
CNPs (mRs≥3 
at 1 month 
due to CNP) 
Number of 
CNPs confirmed 
persisting after 
30 days 
Facial 23 0 4 
Hypoglossal 13 0 2 
Vagus 6 0 4 
Accessory 1 0 0 
Glossopharyngeal 4 1 1 
Trigeminal 1 0 0 
Undetermined 2 0 0 
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The results of univariable regression analysis to determine risk factors for the 
development of CNP within 30 days of the procedure are presented in Figure 11 below. 
The risk of CNP was increased in female patients (RR 1.90, 95% CI 1.08 to 3.36, 
p=0.03) and decreased in those with a high degree of contralateral carotid artery 
stenosis. Other demographic factors did not predict the risk of CNP. Technical factors, 
including the type of arterial reconstruction (standard closure, patch closure, eversion 
endarterectomy or vein interposition), type of anaesthesia or shunt use, were not 
significant predictors of risk. 
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Figure 11. Univariable predictors of the risk of cranial nerve palsy within 30 days of 
endarterectomy in 821 ICSS per-protocol participants in whom the procedure 
was initiated 
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Figure 11 continued 
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Figure 11 continued 
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The result of multivariable analysis of independent predictors of the risk of CNP is 
given in one possible model in Table 10 below. In this model, independent predictors of 
risk were cardiac failure (RR 2.66, 95% CI 1.11 to 6.40, p=0.03), female sex (RR 1.80, 
95% CI 1.02 to 3.20, p=0.04), the degree of contralateral carotid artery stenosis and a 
time of greater than 14 days from randomization in the trial to surgery (RR 3.33, 95% 
CI 1.05 to 10.57, p=0.04). 
The risk of cranial nerve palsy in the stenting group in ICSS was 1/828 (0.12%), and on 
adjudication this complication was attributed to a second procedure (CEA) carried out 
before 30-day follow-up. 
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Table 10. Independent predictors of risk of cranial nerve palsy within 30 days of 
endarterectomy in 805* ICSS per-protocol participants in whom the procedure 
was initiated 
Variable Adjusted Risk Ratio (95% CI) Adjusted p-value 
Cardiac failure 2.66 (1.11 to 6.40) p=0.03 
Female sex 1.80 (1.02 to 3.20) p=0.04 
Time from randomization 
to treatment >14 days 
3.33 (1.05 to 10.57) p=0.04 
Degree of 
contralateral stenosis  
0-50%  
50-69% 
>70% 
 
 
1.00 
1.18 (0.62 to 2.27) 
0.13 (0.02 to 0.91) 
Overall p<0.01 
 
 
p=0.62 
p=0.04 
  
* patients with missing data excluded from this analysis 
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 Results – haematoma 16.4
50/828 (6.1%) patients in the CEA arm of ICSS who had their procedure initiated 
developed haematoma. 28/828 (3.4%) patients had severe haematoma, requiring 
transfusion, re-operation or prolonging hospital stay. 12 of those 50 patients who 
suffered haematoma also developed CNP, and there was a significant association 
between these complications (p<0.01, Fisher’s exact test). 
The results of univariable analysis of factors predicting the risk of haematoma within 30 
days of CEA are presented in Table 11 below. Those factors that increased the risk of 
haematoma were preoperative prescription of anticoagulant medication (RR 1.83, 95% 
CI 1.04 to 3.23, p=0.04), atrial fibrillation (RR 2.29, 95% CI 1.08 to 4.85, p=0.03), 
previous cardiac bypass graft surgery (RR 2.46, 95% CI 1.37 to 4.42, p<0.01) and the 
duration of arterial clamping (RR per each 20 minutes 1.13, 95% CI 1.04 to 1.24, 
p<0.01). Factors that decreased the risk of haematoma were shunt use (RR 0.54, 95% 
CI 0.29 to 0.99, p=0.05), the prescription of an antiplatelet agent pre-procedure (RR 
0.44, 95% CI 0.21 to 0.93, p=0.03) and each increase in 1mmol/l of cholesterol at 
baseline (RR 0.69, 95% CI 0.55 to 0.88, p<0.01). Other demographic and technical 
factors were not statistically significant predictors of the risk of haematoma. 
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Table 11. Univariable predictors of risk of haematoma within 30 days of endarterectomy in 821 ICSS per-protocol participants in whom the 
procedure was initiated  
Variable Category 30-day risk of haematoma (%) Risk Ratio (95% CI) P-value 
Type of reconstruction Standard 9.3 1 0.26 
Eversion 8.2 0.87 (0.31 to 2.48) 
Patch 5.2 0.56 (0.31 to 1.02) 
Vein interposition 0 N/A 
Shunt use No 7.5 1 0.05 
Yes 4.0 0.54 (0.29 to 0.99) 
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Table 11 continued 
 
  
Variable Category 30-day risk of haematoma (%) Risk Ratio (95% CI) P-value 
Type of anaesthesia GA or LA/GA combined 6.5 1 0.69 
LA alone 5.6 0.86 (0.41 to 1.79) 
Antiplatelet agent pre-procedure No 13.5 1 0.03 
Yes 5.9 0.44 (0.21 to 0.93) 
Two or more antiplatelet agents pre-procedure No 6.0 1 0.50 
Yes 7.3 1.21 (0.69 to 2.11) 
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Table 11 continued 
 
  
Variable Category 30-day risk of haematoma (%) Risk Ratio (95% CI) P-value 
Anticoagulant pre-procedure No 5.5 1 0.04 
Yes 10.1 1.83 (1.04 to 3.23) 
Antiplatelet agent post-procedure No 9.2 1 0.26 
Yes 6.1 0.66 (0.32 to 1.36) 
Anticoagulant post-procedure No 5.6 1 0.11 
Yes 8.8 1.58 (0.91 to 2.76) 
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Table 11 continued 
Variable Category 30-day risk of haematoma (%) Risk Ratio (95% CI) P-value 
Sex Male 5.2 1 0.10 
Female 8.2 1.59 (0.92 to 2.74) 
Age <70 years 6.1 1 0.96 
≥70 years 6.0 0.99 (0.58 to 1.69) 
Treated hypertension No 5.0 1 0.36 
Yes 6.6 1.34 (0.71 to 2.52) 
  
 
1
0
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Table 11 continued 
 
 
  
Variable Category 30-day risk of haematoma (%) Risk Ratio (95% CI) P-value 
Cardiac failure No 6.1 1 0.85 
Yes 6.8 1.12 (0.36 to 3.45) 
Angina No 6.1 1 0.77 
Yes 6.9 1.15 (0.47 to 2.79) 
Previous MI No 5.4 1 0.07 
Yes 9.3 1.72 (0.95 to 3.11) 
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Table 11 continued 
 
 
  
Variable Category 30-day risk of haematoma (%) Risk Ratio (95% CI) P-value 
Previous CABG No 5.1 1 <0.01 
Yes 12.6 2.46 (1.37 to 4.42) 
Atrial fibrillation No 5.7 1 0.03 
Yes 13.0 2.29 (1.08 to 4.85) 
Other cardioembolic source of embolus No 6.1 1 0.99 
Yes 6.3 1.02 (0.15 to 6.92) 
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Table 11 continued 
 
 
Variable Category 30-day risk of haematoma (%) Risk Ratio (95% CI) P-value 
Diabetes No 6.3 1 0.81 
Yes 5.7 0.92 (0.47 to 1.80) 
Peripheral arterial disease No 6.3 1 0.68 
Yes 5.3 0.85 (0.39 to 1.85) 
Smoking status Never smoked 4.1 1 0.23 
Former smoker 7.4 1.82 (0.88 to 3.75) 
Current smoker 5.8 1.42 (0.60 to 3.34) 
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Table 11 continued 
 
Variable Category 30-day risk of haematoma (%) Risk Ratio (95% CI) P-value 
Treated hyperlipidaemia No 6.5 1 0.73 
Yes 5.9 0.91 (0.52 to 1.59) 
Degree of stenosis in treated artery 50 – 69% 6.9 1 0.75 
70 – 99% 6.0 0.87 (0.36 to 2.11) 
Degree of stenosis in contralateral artery 0 to 49% 6.1 1 0.39 
50 to 69% 7.4 1.20 (0.61 to 2.38) 
70 to 99% 2.9 0.47 (0.15 to 1.51) 
Occluded 8.6 1.40 (0.45 to 4.34) 
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Table 11 continued 
Variable Category 30-day risk of haematoma (%) Risk Ratio (95% CI) P-value 
Nature of ipsilateral index event Stroke 5 1 0.32 
Retinal stroke 4.5 0.91 (0.13 to 6.51) 
TIA 6.2 1.23 (0.65 to 2.33) 
Amaurosis fugax 9.7 1.94 (0.98 to 3.85) 
Multiple ipsilateral events prior to randomization No 5.5 1 0.33 
Yes 7.1 1.31 (0.76 to 2.25) 
Prior ipsilateral stroke No 5.8 1 0.45 
Yes 7.8 1.33 (0.64 to 2.75) 
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Table 11 continued 
 
Variable Category 30-day risk of haematoma (%) Risk Ratio (95% CI) P-value 
Baseline Rankin score 0 6.5 1 0.42 
1 6.2 0.95 (0.48 to 1.90) 
2 7.1 1.09 (0.57 to 2.07) 
3 1.4 0.21 (0.03 to 1.52) 
4 5.9 0.90 (0.13 to 6.33) 
5 0 N/A 
Side of procedure Left 5.9 1 0.77 
Right 6.3 1.08 (0.63 to 1.86) 
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Table 11 continued 
 
Variable Category 30-day risk of haematoma (%) Risk Ratio (95% CI) P-value 
Time from randomization to treatment ≤14 days 4.6 1 0.41 
>14 days 6.4 1.39 (0.64 to 3.03) 
Clamping time (Per 20 minutes of clamp applied) 6.9 1.13 (1.04 to 1.24) <0.01 
Duration of surgery (Per 20 minutes of operation length) 6.4 0.97 (0.86 to 1.10) 0.66 
Age (Per 5 years of age) 6.1 1.02 (0.88 to 1.18) 0.84 
Baseline systolic blood pressure (Per 10mmHg of blood pressure) 6.3 1.08 (0.98 to 1.21) 0.13 
Baseline diastolic blood pressure (Per 10mmHg of blood pressure) 6.2 0.92 (0.74 to 1.14) 0.45 
Baseline cholesterol (Per each mmol/l total cholesterol) 6.3 0.69 (0.55 to 0.88) <0.01 
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The results of multivariable analysis of predictors of the risk of haematoma are 
presented in Table 12 which illustrates one possible model. Independent predictors of 
increased risk were female sex (RR 2.03, 95% CI 1.13 to 3.62, p=0.02), atrial fibrillation 
(RR 2.38, 95% CI 1.07 to 5.27, p=0.03) and the prescription of an anticoagulant drug 
pre-procedure (RR 1.86, 95% CI 1.01 to 3.42, p=0.05). Independent factors that 
decreased the risk were shunt use (RR 0.40, 95% CI 0.21 to 0.80, p<0.01) and 
baseline cholesterol level (RR 0.68 per 1mmol/l increase, 95% CI 0.54 to 0.86, 
p<0.01).
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Table 12. Independent predictors of the risk of haematoma within 30 days of endarterectomy in 639 ICSS per-protocol participants in whom the 
procedure was initiated 
Variable Risk Ratio (95% CI) Adjusted p-value 
Anticoagulant pre-procedure 1.86 (1.01 to 3.42) 0.05 
Shunt use 0.40 (0.21 to 0.80) <0.01 
Cholesterol (per each mmol/l) 0.68 (0.54 to 0.86) <0.01 
Female 2.03 (1.13 to 3.62) 0.02 
Atrial fibrillation 2.38 (1.07 to 5.27) 0.03 
 
* patients with missing data excluded from this analysis 
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 Results – impact of adding CNP to ICSS trial primary outcomes 16.5
Table 13 below details the impact of adding cranial nerve palsy to the primary and 
secondary outcomes of ICSS in interim analysis [82]. For the combined outcome of 
stroke, MI, death or cranial nerve palsy within 30 days of CEA there was no significant 
difference in risk between CAS and CEA groups (RR 0.81, 95% CI 0.59 to 1.12, 
p=0.20). For the combined outcome of disabling stroke, disabling CNP or death only 
there was also no significant difference in risk (RR 1.41, 95% CI 0.79 to 2.51, p=0.24).
  
1
1
0
 
Table 13. Composite outcome events within 30 days of CEA versus CAS in ICSS 
Endpoint 
(within 30 days of the procedure) 
CAS (n=828) 
Events (%) 
CEA (n=821) 
Events (%) 
Risk ratio  
(95% CI) 
Risk difference  
(95% CI) 
P-value  
(Chi-squared) 
Stroke, MI or death 61 (7.4%) 33 (4.0%) 1.83 (1.21, 2.77) 3.3% (1.1, 5.6) <0.01 
Stroke, MI, death or CNP 62 (7.5%) 76 (9.3%) 0.81 (0.59, 1.12) -1.8% (-4.4, 0.9) 0.20 
 
Disabling stroke or death 26 (3.1%) 18 (2.2%) 1.43 (0.79, 2.59) 0.9% (-0.6, 2.5) 0.23 
Disabling stroke, disabling CNP or 
death 
27 (3.3%) 19 (2.3%) 1.41 (0.79, 2.51) 
 
0.9% (-0.6, 2.5) 0.24 
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 Results – influence of sex on combined outcomes 16.6
Table 14 below summarises the findings of both Chapter 14 and this chapter 
regarding the influence of sex on the outcomes of CNP, haematoma, or stroke, 
MI or death. Women had a statistically significantly higher risk of each of these 
outcomes in the surgical arm of ICSS. When these outcomes were combined, the 
risk of any surgical complication (i.e. CNP, haematoma, stroke, MI or death) in 
the endarterectomy arm of ICSS was considerably higher in women (19.7%) 
compared with men (10.9%, p<0.01). 
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Table 14. Results of univariable binomial regression analyses of female vs male in 
821 per-protocol CEA patients in whom the allocated procedure was initiated 
30-day outcome Number events / Number patients (%) Risk Ratio (95% 
CI), p-value 
Females Males 
CNP 20/243 (8.2%) 25/578 (4.3%) 1.90 (1.08, 3.36), 
p=0.03 
Haematoma 20/243 (8.2%) 30/578 (5.2%) 1.59 (0.92, 2.74), 
p=0.10 
Stroke, MI or death 15/243 (6.2%) 18/578 (3.1%) 1.98 (1.02, 3.87), 
p=0.05 
    
CNP, haematoma, 
stroke, MI or death 
48/243 (19.7%) 63/578 (10.9%) 1.81 (1.28, 2.56), 
p<0.01 
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 Discussion and conclusion 16.7
16.7.1 Summary 
5.5% of ICSS patients who were allocated to carotid endarterectomy, and in whom the 
procedure was initiated, developed CNP. 6.1% developed haematoma within 30 days. 
There was a statistically significant association between the two outcomes. The most 
commonly-affected nerves were facial and hypoglossal, although only one CNP was 
classified as disabling at 30 days. Independent predictors that increased of the risk of 
cranial nerve palsy were cardiac failure, female sex, the degree of contralateral carotid 
stenosis and a time between randomization and surgery of >14 days. The risk of 
haematoma was raised in female patients, those with atrial fibrillation and those taking 
anticoagulant medications pre-procedure. 
16.7.2 Discussion - cranial nerve palsy 
The European Carotid Surgery Trial found a motor CNP risk of 5.1% and a long-term 
CNP risk of 0.5% at 4 months [179]. Similarly, the North American Symptomatic 
Carotid Endarterectomy Trial found a postoperative risk of CNP of 8.6%, the majority of 
which were mild in severity [175]. The finding of a 5.5% risk of CNP in ICSS, the 5.6% 
risk of CNP in 6878 patients included in the Vascular Study Group of New England 
study [180] and recent results from CREST showing a CNP risk of 4.6%, four-fifths of 
which resolved within 1 year [181], suggests that the risk of CNP following CEA has 
remained relatively constant over time. However, reassuringly, the risk of disabling 
CNP is small – around 1 in 1000 operations. The symptoms of CNP may persist for 
several weeks, but half of patients in whom the lesion resolves will experience an 
improvement within 30 days. 
The higher risk in female patients has not previously been described, and this finding is 
worth confirming in other patient groups. It may be that surgical anatomy is more 
challenging in female patients, who have a smaller diameter of carotid artery on 
average [142], leading to inadvertent trauma to the cranial nerves running adjacent. 
Female patients were also at risk of haematoma, perhaps for the same reason. 
16.7.3 Discussion - haematoma 
Female sex, anticoagulants and atrial fibrillation were independent risk factors for the 
development of neck haematoma in this patient population. Although less well-studied 
than cranial nerve palsy and major outcomes, previously-identified causes of 
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haematoma following CEA have included postoperative hypertension, anticoagulants 
and antiplatelet agents [182] [183] (which might cause increased bleeding), as well as 
inadequate surgical drainage [184]. Independent risk factors in another study were 
found to be non-reversal of heparin, intraoperative hypotension and carotid shunt 
placement [178]. 
A risk of haematoma in ICSS of 6.1% is similar to the risk of “wound complications” 
(haematoma and infection) of 6.0% seen in a large multicentre case series of 1998 
patients undergoing CEA [51], and a severe haematoma risk of 3.4% is similar to the 
reported risk of requiring re-exploration in patients undergoing CEA while taking 
antiplatelet medication of 3.6% [52]. 
Antiplatelet agents prevent recurrent stroke in patients with symptomatic carotid 
stenosis [21] [185] [186] [187]. However, there is concern that clopidogrel, or 
clopidogrel in combination with aspirin increases the risk of haematoma following 
surgery [52]. Importantly, in ICSS there was no evidence that dual antiplatelet therapy 
increased the risk of haematoma.  Indeed, the clinical practise of most UK surgeons is 
to continue single or dual antiplatelet therapy in the perioperative period where patients 
are already taking these medications [188].  
The association between neck haematoma and preoperative anticoagulation is not 
unexpected, but our results reinforce the importance of careful attention to haemostasis 
before closure of the wound.  
16.7.4 Discussion – adding CNP to composite trial outcomes 
Some systematic reviews have included CNP in a composite outcome of death or 
neurological complications up to 30 days after treatment [176]. In ICSS, the total 
number of events in the composite outcome of any stroke, myocardial infarction or 
death was greater after CEA compared with CAS, the numbers in the composite 
outcome of disabling stroke, disabling CNP or death were greater after CAS compared 
with CEA, but neither difference was statistically significant. Thus it is unlikely to be 
useful to include CNP in the composite endpoints of future trials, and it would not be 
appropriate exclude patients from CEA because of an increased risk of CNP as 
compared with CAS. 
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16.7.5 Discussion – the influence of sex on composite trial outcomes 
Women were at higher risk of any surgical complication within 30 days of CEA in ICSS. 
Indeed, the combined risk of CNP, haematoma, stroke, MI or death reached nearly 
20%. While this finding may inform discussions with patients about procedural risk, it 
should be remembered that female sex was not an independent predictor of the risk of 
a major complication (stroke, MI or death) and that the impact of CNP appears to be 
limited in duration and severity. Nonetheless, outcome data captured in clinical trials 
may underestimate the quality of life impact of, for example, permanent facial nerve 
palsy. 
16.7.6 Limitations 
Baseline and technical information regarding the procedure was missing for some 
patients, limiting the ability to include them in multivariable modelling. Information about 
the clinical effects and duration of CNP was limited in some patients. Multiple 
comparisons in the univariable analysis raise the possibility of type 1 (false positive) 
error, and no statistical correction was made for the number of tests carried out. 
Patients were not randomized to particular techniques or medication regimens, and it is 
likely that unmeasured confounders such as surgical expertise also influence the risk of 
CNP or haematoma. 
16.7.7 Conclusion 
Long-term disability due to cranial nerve palsy following carotid endarterectomy 
appears to be rare. As a result of this finding, CNP is unlikely to be included in 
composite endpoints of future trials involving carotid surgery. However, CNP remains 
common following CEA and is associated with haematoma. The results presented here 
should give surgeons confidence to reassure patients that long-term disability due to 
cranial nerve palsy following carotid endarterectomy is rare, to continue antiplatelet 
therapy around the time of surgery, and to carefully consider the risk-benefit ratio for 
revascularization in female patients. 
Measurement of quality of life after CNP or haematoma might reveal that apparently 
“minor” clinical outcomes have disproportionate effects on the patient’s well-being, and 
future studies should focus on the quality of life impact of these complications.  
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17. Risk factors for stroke, myocardial infarction or death 
following carotid stenting 
 Introduction 17.1
Carotid artery stenting was developed as a less-invasive alternative to carotid 
endarterectomy for the prevention of TIA or stroke in patients with atheromatous 
carotid stenosis. However, in interim analysis of the International Carotid Stenting 
Study the risk of stroke, myocardial infarction or death within 30 days of 
revascularization was higher in those patients who received their allocated CAS 
procedure than in those who received their allocated CEA procedure (7.4% vs 4.0%, 
p<0.01) [82]. 
Endovascular revascularization is a complex procedure requiring attention to pre-
procedure medication, haemodynamic control, stent design and optimal adjuvant 
medical therapy [153]. Optimal stenting technique, patient selection and processes of 
care for CAS have yet to be determined. For example, the use of cerebral protection 
devices has become more common in recent years in the UK [97], but there is 
conflicting evidence of their efficacy. 
This analysis examines patients allocated to CAS in ICSS to determine whether there 
are specific techniques, processes of care or baseline patient characteristics that are 
associated with stroke, MI or death within 30 days of the procedure. 
 Methods 17.2
17.2.1 The stenting procedure 
The trial protocol and inclusion/exclusion criteria for ICSS are summarised in Chapter 
13 and presented in full in Appendix IV. Patients with more than 50% recently-
symptomatic carotid stenosis were eligible for randomization in the study if they were 
felt suitable to undergo either CEA or CAS. Patients were excluded from enrolment in 
the trial if the stenosis was due to non-atheromatous disease, if cardiac bypass was 
planned within 1 month of the carotid procedure, or if there was previous stenting or 
surgery on the symptomatic artery. Additionally, patients were specifically excluded 
from CAS if their vascular anatomy was “unfavourable” – if there was vessel tortuosity 
proximal or distal to the stenosis, visible thrombus, proximal CCA disease or “pseudo-
occlusion” (99% or more stenosis but with normal distal runoff on angiography). 
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Centres enrolling patients into ICSS were required to provide evidence that CAS 
interventionists were sufficiently experienced in the procedure, having performed a 
minimum of 50 stenting procedures and at least 10 of those in the carotid territory with 
an acceptable complication rate. More inexperienced interventionists joined the trial in 
probationary centres where procedures were supervised by a proctor until such time as 
the required level of competency was achieved. 
CAS in ICSS was performed in accordance with trial protocol: aspirin and clopidogrel 
prior to the procedure was recommended, as was the use of a CPD whenever the 
interventionist thought one could be safely deployed. CPDs and stents used at each 
centre were approved by the ICSS steering committee and were CE-marked. The 
administration of heparin during the procedure was mandatory. A CAS technical data 
form was returned to the trial office by interventionists giving details of the equipment 
and medications used in the procedure. 
17.2.2 Outcome events 
The combined endpoint of stroke, MI or death within 30 days of CAS is examined in 
this analysis, and was reported to the trial office by investigators at each centre. For 
each of these outcomes, confirmatory evidence was required (brain scan in the case of 
stroke, ECG and / or cardiac enzyme levels for MI, death certificate and autopsy report 
if available for death). Stroke was defined as “an acute disturbance of focal 
neurological function with symptoms lasting more than 24 hours resulting from 
intracranial vascular disturbance”. Two out of the three following criteria were required 
for a diagnosis of MI – a clinical history of chest discomfort lasting more than 30 
minutes, the development of specific ECG abnormalities consistent with MI or cardiac 
enzyme levels more than twice the upper limit of the reference range. Two 
investigators from the trial office adjudicated each event and then it was sent to a third, 
independent, clinician for adjudication. Disagreements between investigators were 
resolved by consensus after a second independent review. 
17.2.3 Statistical analysis 
A per-protocol analysis, including only those patients randomized to CAS in ICSS in 
whom the stenting procedure was initiated, is presented in this chapter. Stenting was 
deemed initiated if the patient received local or general anaesthesia prior to the 
procedure. Patients crossing over to surgery or best medical therapy were therefore 
excluded. Risk factors for stroke, MI or death within 30 days of the CAS procedure 
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were investigated sequentially in a binomial regression model. Patients with missing 
data were excluded from each relevant analysis. The effect of cerebral protection type 
and stent type could only be investigated in patients in whom these devices were 
deployed, and the effect of post-stent dilation was examined only in those patients in 
whom a stent was deployed. A multivariable model was developed using a forward 
stepwise approach including variables potentially available for all CAS patients, 
therefore excluding CPD type, stent type and post-dilation. A p-value of <0.05 was 
considered “significant” in all analyses. Analyses were performed with Stata 
(StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: 
StataCorp LP). 
 Results 17.3
17.3.1 Patient and procedure characteristics 
1713 patients were randomized in ICSS, of whom 853 were allocated to CAS. In this 
group, 828 procedures were initiated. Baseline characteristics of included patients are 
presented in Figure 12 below. In summary, 70.4% of patients were male, and 53.5% of 
patients were over the median age of 70 years. A stent was deployed in 752/816 
(92.2%) procedures for which data were available. 367/816 (48.8%) of these 
procedures used an open-cell design of stent, 371/816 (49.3%) used a closed-cell 
stent. A CPD was deployed in 585/828 (70.6%) procedures, of which the majority 
(n=464) were distal filter-type devices. 71.7% of patients were taking the combination 
of aspirin and clopidogrel prior to the procedure. 
17.3.2 Timing and cause of events 
61/828 (7.4%) patients undergoing CAS suffered stroke, MI or death within 30 days of 
the procedure. The events reported in these patients were 58 strokes, three myocardial 
infarctions and one death unrelated to stroke or MI. One patient with stroke suffered a 
subsequent (fatal) MI. 44/61 (72.1%) events occurred on the day of the procedure itself 
(day 0), of which 21 were adjudicated to have occurred during the procedure. 21 
occurred between the end of the procedure and day 1. In one patient a retinal infarct 
was noted during follow-up and attributed to the procedure on day 0, but the timing in 
relation to CAS was uncertain. In one further patient there was insufficient information 
to determine the timing of the event. 
Table 15 below summarizes the immediate cause or timing of the event, as reported by 
the interventionist, in the 21 patients whose event was adjudicated to have occurred 
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during the procedure itself. The majority of these events (12/21) were precipitated by 
the insertion, retrieval or use of endovascular equipment around the site of the lesion 
itself. 
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Table 15. Reported immediate cause or timing of event in patients undergoing 
CAS in ICSS 
Precipitant Number of events (n=21) 
Uncertain / undetermined 6 
Post-dilation 5 
Stent deployment 4 
CPD manipulation 3 
Intra-operative hypotension 2 
Catheter angiography 1 
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17.3.3 Demographic and technical risk factors for stroke, MI or death within 30 
days of the procedure 
The results of univariable analysis of the influence of baseline demographic and 
technical risk factors on the risk of stroke, MI or death within 30 days of CAS are 
presented in Figure 12. The risk of the combined outcome increased 1.24 times for 
each 5 years increase in age (95% CI 1.07 to 1.42, p<0.01). The risk was also 
increased in patients with an open-cell carotid stent (RR 1.86, 95% CI 1.09 to 3.19, 
p=0.02) and in patients with atrial fibrillation (RR 2.31, 95% CI 1.16 to 4.61, p=0.02). 
The risk was lower in those who were current or former smokers at baseline as 
compared to those who had never smoked (RR 0.25, 95% CI 0.10 to 0.63 and RR 
0.77, 95% CI 0.46 to 1.29 respectively, global p<0.01) and those with amaurosis fugax 
as the initial event prompting randomization in the trial as compared with those who 
suffered stroke as the index event (RR 0.25, 95% CI 0.08 to 0.80 respectively, global 
p<0.01). The risk was also lower in patients undergoing a right-sided procedure (RR 
0.54, 95% CI 0.32 to 0.91, p=0.02). Patients in whom a CPD was used had a higher 
risk of stroke, MI or death with nearly double the number of events, but this increase 
was not statistically significant (RR 1.86, 95% CI 0.98 to 3.52, p=0.06). 
Patients treated in centres who enrolled more than 50 patients in ICSS experienced a 
lower risk of stroke, death or MI within 30 days of CAS (RR 0.60, 95% CI 0.37 to 0.96, 
p=0.04), although the results in provisional centres where procedures were supervised 
were not statistically different from those at more experienced centres. 
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Figure 12. Univariable predictors of the risk of stroke, myocardial infarction or death 
in 828 patients undergoing CAS in whom the procedure was initiated 
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Figure 12 continued 
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One possible multivariable model investigating the effect of all variables potentially 
available for all CAS patients (i.e. excluding those in whom a stent or CPD was not 
deployed) is presented in Table 16. Independent predictors of the risk of stroke, MI or 
death within 30 days of CAS were increasing age (RR 1.17 per 5 years increase, 95% 
CI 1.01 to 1.37, p=0.04) and a right-sided procedure (RR 0.54, 95% CI 0.32 to 0.91, 
p=0.02). The risk was significantly lower in patients taking the combination of aspirin 
and clopidogrel prior to the procedure, as compared with any other antiplatelet regimen 
(RR 0.59, 95% CI 0.36 to 0.98, p=0.04), and higher in those with retinal stroke as the 
index event prompting randomization in the trial. 
The model was reconstructed in a sensitivity analysis to exclude those patients in 
whom a stent was not deployed. In this model, the use of an open-cell stent conferred 
higher risk (RR 1.92, 95% CI 1.11 to 3.33, p=0.02).  
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Table 16. Independent predictors of risk of stroke, MI or death within 30 days of CAS in 748 ICSS per-protocol participants in whom the 
procedure was initiated and for whom complete predictor data are available. Results obtained from multivariable binomial regression. 
Variable Adjusted Risk Ratio (95% CI) P-value 
Age (per 5 years increase) 1.17 (1.01 to 1.37) 0.04 
Smoking status 
    Never smoked 
    Ex- smoker 
    Current smoker 
 
1.00 
0.86 (0.52 to 1.43) 
0.33 (0.13 to 0.85) 
 
N/A 
0.55 
0.02 
Right-sided procedure 0.54 (0.32 to 0.91) 0.02 
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Table 16 continued 
Variable Adjusted Risk Ratio (95% CI) P-value 
Type of index event pre randomization in 
ICSS 
    Stroke 
    Retinal Stroke 
    TIA 
    Amaurosis Fugax 
 
 
1.00 
2.47 (1.11 to 5.52) 
0.99 (0.58 to 1.68) 
0.32 (0.10 to 1.02) 
 
 
N/A 
0.03 
0.96 
0.06 
Type of antiplatelet regimen 
    Any other antiplatelet 
    Aspirin and  clopidogrel in combination 
 
1 
0.59 (0.36 to 0.98) 
 
N/A 
0.04 
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 Discussion and conclusion 17.4
17.4.1 Summary 
The risk of stroke, myocardial infarction or death within 30 days of carotid stenting in 
ICSS was significantly higher in older patients, those undergoing a left-sided 
procedure, in non-smokers, in patients who were not taking the recommended 
combination of aspirin and clopidogrel and in those with retinal stroke as the index 
event prompting randomization on the trial. Restricting the analysis to only those 
patients in whom a stent was deployed revealed the use of an open-cell stent design to 
be an independent predictor of increased risk compared with a closed-cell design.  
17.4.2 Discussion 
Evidence is building that CAS is less safe in older patients. Individual patient data 
meta-analysis from the three European trials of CAS vs CEA found that although the 
risks of stroke or death within 120 days of revascularization was similar between 
patients allocated to CAS or CEA under the age of 70 years (5.8% vs 5.7%, RR 1.00, 
95% CI 0.68 to 1.47), the risk of these complications with CAS were much higher in 
patients 70 years or older (12.0% vs 5.9%, RR 2.04, 95% CI 1.48 to 2.82, interaction 
p<0.01) [189]. There was no reduction in the severity of events in older patients. The 
CREST study also showed a similar effect of age [84]. Age should therefore be taken 
into account when selecting patients for the procedure, and the use of CAS in patients 
over 70 years old should be largely reserved for those with a clear indication (e.g. 
“hostile” surgical anatomy or post-radiotherapy). 
Patients in ICSS in whom an open-cell stent was deployed were at higher risk of 
complications, a finding echoed in other studies. A higher rate of ipsilateral stroke or 
ipsilateral stroke death was found in patients treated with an open-cell stent in the 
SPACE study (OR 2.13, 95% CI 1.07 to 3.76) [190], and similar trends have been 
found by other groups [191] [192]. The effect of stent design may be more pronounced 
in symptomatic patients because plaque is unstable, ulcerated or recently-complicated 
with fresh thrombus which is stabilized by the greater coverage of closed-cell stents 
with a smaller open area between cell struts, containing debris generated during 
deployment of the stent to the site of the lesion. The structural difference between 
open- and closed-cell stents is illustrated in Figure 13 below. 
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Figure 13. A scanning electron micrograph of closed-cell stent design before (a) 
and after (b) expansion, and an open-cell stent before (c) and after (d) 
expansion. 
 
 
 
From [193] with kind permission from Lippincott Williams and Wilkins / Wolters Kluwer 
Health  
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CPDs were developed for use in CAS in the assumption that they would reduce 
embolism during stent deployment or lesion dilation. However, it is conceivable that the 
passage of the device itself may produce particulate debris, and the deployment of a 
filter could damage the distal vessel endothelium such that post-procedure thrombus 
may form. The combination of findings in this chapter that many procedural minor 
strokes were caused by manipulation of equipment around the site of the lesion itself,  
and that certain types of patients were at higher risk of stroke, suggests that perhaps 
both the generation of a shower of emboli during stenting and the brain’s ability to 
tolerate these may be the clinical mechanism of causation in procedural stroke [194]. 
A systematic review comparing older case series with results after the introduction of 
CPDs appeared to confirm the case for their use [195], but these results could be 
improved by changes in patient selection and other developments in CAS technique 
over time. The EVA-3S trial issued a clinical alert after randomizing 80 patients when 
their finding that the 30-day risk of stroke in patients undergoing unprotected CAS was 
four times that of those undergoing protected CAS [63], but the excess strokes in this 
group may not have been down to CPD use alone, since only two strokes in those 
treated without a CPD occurred on the day of the procedure itself. This analysis found 
that CPD use in ICSS did not protect against stroke, MI or death within 30 days of the 
procedure. Indeed ICSS patients enrolled in the ICSS-MRI Substudy in centres with a 
general policy of CPD use experienced a 2.7-fold higher risk of new ischaemic brain 
lesions seen on diffusion-weighted MRI following the procedure than those enrolled in 
other centres where CPDs were not routinely used [64]. 
Two small randomized trials of CAS with and without filter-type CPDs have reported 
results. One carried out in the United States showed no reduction in new DWI lesions 
post-procedure in the CPD group [196], while the other which enrolled patients in the 
UK demonstrated an increase in new ischaemic brain lesions post-procedure and 
procedural micro-emboli as detected by transcranial Doppler in the CPD group [197]. 
The predominant design of CPD used in ICSS was a distal filter type, and newer 
systems such as flow reversal devices may be more effective [65]. In the meantime, 
the routine use of CPDs for the prevention of procedural stroke cannot be supported by 
the results of ICSS and further research on newer devices is required to ensure their 
safety and efficacy. 
The reduction in 30-day neurological complications in patients taking combination 
antiplatelet therapy to cover their CAS procedure has been described before [198], and 
reinforces the recommendation that all CAS patients receive aspirin and clopidogrel 
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where appropriate to prevent thrombus forming on the metallic stent struts. The finding 
that smoking was associated with a lower risk of complications is more difficult to 
explain, and has not previously been described. It is therefore possibly a chance 
finding, or one due to residual confounding. 
It is interesting to contrast findings regarding the possible procedural precipitants of 
stroke with findings from the Stenting and Aggressive Medical Management for 
Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) study [199]. This 
trial involved potentially more hazardous intracranial artery stenting, but included those 
with carotid and vertebral disease. Of 19 periprocedural ischaemic strokes, 12 were 
thought to have been caused by perforator artery occlusion and 2 by delayed stent 
occlusion. Embolism was only thought to be a contributing event in 5 patients. These 
different mechanisms of stroke aetiology perhaps reflect the unique hazards of 
intracranial artery stenting as compared with carotid stenting, but the contribution of 
embolism to the mechanism of stroke in several patients highlights the extra danger of 
stenting in symptomatic patients who may have fresh thrombus at the site of the 
stenosis. 
17.4.3 Limitations 
The technology of carotid stenting is developing rapidly and findings related to the 
specific stent types and device types used in ICSS may be superseded as newer 
equipment enters common use. In some patients, information regarding baseline risk 
factors was unavailable, and these patients were excluded from each relevant analysis. 
Some procedures were abandoned before the deployment of a CPD or stent, and 
these patients were not included in multivariable modelling which included as many 
patients as possible with baseline predictor data. Multiple comparisons have been 
made without statistical correction, raising the possibility of a Type I (false positive) 
error. This is not a randomized comparison of stenting technique or processes or care, 
and it is possible that unmeasured confounders are associated with the risk of stroke, 
MI or death within 30 days of CAS. The limited number of outcome events in ICSS 
limited the number of variables supported in a multivariable model. 
17.4.4 Conclusion 
Interventionists selecting patients suitable for CAS should take into account risk factors 
for periprocedural stroke, MI or death that include the patient’s age, the side of the 
procedure, and the nature of the event prompting intervention. Until such time as 
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consistently safe results can be demonstrated in older patients, stenting for those over 
the age of 70 should have a clear indication (surgically-inaccessible stenosis, post-
radiotherapy or the patient’s wish to avoid surgery, for example). Those who require 
revascularization of the left carotid artery should be aware of a potentially higher 
procedural risk – although this of course should be balanced against the risk of stroke 
without treatment. The results presented in this chapter favour the use of a closed-cell 
stent without routine deployment of a cerebral protection device. They also reinforce 
the need for dual antiplatelet cover with aspirin and clopidogrel in all patients.  
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18. Vascular anatomical factors influencing the risk of new 
ischaemic brain lesions following carotid artery stenting 
 Introduction 18.1
Patients in the CAS arm of ICSS experienced a higher rate of stroke, MI or death within 
30 days of the procedure than patients in the CEA arm, mostly attributable to an 
excess of minor stroke [82]. Patients enrolled in the ICSS-MRI Substudy were 
examined further with pre- and post-procedure brain scans to determine the number 
and volume of new diffusion-weighted imaging (DWI) lesions – indicative of ischaemia 
or infarction. 50% of patients allocated to CAS in the substudy were discovered to have 
developed at least one new ischaemic brain lesion due to the procedure, compared 
with just 17% of those allocated to CEA (OR 5.21, 95% CI 2.78 to 9.79, p<0.01) [64]. 
Lesions were more numerous in patients undergoing CAS, and were also more likely to 
occur in cortical and adjacent white matter areas than those in CEA patients [200]. 
CAS is a technically demanding procedure that requires the passage of equipment 
through the vascular tree up to and beyond the atherosclerotic lesion. There is 
emerging evidence from the randomized clinical trials of CAS versus CEA that patients 
undergoing CAS procedures performed by operators with low annual volumes of cases 
may be at higher risk of stroke or death within 30 days of the procedure [126]. 
A number of vascular anatomical characteristics have been proposed by expert opinion 
as contributing to a technically challenging procedure [123] [201]. This analysis 
investigates the influence of baseline patient characteristics, procedural technique and 
variation in vascular anatomy seen on pre-stenting catheter angiography on the risk of 
new DWI brain lesions following CAS in patients enrolled into the ICSS-MRI Substudy. 
 Methods 18.2
18.2.1 The ICSS-MRI Substudy 
The ICSS-MRI Substudy is discussed in Chapter 13 and the full protocol is supplied in 
Appendix V. To be eligible for randomization in ICSS patients over 40 years old with 
recently-symptomatic carotid stenosis were required to be suitable for revascularization 
by either CAS or CEA. Importantly, they were excluded from randomization if they 
presented with a stenosis that was known to be unsuitable for stenting due to pseudo-
occlusion (distal collapse of the artery with “string sign” indicating poor runoff from the 
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lesion), tortuous vascular anatomy, proximal common carotid artery stenosis or visible 
thrombus on vascular imaging. CAS was carried out by accredited interventionists 
according to trial protocol described in Appendix IV. CPD use was recommended 
whenever the interventionist could “safely deploy” one, but was not mandatory. 
Operators were required to use devices approved by the trial steering committee. 
Patients who additionally enrolled in the ICSS-MRI Substudy underwent pre-procedure 
brain MRI at either 1.5T or 3.0T field strength carried out up to a week before 
revascularization. MRI was then repeated post-procedure at one to three days after 
CAS and then at one month after CAS. Scan protocols contained diffusion-weighted 
imaging (DWI) sequences to identify recent ischaemic brain lesions. 
Patients underwent carotid stenting as per the ICSS protocol. This analysis includes 
patients allocated to CAS in whom the stenting procedure was initiated and for whom a 
baseline or pre-stenting catheter angiogram was available and of sufficient quality to be 
analysed. 
18.2.2 Analysis of brain and vascular imaging 
A “lesion count” for each DWI sequence was obtained by the consensus reading of a 
neurologist and neuroradiologist blind to the patient’s identity, the date and the nature 
of the scan (e.g. pre- or post-procedural). The location (ipsilateral or contralateral) and 
the total volume of lesions were also recorded. 
Catheter angiograms showing vascular anatomy before stent insertion were evaluated 
initially by one trained reader and then read again by the author to enable inter-rater 
reliability to be calculated. Both readers were blind to the patient’s identity and the 
selected outcome variable (number of new ischaemic brain lesions on post-procedure 
DWI MRI). Standard definitions were agreed between the ICSS-MRI Substudy 
investigators prior to the first scans being read. The degree of carotid artery stenosis 
was calculated using the formula developed in NASCET [40], being the ratio of the 
smallest diameter of the ICA at the level of the lesion divided by the distal ICA diameter 
expressed as a percentage. ECA stenosis was measured in the same way, using the 
distal ECA diameter. “Ulceration” and “irregularity” of the atherosclerotic plaque was 
also defined according to the NASCET investigators’ methods [202], as illustrated in 
Figure 14. “Pinhole” stenosis was defined as a luminal diameter too small to accurately 
measure but with normal distal run-off in the vessel and no distal collapse. Many digital 
copies of catheter angiography in the ICSS-MRI Substudy did not contain calibration 
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information, so “lesion length” was defined as the distance between proximal and distal 
shoulders of the atherosclerotic lesion where the luminal diameter decreased to 20% of 
its maximum expressed as a fraction of the common carotid artery on angiographic 
views that most elongated that stenosis [203], as illustrated in Figure 15. A “diseased 
CCA” was one that had the appearance of luminal stenosis or irregularity consistent 
with atherosclerosis. The contralateral carotid artery was not always imaged in the 
sequences available to the readers, so the measurement of contralateral carotid 
stenosis provided by trial investigators at the time of the patient’s enrolment in ICSS 
was used in the analysis. Images were prepared and analysed using Osirix MD, 
(Pixmeo SARL, 2012). 
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Figure 14. Determination of smooth (D, E), irregular (C) or ulcerated (A, B) 
atheromatous plaque at the carotid bifurcation 
 
 
From [202] with kind permission from Lippincott Williams & Wilkins / Wolters Kluwer 
Health
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Figure 15. Measuring the length of maximal stenosis in three vascular anatomical profiles 
CCA = common carotid artery, ICA = internal carotid artery, ECA = external carotid artery 
Adapted from [203] under the terms of the Creative Common Attribution License. Original figure ©The Authors.  
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18.2.3 Statistical Methods 
Each demographic, vascular or anatomical risk factor was investigated sequentially in a 
negative binomial regression model, with the number of new DWI brain lesions on post-
procedure scan set as the dependent (outcome) variable. Comparisons between 
groups are expressed as an odds ratio with 95% confidence interval, demonstrating 
how many times more or less lesions occurred. Factors with statistical significance, 
p<0.05, were considered for entry into a multivariable model constructed using a 
forward stepwise approach. Patient with missing data were excluded from each 
relevant analysis. Post-hoc sensitivity analyses for lesions ipsilateral to the treated 
artery only as the outcome variable and for lesion volume as the outcome variable 
were carried out in the same manner. Inter-rater reliability was calculated to produce a 
kappa (κ) statistic and p-value, interpreted as proposed by Landis and Koch [204]. All 
analyses were performed using SPSS version 22.0.0.0 (IBM Corp, 2013). 
 Results 18.3
18.3.1 Baseline patient characteristics 
A total of 127/231 patients randomized in the ICSS-MRI Substudy were allocated to 
CAS. Baseline (n=7) or pre-procedural (n=110) catheter angiograms with views 
sufficient for analysis were available for 115 patients. The baseline demographic 
characteristics and vascular risk factors of the patients included in this analysis are 
shown in Table 17. Measured vascular anatomical features are shown in Table 18 
below. 
The median age of patients in this analysis was 71 years. 70% of patients were male. A 
protection device (CPD) was used in 46/115 (40%) procedures, of which 91% were 
distal filters and 9% were flow reversal systems. 53% procedures were on the right 
carotid artery, 47% on the left.  
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Table 17. Demographic and procedural characteristics of 115 patients allocated to 
CAS in the ICSS-MRI Substudy for whom adequate pre-procedure catheter 
angiography was available 
Parameter Number of patients (%) n=115 
Right-sided procedure 61 (53%) 
Cerebral protection device used 46 (40%) 
Age (mean) 70.4 years 
Female 34 (30%) 
Treated hypertension 77 (67%) 
Diabetes (any type) 22 (19%) 
Treated hyperlipidaemia 71 (62%) 
Current or former smoker 87 (76%) 
Coronary heart disease 26 (23%) 
Other cardioembolic source of thrombus 7 (6%) 
Cardiac failure 3 (3%) 
Peripheral arterial disease 21 (18%) 
Contralateral carotid occlusion 7 (6%) 
Contralateral carotid stenosis 70-99% 23 (20%) 
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Table 17 continued 
Parameter Number of patients (%) n=115 
Contralateral carotid stenosis 50-69% 12 (10%) 
Contralateral carotid stenosis <50% (reference 
group) 
73 (64%) 
Baseline mRS=4 2 (2%) 
Baseline mRS=3 6 (5%) 
Baseline mRS=2 28 (24%) 
Baseline mRS=1 29 (25%) 
Baseline mRS=0 (reference group) 50 (44%) 
Cholesterol (mean) 4.9 mmol/l 
Diastolic blood pressure (mean) 83.0 mmHg 
Systolic blood pressure (mean) 157.3 mmHg 
ARWMC (median) 4 
Qualifying event was stroke 49 (43%) 
Qualifying event was TIA 41 (36%) 
Qualifying event was retinal TIA or retinal stroke  25 (22%) 
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Table 18. Vascular anatomical characteristics of 115 patients allocated to CAS in 
the ICSS-MRI Substudy for whom adequate pre-procedure catheter 
angiography was available 
Parameter Value 
Carotid artery NASCET degree of stenosis (median) 62.7% 
Ratio of maximal stenosis length to CCA diameter (mean) 0.41 times 
Angle between common and internal carotid arteries (median) 23.6 degrees 
External carotid artery stenosis >50% 6 (5%) 
Plaque ulceration 40 (35%) 
Pinhole stenosis 2 (2%) 
Common carotid artery atheroma 13 (11%) 
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18.3.2 Patient, procedural and vascular anatomical risk factors for new 
ischaemic brain lesions on the post-procedural scan following CAS 
62/115 (50.4%) of patients had at least one new DWI-MRI-positive lesion on their post-
procedure scan. The results of negative binomial regression analysis of the influence of 
baseline demographic variables, vascular risk factors and vascular anatomical 
characteristics on the number of new DWI-positive lesions on the post-procedure MRI 
are summarized in Tables 19 and 20 below. 
Factors that increased the risk of new DWI lesions on the post-procedure scan were 
increasing age (OR 2.26 for each 10 years increase in age, 95% CI 1.74 to 2.89, 
p<0.01), treated hypertension (OR 2.61, 95% CI 1.68 to 4.05, p<0.01), increasing 
ARWMC (age-related white matter change score seen on baseline brain imaging) (OR 
1.13 for each point increase, 95% CI 1.06 to 1.20, p<0.01) and stroke or TIA as the 
qualifying event for enrolment into ICSS as compared with those who experienced a 
retinal event (OR 4.30, 95% CI 2.46 to 7.53, p<0.01 for stroke and OR 1.91, 95% CI 
1.06 to 3.43, p=0.03 for TIA). 
Factors associated with a lower number of new DWI lesions on the post-procedure 
scan were being female (OR 0.49, 95% CI 0.31 to 0.76, p<0.01), being a current or 
former smoker (OR 0.48, 95% CI 0.31 to 0.76, p<0.01), cardiac failure (OR 0.17, 95% 
CI 0.03 to 0.85, p=0.03) and 50-69% contralateral carotid artery stenosis as compared 
with <50% contralateral carotid artery stenosis (OR 0.18, 95% CI 0.08 to 0.40, p<0.01). 
Patients with a mRS score of 3 at baseline had a lower number of new lesions 
compared with patients with no disability scoring 0 (OR 0.20, 95% CI 0.06 to 0.62, 
p<0.01). The number of new DWI lesions was lower in patients undergoing right-sided 
procedure (OR 0.57, 95% CI 0.38 to 0.85, p<0.01). 
The vascular anatomical variables measured for this analysis – the degree of ipsilateral 
carotid stenosis, the length of maximum stenosis, the CCA/ICA angle, plaque 
ulceration, the presence of CCA atheroma or the presence of “pinhole” stenosis did not 
significantly influence the number of new lesions. 
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Table 19. Univariable demographic and procedural predictors of new DWI-MRI 
lesions following CAS in 115 patients in the ICSS-MRI Substudy for whom 
adequate pre-procedure catheter angiography was available  
Parameter p-
value 
Odds Ratio 
(OR) 
95% confidence interval 
for OR 
Lower Upper 
Right-sided stenosis <0.01 0.57 0.38 0.85 
Cerebral protection device used 0.22 1.30 0.83 1.88 
Age (per 10-year increase) <0.01 2.26 1.74 2.89 
Female <0.01 0.49 0.31 0.76 
Treated hypertension <0.01 2.61 1.68 4.05 
Diabetes (any type) 0.07 1.59 0.97 2.61 
Treated hyperlipidaemia 0.69 0.92 0.61 1.38 
Current or former smoker <0.01 0.48 0.31 0.76 
Coronary heart disease 0.43 1.21 0.76 1.94 
Other cardioembolic source of 
thrombus 
0.28 1.56 0.69 3.49 
Cardiac failure 0.03 0.17 0.03 0.85 
Peripheral arterial disease 0.29 0.75 0.45 1.27 
Contralateral carotid occlusion 0.21 1.69 0.75 3.80 
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Table 19 continued  
Parameter p-
value 
Odds Ratio 
(OR) 
95% confidence 
interval for OR 
Lower Upper 
Contralateral carotid stenosis 70-
99% 
0.12 0.66 0.39 1.11 
Contralateral carotid stenosis 50-
69% 
<0.01 0.18 0.08 0.40 
Contralateral carotid stenosis <50% 
(reference group) 
N/A 1 N/A N/A 
Baseline mRS=4 0.14 0.26 0.04 1.57 
Baseline mRS=3 <0.01 0.20 0.06 0.62 
Baseline mRS=2 0.20 1.38 0.84 2.26 
Baseline mRS=1 0.40 0.81 0.49 1.33 
Baseline mRS=0 (reference group) N/A 1 N/A N/A 
Cholesterol (1 mmol increase in 
serum total cholesterol) 
0.30 0.89 0.71 1.11 
Diastolic blood pressure (per 
10mmHg increase) 
0.13 0.90 0.98 1.00 
Systolic blood pressure (per 
10mmHg increase) 
0.98 1.00 0.91 1.09 
 144 
Table 19 continued 
Parameter p-value Odds Ratio 
(OR) 
95% confidence interval for OR 
Lower Upper 
ARWMC (per unit 
increase) 
<0.01 1.13 1.06 1.20 
Qualifying event was 
stroke 
<0.01 4.30 2.46 7.53 
Qualifying event was TIA 0.03 1.91 1.06 3.43 
Qualifying event retinal TIA 
or retinal stroke (ref. 
group) 
N/A 1 N/A N/A 
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Table 20. Univariable vascular anatomical predictors of new DWI-MRI lesions 
following CAS in 115 patients in the ICSS-MRI Substudy for whom adequate 
pre-procedure catheter angiography was available  
Parameter p-
value 
Odds 
Ratio (OR) 
95% confidence 
interval for OR 
Lower Upper 
Carotid artery NASCET degree of 
stenosis (per 10% increase) 
0.69 0.97 0.83 1.13 
Ratio of maximal stenosis length to 
CCA diameter (per unit increase) 
0.46 1.28 0.67 2.45 
Angle between common and internal 
carotid arteries 
0.12 0.99 0.98 1.00 
External carotid artery stenosis >50% 0.08 0.42 0.16 1.10 
Plaque ulceration 0.66 1.10 0.73 1.66 
Pinhole stenosis 0.88 1.13 0.25 5.05 
Common carotid artery atheroma 0.69 0.88 0.47 1.65 
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Factors in the univariable analysis with significance <0.05 were considered for entry 
into a multivariable model. One possible model is illustrated below in Table 21. Factors 
independently increasing the number of new DWI brain lesions on the post-procedure 
scan in this model are a left-sided procedure (OR 1.59, 95% CI 1.04 to 2.44, p=0.03), 
increasing age (OR 2.10 per 10 years increase, 95% CI 1.61 to 2.74, p<0.01), being 
male (OR 2.83, 95% CI 1.72 to 4.67, p<0.01), treated hypertension (OR 2.04, 95% CI 
1.25 to 3.33, p<0.01) and absence of a diagnosis of cardiac failure (OR 6.58, 95% CI 
1.23 to 35.07, p=0.03). 
Inter-rater agreement, calculated for binary anatomical characteristics, was moderate 
for CCA atheroma (κ=0.50, p<0.01), substantial for the type of stenosis (smooth, 
irregular or ulcerated, κ=0.76, p<0.01) and slight for pinhole stenosis (κ=0.13, p=0.06). 
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Table 21. Independent predictors of new DWI-MRI lesions following CAS in 115 
patients in the ICSS-MRI Substudy for whom adequate pre-procedure catheter 
angiography was available  
Parameter p-
value 
Odds 
ratio 
(OR) 
95% confidence interval for OR 
Lower Upper 
Left-sided stenosis 0.03 1.59 1.04 2.44 
Age (per 10-year 
increase) 
<0.01 2.10 1.61 2.74 
Male <0.01 2.83 1.72 4.67 
Treated hypertension <0.01 2.04 1.25 3.33 
Absence of cardiac 
failure 
0.03 6.58 1.23 35.07 
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 Discussion and conclusions 18.4
18.4.1 Summary 
Of the vascular anatomical characteristics measured specifically for this analysis, none 
significantly influence the risk of new DWI-positive lesions on the post-procedure scan. 
Independent factors increasing the number of new lesions were age, approximately 
doubling risk for each advancing decade of life, and treated hypertension. A diagnosis 
of cardiac failure, being female and undergoing a right-sided procedure all 
independently decreased the number of new lesions. 
18.4.2 Discussion 
The assumption that a difficult procedure – technically challenging for an inexperienced 
investigator – will be associated with an increased procedural risk has led to attempts 
to define which vascular anatomical variants require extra skill to navigate during CAS. 
A Delphi panel of CAS experts proposed a scoring system for rating difficulty based on 
vessel angulation, tortuosity of the arteries, the presence of external or common carotid 
artery disease or aortic arch variants [123]. Studies focussing on clinical endpoints, 
usually stroke or death, have found a number of vascular anatomical factors that 
increase the risk of an adverse outcome – lesion length [203] [122] [120], plaque 
ulceration or plaque calcification [122], aortic arch variants [122] [205], angulation of 
the ICA-CCA bifurcation [120] and the side of the procedure [120]. Atypical aortic arch 
configuration may also be linked to longer catheter manipulation times, which itself may 
be linked to adverse outcome [206]. However, other authors have failed to find a link 
between lesion or vascular characteristics and outcome [207]. 
Factors specifically associated with an increased risk of new DWI-MRI lesions following 
CAS in other studies include age [208], the presence of an ulcerated stenosis [208], 
aortic atherosclerotic lesions [209] and increasing lesion length [208]. 
New ischaemic brain lesions following CAS are of concern. Subclinical injury to the 
brain from microemboli generated during the procedure, i.e. insufficient to cause 
clinically-apparent focal neurological symptoms, is thought to be a risk factor for 
cognitive dysfunction perhaps too subtle to be detected without neuropsychological 
testing [210]. CAS was associated with a larger decrease in cognitive ability than CEA 
in selected patients enrolled at two ICSS centres, although the difference was not 
statistically significant and the sample size was relatively small compared to the overall 
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trial size [211]. A decrease in cognitive performance in both groups occurred 
regardless of the baseline white matter lesion burden of the patients studied [212]. 
This analysis demonstrated a higher number of new DWI-MRI lesions following CAS in 
patients undergoing left-sided procedures, but was not able to replicate the findings of 
others of an increased procedural risk with pinhole stenosis, length of stenosis or ICA-
CCA angulation. In ICSS the anatomical suitability of the stenosis for CAS or CEA (the 
patient was required to be suitable for either to be included in the trial) was determined 
prior to randomization using non-invasive imaging including duplex ultrasound or CT or 
MR angiography. Pre-stenting catheter angiograms were primarily obtained to plan 
procedures, and thus the films or DICOM images available for this analysis did not 
routinely include the contralateral carotid artery or the aortic arch and CCA origin. It is 
possible that patients thought to be “high risk” for stenting because of their vascular 
anatomy were excluded from enrolment in ICSS. The trial protocol specified tortuous 
anatomy proximal or distal to the stenosis, the presence of visible thrombus, proximal 
CCA stenotic disease or pseudo-occlusion as examples of high risk anatomies. The 
relatively low percentage of patients with pinhole stenosis and the low average CCA-
ICA angle in our study may reflect this. Inter-rater agreement for some of the measured 
features, such as plaque ulceration, has also been shown to be poor [202]. 
Given the lack of inter-rater agreement for binary features, and the lack of a strong 
association between vascular characteristics and the outcome, this data does not 
support selecting patients for CAS based on “safe” vascular anatomy. In future, newer 
imaging techniques such as 3T MRI looking at the composition of carotid plaque may 
prove more useful in risk stratification if they are able to accurately identify fragile 
plaques vulnerable to fragmentation and dislodgement by a vascular catheter [213]. 
Older patients in the ICSS-MRI Substudy were found to have a higher number of new 
ischaemic brain lesions after stenting, and the trial also demonstrated as association 
between the total volume of DWI lesions and hemispheric stroke in this patient group 
[64] [200]. This finding agrees with clinical data from the Carotid Stenting Trialists’ 
Collaboration (CTSC) which conducted a meta-analysis of individual patient data from 
ICSS [82], EVA-3S [79] and SPACE [77]. This revealed a doubling of risk of stroke, 
myocardial infarction or death within 30 days of CAS compared with CEA in patients 
over the age of 70 years with no significant difference in the risk in younger patients. 
The mechanism by which age increases risk is not apparent from this analysis, but 
could be related to an increase in the overall burden of atheroma in the vasculature 
over time, a greater baseline ARWMC score and therefore decreased “cerebral 
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reserve” when ischaemia occurs, or age may be a marker of decreased physiological 
reserve to tolerate the procedure and hospitalization. An increase in atheroma in the 
aorta with age may also go some way to explaining concerns about the occurrence of 
new DWI lesions on MRI brain following catheterization of the coronary arteries where 
the carotid artery is not manipulated [214]. 
That cerebral protection devices did not protect against the occurrence of new DWI 
brain lesions in our analysis agrees with the findings of two small randomized studies 
of protected vs unprotected CAS [196] [197], but disagrees with one other study and 
one systematic review which found a reduction in embolic load with CPD use [215] 
[192]. However, even these two analyses demonstrate that new DWI lesions still 
frequently occur following protected CAS. Most CPDs in ICSS and the ICSS-MRI 
Substudy were of the distal filter type, and newer flow-reversal devices may offer better 
protection against distal embolism [66]. 
18.4.3 Limitations 
Views on catheter angiography were often limited, and thus it was not possible to 
evaluate the anatomy of the intracranial portion of the ICA, the proximal CCA or the 
anatomy of the aortic arch. All of these may be important areas of technical difficulty, 
and could be further studied on CT or MR angiogram in the ICSS-MRI Substudy or 
other patient cohorts. There is no correction in this analysis for multiple statistical 
comparisons, and there is therefore a possibility of type I (false positive) error in 
interpreting a positive result. 
18.4.4 Conclusions 
It is unlikely that the excess of new DWI brain lesions seen in CAS patients in the 
ICSS-MRI Substudy was due to vascular anatomical variation alone. Patients who 
match the inclusion criteria for ICSS and in whom stenting is thought viable need not 
be excluded from the procedure on the basis of individual vascular anatomical 
characteristics as assessed on catheter angiogram. In agreement with other studies, 
age remains a risk factor for CAS and should be taken into account when deciding 
between CAS and CEA. Caution should be exercised in offering CAS to patients over 
the age of 70, as discussed in Chapter 17. There is mounting evidence that filter-type 
CPDs do not offer protection against brain ischaemia during CAS, and our findings 
therefore do not support their routine use.  
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19. Validation of an existing risk score for carotid stenting 
 Introduction 19.1
Patients allocated to stenting in the International Carotid Stenting Study experienced a 
higher risk of stroke than patients allocated to endarterectomy in an analysis limited to 
those whose procedures were initiated (7.0% vs 3.3%, p<0.01). This was mostly 
attributable to an excess of minor (non-disabling) stroke [82]. Matching this finding, 
three times the number of patients allocated to CAS in the ICSS-MRI Substudy were 
found to have new ischaemic brain lesions on post-treatment MRI scans compared 
with those undergoing endarterectomy [64]. CAS patients not only had higher numbers 
of ischaemic lesions after revascularization, but these were more likely to occur in 
cortical tissue and sub-adjacent white matter areas [200]. Patients who developed 
clinical signs of hemispheric stroke had a higher overall lesion volume than those who 
did not [64]. “Silent” brain infarction has been associated with dementia and cognitive 
decline in other patient cohorts [216], and new lesions are thus of concern in the 
context of carotid revascularization. 
A risk score for the development of new ischaemic brain lesions following CAS, 
constructed by Gröschel et al, was developed from a dataset of 176 patients 
undergoing CAS at one centre from 2000-2006 who underwent diffusion-weighted 
brain MRI sequences before and up to 48 hours after the procedure. Just over 51% of 
their patients were symptomatic, and all had ≥70% carotid stenosis. Age over 70 years, 
the presence of an ulcerated stenosis and lesion length over 1cm were identified as 
risk factors for any new ipsilateral lesion on diffusion-weighted MRI following CAS 
[208]. An analysis of the performance of this risk score is presented in this chapter. 
Other risk prediction scores for CAS complications have been developed, but are not 
studied here as they focus on clinical endpoints [122], address the choice between 
CAS and CEA [217] [171], use MR plaque imaging techniques not in routine use in 
ICSS [217] or focus on “high risk” patients not suitable for surgery [218] that would not 
meet the inclusion criteria for the ICSS-MRI Substudy. 
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 Methods 19.2
19.2.1 The ICSS-MRI Substudy and anatomical feature rating 
The ICSS-MRI Substudy protocol is summarized in Chapter 13 and described in 
greater detail in Appendix V. In summary, patients over the age of 40 with greater than 
50% symptomatic carotid stenosis and capable of giving informed consent to trial 
participation were randomized in ICSS to either CAS or CEA. CAS was carried out 
according to ICSS trial protocol [81], including the use of a cerebral protection device 
when the operator thought it safe to deploy one. It was recommended that patients be 
prescribed aspirin and clopidogrel to cover the procedure. 
Patients who additionally enrolled in the ICSS-MRI Substudy underwent pre-procedural 
MRI at 1.5T or 3.0T field strength up to 7 days before CAS with repeat sequences one 
to three days after the procedure. Scan protocols included diffusion-weighted 
sequences to demonstrate areas of acute of subacute brain ischaemia or infarction. 
The presence or absence of at least one new ipsilateral DWI-positive lesion was 
decided by the consensus reading of a neurologist and neuroradiologist. Vascular 
anatomical features – lesion length and the presence or absence of ulceration – were 
recorded by a trained reader in a separate analysis blind to the selected outcome of 
any new ipsilateral ischaemic brain lesion on the post-procedure scan as detailed in 
Chapter 18. 
Patients in the ICSS-MRI Substudy allocated to CAS in whom the procedure was 
initiated, and for whom sufficient baseline or procedural catheter angiography was 
available, were studied in this analysis. A score was allocated to each patient in the 
analysis according to the characteristics in Table 22 below. The patient’s age in years 
on the day of enrolment in ICSS is used in this analysis. Many digital angiograms did 
not contain calibration information to directly measure the length of stenosis. Therefore 
the “total stenosis length” was defined as the distance between the most proximal and 
distal shoulders of the lesion, expressed as a fraction of the common carotid artery 
diameter as illustrated in Figure 16. This was then multiplied by an assumed “average” 
common carotid diameter of 0.65cm [142] to give a total length of stenosis in 
centimetres. “Ulceration” was defined, as proposed by the NASCET investigators, as “a 
crater penetrating into a stenotic plaque and double density on ‘en face’ view” [202], 
illustrated in Figure 14 (Chapter 18). DICOM images were evaluated using Osirix MD, 
(Pixmeo SARL 2012). 
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Figure 16. Measuring the total length of stenosis in three vascular anatomical profiles 
CCA = common carotid artery, ICA = internal carotid artery, ECA = external carotid artery  
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Table 22. Allocation of risk points in the Gröschel (2008) risk score 
Study Risk factors Risk points 
Gröschel et al. 
(2008) [208] 
Age ≥ 70 years 1 
Age ≥ 80 years 1 
Lesion length > 1cm 1 
Ulcerated stenosis 1 
 
 155 
19.2.2 Statistical Methods 
The proportion of patients with at least one new ipsilateral DWI-positive lesion on post-
procedure imaging was calculated for patients in each score bracket, expressed as a 
percentage. A 95% confidence interval is given for each proportion. Differences 
between the proportions of patients with a new DWI lesion in each group was assessed 
by means of a chi-squared (χ2) test for trend. A receiver operator curve was 
constructed to assess the performance of the score in our dataset, and the area under 
the curve calculated with 95% confidence interval. In all analyses p<0.05 was assumed 
to confer statistical significance. Analyses were performed using GraphPad (GraphPad 
Software, 2013. GraphPad Instat version 3.00 for Windows 95. San Diego, California: 
www.graphpad.com). 
 Results 19.3
Baseline characteristics of patients included in this analysis are presented in Tables 17 
and 18 (Chapter 18). In summary, the mean age was 70.4 years, and 70.4% of patients 
were male. 52/115 (45.2%) patients had at least one new DWI-positive lesion ipsilateral 
to the treated artery of post-procedure MRI. 
Using an assumed diameter of 0.65cm, the mean length of stenosis was 1.35cm. 
18/115 (15.7%) patients had an ulcerated lesion. 
33.3% of patients with a Gröschel score of 0 had at least one new ipsilateral ischaemic 
brain lesion on the post-procedure MRI scan, 36.6% of those with a score of 1, 51.6% 
of those with a score of 2, 61.1% of those with a score of 3 and 75.% of those with a 
score of 4. The numbers of patients in each group and 95% confidence interval for the 
proportion with a new ischaemic lesion is presented in Table 23. The observed 
increase in patients with an increasing Gröschel score was statistically significant 
(p=0.02, χ2 test for trend). 
The receiver operator curve for the performance of the Gröschel risk score is presented 
in Figure 17 below. The area under the curve is 0.62 (95% CI 0.52 to 0.73, p=0.02). 
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Table 23. Results of application of the Gröschel (2008) risk score to 115 patients undergoing CAS in the ICSS-MRI Substudy 
Gröschel 
Score 
Number of patients with 
no new ipsilateral DWI-
positive lesions following 
after CAS (n) 
Number of patients with new 
ipsilateral DWI-positive 
lesions following CAS (n) 
Proportion of patients with 
new ipsilateral DWI-positive 
lesions following CAS (%) 
95% CI for proportion of patients 
with new ipsilateral DWI-positive 
lesions following CAS 
0 14 7 33.3% 17.1% to 51.4% 
1 26 15 36.6% 23.6% to 51.9% 
2 15 16 51.6% 34.8% to 68.0% 
3 7 11 61.1% 38.5% to 79.8% 
4 1 3 75.0% 28.9% to 96.6% 
 
χ2 test for trend p=0.02
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Figure 17. Receiver-operator curve for the application of the Gröschel (2008) risk 
score in 115 patients undergoing CAS in the ICSS-MRI Substudy 
 
 
Darker line represents receiver operator curve 
Straight line represents area under curve =0.5 
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 Discussion and conclusions 19.4
19.4.1 Summary 
45.2% of patients in the ICSS-MRI Substudy who were allocated to CAS, and in whom 
adequate baseline or pre-procedure catheter angiography was available, suffered at 
least one new ipsilateral ischaemic brain lesion on the post-procedure DWI-MRI scan. 
While the Gröschel score distinguished between lower-risk and higher-risk groups (χ2 
test for trend p=0.02), the sensitivity and specificity of the score in a receiver operator 
curve was limited (AUC 0.62, 95% CI 0.52 to 0.73, p=0.02).  
19.4.2 Limitations 
The length of stenosis as measured in our study is an approximation – calibration 
information was not contained in many digital angiograms, so to maintain consistency 
we use the diameter of the CCA to derive a calculated length. However, the diameter of 
the CCA has previously been found to vary by the side of the artery, sex, age, body 
surface area, blood pressure and neck length [142] and in fact may vary as much as 
14% within individuals depending on the phase of the cardiac cycle during which it is 
imaged [219]. Patients randomized in the ICSS-MRI Substudy were required to be 
equally suitable for both CAS and CEA, and it is possible that patients with very long or 
ulcerated stenosis were excluded from randomization if interventionists thought them 
unsuitable for CAS because of a high anticipated procedural risk.  
19.4.3 Discussion 
The area under the receiver operator curve (AUC) in this analysis (0.62) compares 
unfavourably with the original performance of this score in the patient population from 
which it was derived, which was 0.71 (0.76 for patients treated after the year 2004 only, 
n=75) [208]. It should be noted that as the AUC corresponds to sensitivity and 
specificity cut-offs for discriminating between those with or without new ischaemic brain 
lesions, it does not necessarily indicate the level of clinical relevance [220]. The high 
proportion of patients suffering new lesions in the lowest risk group in the ICSS-MRI 
Substudy suggests that the Gröschel score is not sufficiently sensitive to be clinically 
useful in classifying patients at risk of MRI-detected ischaemic brain lesions after 
following CAS. 
Chapter 18 illustrates that while age was a significant risk factor for the occurrence of 
new ischaemic lesions in the ICSS-MRI Substudy, ulceration and the length of the 
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target lesion appeared to have little influence. This finding suggests that the 
performance of the score in this patient cohort was mainly driven by the effect of age 
on the outcome. Therefore it is more likely that the key factor in the formation of new 
ischaemic brain lesions during the procedure is the ability of the brain to tolerate 
microemboli, rather than an increased risk of generation of debris during the procedure. 
Indeed, the clinical outcome of CAS also appears to be strongly influenced by the age 
of the patient, with a higher rate of stroke in this patient population [221] [222] [189] 
[116] [223]. Reduced physiological reserve to tolerate the procedure, medications and 
hospitalization, a higher burden of white matter disease with decreased cerebral 
reserve to tolerate emboli, or an association between ageing and anatomical features 
increasing the complexity of intervention [224] are all possible explanations for this 
effect. 
As detailed in Chapter 18, inter-rater agreement for the detection of carotid plaque 
ulceration was limited in the ICSS-MRI Substudy, and other authors have reported little 
agreement between angiographic appearances and subsequent histology [202] [225]. 
However, it should also be noted that while lesion ulceration was not a strong predictor 
of subsequent brain ischaemia in the ICSS-MRI Substudy the risk of stroke without any 
revascularization procedure may be higher than in patients with smooth lesions. 
Patients enrolled in NASCET with a high degree of stenosis and an ulcerated lesion 
experienced an up to 73% risk of subsequent ipsilateral stroke within 24 months 
compared to a 21% risk in those patients without ulceration of the plaque [226]. 
Likewise, increasing age is a risk factor for stroke on medical therapy alone for 
symptomatic carotid stenosis [43]. Thus the Gröschel score tested in this chapter may 
give an indication of the risk of intervention, but it does not give an indication of the 
likely risks of stroke on medical treatment alone or the likely risk of CEA, and therefore 
is of limited use in selecting an overall treatment strategy in patients with greater than 
50% symptomatic carotid stenosis. 
19.4.4 Conclusions 
Although there was an increase in the number of new ischaemic brain lesion on post-
procedure MRI after CAS with increasing Gröschel score, this risk score did not exhibit 
adequate discrimination between low- and high-risk groups for routine clinical use, in 
part because 33.3% of the lowest-risk group still suffered at least one new ipsilateral 
ischaemic brain lesion on the post-procedure scan. Its routine use for selection of 
patients for CAS cannot be recommended without validation in further patient groups. 
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Age is a strong predictor of both clinical outcome and “silent” brain embolism, and 
should continue to be taken into account when selecting patients for carotid stenting.  
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20. Discussion, conclusions and future directions 
 Discussion of key findings 20.1
20.1.1 Carotid endarterectomy 
This thesis presents several key findings regarding the safety of carotid 
endarterectomy. Most notably, women had around double the risk of the combined 
endpoint of stroke, myocardial infarction or death and nearly double the risk of the 
combined risk of any major complication (stroke, MI, CNP, haematoma or death) 
following CEA compared with men. That women might experience a greater operative 
risk has been described before [98], and this is of particular concern because of their 
lower risk of stroke on medical therapy alone – hence the observation in ECST that the 
number of patients needed to undergo surgery to prevent one ipsilateral stroke over 5 
years was just nine in men against 36 for women [105]. Surgeons should carefully 
consider the risk-benefit calculation for revascularization in this patient group. 
Although women experienced a higher risk of cranial nerve palsy in ICSS, the risk of 
persisting disabling CNP was around 1 in 1000, with most CNPs resolving within 30 
days. The association between haematoma and CNP suggests that careful attention to 
haemostasis may reduce the latter’s incidence. Although patients should be warned 
about possible symptoms of CNP, they can also be reassured of a generally good 
eventual outcome even when CNP does occur, and this complication should not 
dissuade surgeons from offering revascularization. 
There is evidence that in the last few years the short-term risks associated with CEA 
may have fallen slightly [227]. The risk of surgery was acceptably low in ICSS – only 
3.3% of patients in whom the allocated CEA procedure was initiated suffered a stroke 
within 30 days of the procedure – and the only independent predictor of the risk of 
complications was baseline diastolic blood pressure. Attention to blood pressure in 
symptomatic patients undergoing revascularization might reduce subsequent 
complications, but this should be managed in the clinical context with particular care in 
patients who have contralateral carotid stenosis or vertebral artery stenosis. 
It is not surprising that risk scores derived from other patient populations did not 
adequately discriminate between low- and high-risk groups of ICSS patients given the 
lack of strong predictors of risk. Nonetheless, most published surgical risk scores have 
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not previously been validated, so to be of use in clinical decision-making they should 
be tested in other patient cohorts or updated. 
20.1.2 Carotid stenting 
This thesis identifies advancing age as a risk factor for complications following CAS, 
but not for CEA, in agreement with individual patient meta-analysis across the 
European trials of CAS vs CEA which suggested that CAS was as safe as CEA in 
younger patients [115]. 
The finding that cerebral protection devices – mostly distal filters – offered no 
statistically significant protection from stroke, myocardial infarction or death or the 
occurrence of new ischaemic brain lesions following CAS in ICSS is disappointing, but 
concurs with the results of other randomized comparisons [196] [197]. At best the 
benefit of their deployment in CAS is unproven, and cannot be recommended as 
routine. Similarly, results were disappointing in those patients treated using an open-
cell stent and the findings in this thesis favour the use of a closed-cell stent. 
Inexperienced CAS interventionists are sometimes advised to avoid undertaking 
stenting in patients with “challenging” vascular anatomy [123] thought to make the 
procedure more technically difficult. In Chapter 18, this thesis argues that the influence 
of patient characteristics, such as age, male sex and hypertension, exert a greater 
influence on the number of new post-procedure ischaemic lesions as measured on MRI 
brain, although patients with a left-sided stenosis experience approximately double the 
number of new lesions. While an important observation, it must be kept in mind that 
patients with lesions thought “unsuitable” for stenting were excluded from 
randomization in ICSS, and that more inexperienced operators who performed trial 
procedures were supervised. Indeed, patients treated in supervised centres in ICSS 
experienced a lower risk of stroke, MI or death following CAS [82]. 
 Conclusions 20.2
The case for offering carotid revascularization in suitable patients with ≥50% 
symptomatic carotid stenosis due to atherosclerosis, who would otherwise experience 
a high risk of recurrent stroke on medical therapy alone, is clear. Some groups of 
patients, however, at are increased risk from intervention. In isolation, the subgroup 
analyses presented in this thesis should be interpreted with caution. Yet combined with 
data from individual patient meta-analysis of the European trials of CAS vs CEA, and 
risk modelling data from the original NASCET and ECST trials of carotid surgery versus 
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medical therapy, there is evidence from the work presented in this thesis that in the 
short term stenting is more hazardous in the elderly, that the routine use of filter-type 
cerebral protection devices in CAS is not supported by high-quality evidence, that 
closed-cell stents are safer than open and that women should be informed of a 
potentially small increased risk of stroke, MI, cranial nerve palsy, haematoma or death 
following endarterectomy. 
What is not addressed in these analyses is whether the overall benefits of intervention 
extend to lower-risk patients, and it is this question that is the subject of ongoing 
research. 
 Future directions – who should have what treatment? 20.3
20.3.1 Revisiting the case for intervention 
The standard of care for clinically stable patients with greater than 50% symptomatic 
carotid stenosis has been to perform carotid endarterectomy (in preference to carotid 
stenting in low-risk patients) to remove the symptomatic plaque and thus reduce the 
long-term risk of recurrent stroke or TIA [128] [153] [130]. However, since the landmark 
large randomized trials of CEA vs medical therapy, NASCET and ECST, there have 
been a number of developments in care that call into question the benefit of 
intervention in all patients with this degree of stenosis. This thesis has explored the 
subject of which patients are at risk of complications from CEA or CAS, but in order to 
select patients who will benefit in the long-term from revascularization it is necessary to 
consider their risk of stroke without intervention as well. 
Medical therapy for secondary prevention of stroke has changed. Previous trials of 
CAS or CEA for carotid stenosis did not specify targets for control of vascular risk 
factors, but numerous guidelines now exist for primary and secondary prevention 
therapy [228] [229] [230] [231]. Cholesterol-lowering statins were not available during 
recruitment into NASCET, but their use in secondary prevention for stroke is now 
widespread in the knowledge that they reduce the risk of stroke in patients with carotid 
disease [232] [233].    
The pathology of symptomatic carotid plaque is well-described. An inflamed plaque 
with macrophage infiltration, fresh thrombus, a large lipid core and rupture of the 
fibrous plaque are all histological features associated with stroke (as opposed to TIA or 
amaurosis fugax) [234]. Catheter angiography, the method used to determine the 
degree of stenosis for entry to the NASCET and ECST trials, has fallen out of common 
 164 
use as newer less invasive imaging techniques have been developed – ultrasound, CT 
and MR angiography and advanced plaque imaging with MRI or 3D ultrasound. The 
degree of stenosis on its own is currently used in the selection of patients to undergo 
revascularization and is one potential marker of plaque instability – larger plaques 
causing higher degrees of stenosis are more likely to cause symptoms due to a more 
unstable plaque composition with less fibrous tissue. The ability to directly image 
plaque components associated with high stroke risk such as a lipid-rich core [235] 
[236], ulceration, thin or ruptured fibrous cap [235] [236] or intra-plaque haemorrhage 
[235] [237] [236] with MRI is beginning to change the way patients are risk stratified 
and may blur the line between asymptomatic and symptomatic patients when selecting 
patients for revascularization based on their risk of stroke. Work is underway, for 
example, in the Plaque At Risk (PARISK) study to enrol 300 patients with <70% 
recently-symptomatic carotid stenosis, who are not scheduled to undergo carotid 
endarterectomy. These patients will undergo detailed MR, CT and US of the carotid 
arteries to determine which plaque characteristics confer a high risk of recurrent stroke 
[238]. 
20.3.2 The risks of intervention 
Detailed plaque imaging may similarly give clues as to the risk of the revascularization 
procedure itself. Echolucent plaques on ultrasound – unstable, lipid-rich or 
haemorrhagic plaques more likely to cause neurological symptoms untreated have 
been shown to increase the risk of carotid stenting, perhaps through the dislodgement 
of adherent thrombus during the passage of endovascular equipment across the lesion 
[239]. Ongoing randomized trials with a carotid intervention arm such as ECST-2, 
described below, are incorporating detailed modern carotid imaging into their baseline 
assessment of patients and will use detailed post-procedure MRI to examine the 
occurrence of procedural brain ischaemia, opening up the possibility of further 
characterising the risk of intervention based on radiological plaque appearance. 
Collaborative work continues to establish the determinants of the risks of intervention, 
pooling individual patient data from the European trials of carotid stenting and surgery 
through the Carotid Stenting Trialists’ Collaboration [240]. This larger dataset, which 
includes data from patients enrolled in ICSS, has examined the effect of baseline 
patient characteristics on procedural risk as described in Chapters 14 and 17, and has 
recently published an analysis of the effect of operator experience on the outcome of 
carotid stenting, demonstrating a more favourable outcome in those interventionists 
that performed more than five procedures per year within the trials [126]. 
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20.3.3 Ongoing clinical trials 
The second European Carotid Surgery Trial (ECST-2) [172], designed by many of the 
trialists involved in ICSS, intends to answer some of these questions about how best to 
treat patients with carotid stenosis. It is a prospective randomized trial of patients with 
low-to-intermediate risk carotid stenosis ≥50%, enrolling those with asymptomatic 
plaques and recently-symptomatic patients whose calculated risk of ipsilateral stroke is 
less than 15% over 5 years. The Carotid Artery Risk Score used to calculate risk is 
adapted from an algorithm designed at Oxford University taking into account age, sex, 
the degree of stenosis, the nature of any symptomatic event and how recently it 
occurred, vascular risk factors and plaque morphology [241]. Patients in a medical 
therapy group will receive “optimized medical therapy” (OMT) – antiplatelet therapy, 
target-led control of cholesterol level and blood pressure – while an intervention group 
will receive OMT plus revascularization. The trial tests the hypothesis that patients with 
a low predicted stroke risk on OMT alone will not benefit from revascularization due to 
periprocedural complications. 
SPACE-2 (Stent-Protected Angioplasty in Asymptomatic Carotid Artery Stenosis 
versus Endarterectomy Trial-2) [173] was originally designed as a randomized trial for 
patients with asymptomatic carotid stenosis ≥70% as measured by ultrasound. Its 
protocol called for a recruitment target of 3640 patients in three arms: best medical 
treatment, CEA in addition to best medical treatment, and CAS in addition to best 
medical treatment. The trial investigators recently redesigned the SPACE-2 protocol 
such that now patients are enrolled into SPACE-2a comparing best medical treatment 
with CAS in addition to best medical treatment, and SPACE-2b comparing best medical 
treatment with CEA in addition to best medical treatment [242]. Interestingly, CREST-2 
(the second Carotid Revascularization Endarterectomy versus Stenting Trial) has a 
similar design and inclusion criteria to the new SPACE-2 protocol, in that neither trial 
directly compares CAS with CEA. This role is taken by the second Asymptomatic 
Carotid Surgery Trial (ACST-2) [174], which aims to compare the safety and efficacy of 
CAS with CEA in 5000 patients with asymptomatic carotid stenosis who are “though to 
need some procedural intervention” to prevent future stroke [243]. Recently-published 
interim results from this study indicate that the risk of stroke, myocardial infarction or 
death within 30 days of either procedure was low at 1.0% in 691 patients [174]. 
When clinicians are uncertain about which treatment will provide the greatest benefit to 
the patient in return for an acceptably low risk of harm, it is appropriate to discuss with 
them enrolment in a clinical trial. Patients can benefit from inclusion in randomized 
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clinical trials, even when allocated to the control therapy – close attention to control of 
vascular risk factors and frequent follow-up may improve management of the patient’s 
condition over and above routine clinical care. Almost all patients with low-risk carotid 
stenosis can therefore be enrolled in one of the above trials, provided they can be 
treated at a participating centre. Patients with low-risk symptomatic carotid stenosis 
could be suitable for enrolment in ECST-2. When the medical team are uncertain as to 
whether intervention is warranted in an asymptomatic patient they may enrol in ECST-
2, SPACE-2 or CREST-2. And when intervention is thought necessary in asymptomatic 
patients, ACST-2 compares CAS with CEA for the long-term primary prevention of 
stroke.  
When the pace of change in stroke prevention is fast, there is a need for good-quality 
evidence from randomized clinical trials to inform decision making from the individual 
patient level up to the design of healthcare systems. If these four trials can recruit their 
target numbers and report definitive results, then we may be some way further to 
answering the question of “who should receive what treatment” for carotid stenosis.  
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24. Appendix III – List of ICSS centres and investigators 
Location of ICSS recruiting centres, number of patients recruited at each centre in 
square brackets, and collaborators at each centre (PI) = local principal investigator 
[82]. 
24.1.1 Australia  
Austin Health, Heidelberg [46]: M Brooks, B Chambers (PI), A Chan, P Chu, D Clark, 
H Dewey, G Donnan, G Fell, M Hoare, M Molan, A Roberts, N Roberts 
Box Hill Hospital (Monash University), Melbourne [25]:  B Beiles, C Bladin (PI), C 
Clifford, G Fell, M Grigg, G New  
Monash Medical Centre, Clayton [26]: R Bell, S Bower, W Chong, M Holt, A Saunder, 
PG Than (PI) 
Princess Alexandra Hospital, Brisbane [48]: S Gett, D Leggett, T McGahan (PI), J 
Quinn, M Ray, A Wong, P Woodruff  
Repatriation General Hospital, Daw Park, Adelaide [6]: R Foreman, D Schultz (PI), R 
Scroop, B Stanley  
Royal Melbourne Hospital, Melbourne [57]: B Allard, N Atkinson, W Cambell, S 
Davies (PI), P Field, P Milne, P Mitchell, B Tress, B Yan  
The Royal Hobart Hospital, Hobart [18]: A Beasley, D Dunbabin, D Stary, S Walker 
(PI) 
24.1.2 Belgium 
Antwerp University Hospital, Antwerp [10]: P Cras, O d'Archambeau, JMH Hendriks 
(PI), P Van Schil  
AZ St Blasius, Dendermonde [5]: M Bosiers (PI), K Deloose, E van Buggenhout 
AZ Sint Jan Brugge-Oostende, Campus Brugge, Brugges [18]: J De Letter, V 
Devos, J Ghekiere, G Vanhooren (PI). 
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Cliniques Universitaires St Luc, Bruxelles [1]: P Astarci, F Hammer, V Lacroix, A 
Peeters (PI), R Verhelst 
Imelda Ziekenhuis, Bonheiden [3]: L DeJaegher (PI), A Peeters, J Verbist  
24.1.3 Canada 
CHUM Notre-Dame Hospital, Montreal [30]: J-F Blair, JL Caron, N Daneault, M-F 
Giroux, F Guilbert, S Lanthier, L-H Lebrun, V Oliva, J Raymond, D Roy (PI), G Soulez, 
A Weill 
Foothills Medical Centre, Calgary [4]: M Hill (PI), W Hu, M Hudion, W Morrish, G 
Sutherland, J Wong  
24.1.4 Finland 
Helsinki University Central Hospital, Helsinki [33]: Albäck A., Harno H., Ijäs P., 
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24.1.5 Germany 
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24.1.6 Ireland 
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24.1.7 New Zealand 
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Stewart (PI)  
24.1.8 Norway 
Rikshospitalet University Hospital, Oslo [16]: SJ Bakke (PI), K Krohg-Sørensen , M 
Skjelland, B Tennøe  
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24.1.9 Poland 
Institute of Psychiatry and Neurology (2nd Department of Neurology & 
Department of Neuroradiology) & Medical University of Warsaw (2nd Department 
of General, Vascular and Oncological Surgery), Warsaw [20]: P Bialek, Z Biejat, W 
Czepiel, A Czlonkowska (PI), A Dowzenko, J Jedrzejewska, A Kobayashi, M Lelek, J 
Polanski  
24.1.10 Slovenia 
University Medical Centre, Ljubljana [12]: J Kirbis, Z Milosevic, B Zvan (PI) 
24.1.11 Spain 
Hospital Clinic, Barcelona [18]: J Blasco, A Chamorro (PI), J Macho, V Obach, V 
Riambau, L San Roman 
Parc Taulí Sabadell Hospital, Barcelona [33]: J Branera, D Canovas (PI), Jordi 
Estela, A Gimenez Gaibar, J Perendreu  
24.1.12 Sweden 
Malmö University Hospital, Malmö [67]: K Björses, A Gottsater (PI), K Ivancev,T 
Maetzsch, B Sonesson 
Sodersjukhuset, Stockholm [55]: B Berg, M Delle, J Formgren, P Gillgren, T-B Kall, P 
Konrad (PI), N Nyman, R Takolander  
The Karolinska Institute, Stockholm [5]: T Andersson, J Malmstedt, M Soderman, C 
Wahlgren, N Wahlgren (PI) 
24.1.13 Switzerland 
Centre Hospitalier Universitaire Vaudois, Lausanne [12]: S Binaghi, L Hirt, P Michel 
(PI), P Ruchat  
University Hospital Basel, Basel [94]: LH Bonati, ST Engelter, F Fluri, L Guerke, AL 
Jacob, E Kirsch, PA Lyrer (PI), E-W Radue, P Stierli, M Wasner, S Wetzel 
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University Hospital of Geneva, Geneva [16]: C Bonvin, A Kalangos, K Lovblad, N 
Murith, D Ruefenacht, R Sztajzel (PI) 
24.1.14 The Netherlands 
Academic Medical Centre, Amsterdam [56]: M Koelemaij, PJ Nederkoorn (PI), J 
Reekers, YB Roos 
Erasmus Medical Centre, Rotterdam [75]: JM Hendriks, PJ Koudstaal (PI), PMT 
Pattynama, A van der Lugt, LC van Dijk, MRHM van Sambeek, H van Urk, HJM 
Verhagen  
The Haga Teaching Hospitals, The Hague [45]: CMA Bruijninckx, SF de Bruijn, R 
Keunen, B Knippenberg, A Mosch (PI), F Treurniet, L van Dijk, H van Overhagen , J 
Wever 
Isala Klinieken, Zwolle [14]: FC de Beer, JSP van den Berg (PI), BAAM van Hasselt, 
DJ Zeilstra  
Medical Centre Haaglanden, The Hague [3]: J Boiten (PI), JCA de Mol van Otterloo, 
AC de Vries, GJ Lycklama a Nijeholt, BFW van der Kallen 
UMC St Radboud, Nijmegen [13]: JD Blankensteijn, FE De Leeuw, LJ Schultze Kool 
(PI), JA van der Vliet  
University Medical Centre, Utrecht [270]: GJ de Borst, GAP de Kort, LJ Kapelle (PI), 
TH Lo, WPThM Mali, F Moll, HB van der Worp, H Verhagen 
24.1.15 United Kingdom 
Addenbrookes Hospital, Cambridge [5]: N Higgins, PJ Kirkpatrick, P Martin (PI), K 
Varty 
Birmingham Heartlands Hospital, Birmingham [11]: D Adam, J Bell, AW Bradbury, P 
Crowe, M Gannon, MJ Henderson, D Sandler, RA Shinton (PI), JM Scriven, T Wilmink 
Lancashire Teaching Hospitals NHS Trust, Preston [2]: S D'Souza, A Egun, R Guta, 
S Punekar, DM Seriki (PI), G Thomson  
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Liverpool Royal Infirmary [21] and The Walton Centre, Liverpool [7]: JA Brennan, 
TP Enevoldson, G Gilling-Smith (PI), DA Gould, PL Harris, RG McWilliams, H-C 
Nasser, R White 
Manchester Royal Infirmary, Manchester [2]: KG Prakash, F Serracino-Inglott, G 
Subramanian (PI), JV Symth, MG Walker  
Newcastle Acute Hospitals NHS Foundation Trust, Newcastle-Upon-Tyne [108]: M 
Clarke, M Davis, SA Dixit, P Dorman (PI), A Dyker, G Ford, A Golkar, R Jackson, V 
Jayakrishnan, D Lambert, T Lees, S Louw, S Macdonald, AD Mendelow, H Rodgers, J 
Rose, G Stansby, M Wyatt  
North Bristol NHS Trust, Frenchay Hospital, Bristol [13]: T Baker, N Baldwin (PI), L 
Jones, D Mitchell, E Munro, M Thornton 
Royal Free Hospital, London [1]: D Baker, N Davis, G Hamilton (PI), D McCabe, A 
Platts, J Tibballs 
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield [151]: J Beard, T 
Cleveland, D Dodd, P Gaines, R Lonsdale, R Nair, A Nassef, S Nawaz, G Venables 
(PI) 
St George’s University of London and St George’s NHS Healthcare Trust, London 
[58]: A Belli, A Clifton, G Cloud, A Halliday, H Markus (PI), R McFarland, R Morgan, A 
Pereira, A Thompson  
St Mary’s Hospital, Imperial College Healthcare NHS Trust, London [13]: J 
Chataway (PI), N Cheshire, R Gibbs, M Hammady, M Jenkins, I Malik, J Wolfe  
University College London Hospitals NHS FoundationTrust, London [51]: M 
Adiseshiah, C Bishop, S Brew, J Brookes, MM Brown (PI), R Jäger, N Kitchen  
University Hospital of South Manchester, Wythenshawe, Manchester [58]: R 
Ashleigh, S Butterfield, GE Gamble, C McCollum (PI), A Nasim, P O'Neill, J Wong  
Western Infirmary, Glasgow [5]: RD Edwards, KR Lees, AJ MacKay, J Moss (PI), P 
Rogers   
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25. Appendix IV – ICSS trial protocol 
 Protocol summary 25.1
25.1.1 Background 
Clinical trials have shown that carotid surgery prevents stroke but also has significant 
morbidity. Stenting has become an established alternative treatment for coronary and 
peripheral vascular disease and has the advantage of avoiding general anaesthesia 
and neck incision. In July 1997, randomization was completed in the Carotid and 
Vertebral Artery Transluminal Angioplasty Study (CAVATAS). The results did not show 
a difference in the major risks or benefits of carotid angioplasty and surgery, but the 
trial did show that both methods still carry a significant risk of causing a stroke. 
Techniques of carotid angioplasty have improved and stenting is increasingly used. 
The International Carotid Stenting Study (ICSS or CAVATAS 2) is a follow-on study to 
CAVATAS designed as an international, multicentre, randomized trial, which will 
evaluate stenting of carotid artery stenosis in patients with cerebrovascular disease. 
25.1.2 Centre requirements 
A neurologist or physician with an interest in stoke, a surgeon with expertise in carotid 
endarterectomy and an interventionalist with expertise in carotid angiography and the 
techniques of angioplasty and stenting.  
25.1.3 Inclusion criteria 
Symptomatic atheromatous carotid stenosis, >50% by NASCET criteria, suitable for 
stenting and surgical endarterectomy. 
25.1.4 Treatments 
Patients will be randomised in equal proportions to be treated by carotid 
endarterectomy or stenting. New designs of stents, filters and protection devices will be 
incorporated into the study to allow tracking of new technology if approved by the 
Steering Committee. Surgery can be performed with local or general anaesthesia. 
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25.1.5 Sample size 
N=1500 patients from fully enrolled centres. Sample size calculations show that the 
95% confidence intervals will be 3.0 percentage points for the outcome measure of 30 
day stroke, myocardial infarction and death rate and 3.3 percentage points for the 
outcome measure of death or disabling stroke during follow-up.  
25.1.6 Primary outcome measure 
 Long term survival free of disabling stroke 
25.1.7 Secondary outcome measures 
 Any stroke, myocardial infarction or death within 30 days of treatment, 
treatment-related cranial nerve palsy or haematoma 
 Stenosis (>70%) and occlusion on ultrasound follow-up 
 Transient ischaemic attack 
 Stroke during follow-up 
 Further treatment procedure 
 Quality of life and economic measures 
 Background 25.2
Stroke is the major cause of acquired adult physical disability and is responsible for 
12% of all deaths in the UK. Reducing the burden of stroke is one of the priorities of the 
recent government white paper, Saving Lives: Our Healthier Nation. In Europe alone, 
there are approximately one million new cases of stroke a year. Atherosclerotic 
stenosis of the carotid artery is an important cause of stroke, which may be heralded by 
a transient ischaemic attack (TIA) or minor stroke, which recovers without serious 
disability. The risk of recurrent stroke in recently symptomatic patients with severe 
carotid stenosis is as high as 28% over two years. The European Carotid Surgery Trial 
(ECST) and the North American Symptomatic Carotid Endarterectomy Trial (NASCET) 
have demonstrated convincingly that this risk is reduced significantly by carotid 
endarterectomy [36] [35]. Carotid surgery has therefore become a standard treatment 
for these patients. However, the trials showed a significant risk of stroke or death 
resulting from surgery of between 6 and 8%. Surgery also caused significant morbidity 
from myocardial infarction during the general anaesthetic used in most centres, and 
minor morbidity, including cranial nerve palsy and wound haematoma, from the 
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incision. An increasing number of surgeons are performing carotid endarterectomy 
under local anaesthesia in the belief that it reduces the risks, although there is currently 
little evidence to support this practice, until the data from the General Anaesthesia 
versus Local Anaesthesia for Carotid Endarterectomy (GALA) trial are reported. 
Stenting is a new method of treating carotid stenosis which has evolved from the 
technique of percutaneous transluminal angioplasty (PTA). Stenting avoids some of the 
hazards of surgery and has become an established treatment for peripheral and 
coronary artery stenosis. Stenting is less invasive than carotid endarterectomy and has 
advantages in terms of patient comfort, because the procedure avoids an incision in 
the neck, and is usually conducted under local anaesthesia. Hospital stay need only be 
for 24 hours after treatment if uncomplicated. When given the choice, stenting is 
preferred by many patients. On the other hand, stenting does not remove 
atheromatous plaque, has not been shown to prevent stroke and may have an 
unacceptable incidence of restenosis. We therefore propose a multicentre randomised 
trial to compare carotid stenting with carotid surgery. 
25.2.1 Previous work in the field 
Percutaneous transluminal angioplasty 
A number of groups have published series of patients with carotid stenosis treated by 
PTA. The cumulative total of patients in these series is over 1000, with a reported 
major complication rate of less than 5% at the time of the procedure [244]. These data 
suggested that carotid PTA has a similar risk to carotid surgery, but the results could 
not be taken as definitive because none of the data were from randomised trials. We 
therefore started a randomised trial, known as the Carotid and Vertebral Artery 
Transluminal Angioplasty Study (CAVATAS) in l992. We completed randomisation in 
July 1997. 
Results of CAVATAS 
560 patients were entered, from 24 centres in the UK, Australia, Canada, Finland, 
Germany, Italy, Spain, Switzerland, and the USA. Patients with carotid stenosis 
suitable for surgery were randomised between PTA (n=251) and carotid surgery 
(n=253). Patients with carotid stenosis unsuitable for surgery (n=40) and patients with 
vertebral artery stenosis (n=16) were separately randomised between PTA and 
medical care alone. The number of patients in these last 2 groups was too small to 
form any firm conclusions. The analysis has therefore been restricted to the 504 
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patients with carotid stenosis randomised between PTA and surgery [75]. Baseline 
variables were well matched. Almost all patients had severe stenosis (mean 86%). The 
30-day outcome events were almost identical in the two groups with a rate of death or 
any stroke lasting more than 7 days of 10.0% after angioplasty and 9.9% after surgery, 
giving a hazard ratio of 1.01 (95% CI 0.56 to 1.81, p=NS). Analysis of the other risks of 
treatment has confirmed that PTA was safer than surgery in terms of minor morbidity. 
Cranial or peripheral nerve palsy was reported in 9% of surgical patients, but not in any 
PTA patients (p<0.01). Haematoma requiring operation or prolonging hospital stay was 
reported in 7% of surgical patients compared with 1% of PTA patients (p<0.01). PTA 
also appeared safer than surgery with regard to perioperative myocardial infarction, 
which occurred in 0.8% of surgical patients, but not in any PTA patients. Survival 
analysis from randomisation showed no difference in outcome events of ipsilateral 
stroke and any disabling stroke or death during follow up for up to 3 years with very few 
events in either arm after the treatment period, suggesting that both treatments were 
equally effective at preventing stroke. However, 19% of PTA patients had stenosis of 
>70% or occlusion by ultrasound criteria at 12 months after randomisation compared 
with 5% of surgical patients (p<0.01). Restenosis was not associated with new 
symptoms, but long-term follow up is limited. 
Causes and timing of stroke in CAVATAS 
The cause of stroke within 30 days of first treatment in CAVATAS was cerebral 
infarction in 22 patients in the PTA group and 20 patients in the surgery group. Primary 
cerebral haemorrhage caused the other three strokes in the PTA group and two 
strokes in the surgery group. All but one stroke was ipsilateral to the randomised artery. 
Surprisingly, a significant proportion of these treatment-related strokes were delayed 
after the day of treatment. Eight (36%) of the strokes in PTA patients occurred between 
the second and 21st day after treatment. Delayed stroke was also found in six (27%) of 
the surgical group between the third and 10th day after operation. Delayed stroke may 
account for the relatively high rate of 30-day morbidity in CAVATAS at 10% compared 
to 7.5% in ECST and 5.8% in NASCET. 
Carotid stenting 
Stents suitable for carotid use have only become available recently. The CAVATAS 
Steering Committee decided to allow the use of stents at the discretion of the 
interventionist. Stents were used in 55 patients randomised to PTA, usually as a 
secondary procedure i.e. after initial balloon dilation. The indication for using a stent in 
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these cases was usually an inadequate angiographic result and in some cases stents 
were deployed because of stroke at the time of full balloon inflation, as a ‘bail-out’ 
procedure. Only one stroke occurred at the time of stent deployment (1.8%), although 
there were a small number of delayed strokes after stenting.  
The need for a trial of carotid stenting 
It would be inappropriate to use the results of CAVATAS to propose the widespread 
introduction of PTA for the treatment of carotid stenosis as an alternative to surgery, 
because the 95% confidence interval surrounding the 10% risk of any stroke within 30 
days of treatment in the surgical and angioplasty groups is ±5%. Nevertheless, the 
results support the need for further randomised studies. The interventional technique 
used to treat carotid stenosis has evolved over the 7 years since we started CAVATAS, 
from the use of simple inflatable balloon catheters at the beginning of the trial to the 
increasing use of stenting towards the end of the trial. Initially stents were used only as 
a secondary procedure after full balloon inflation for inadequate results or 
complications of treatment. The desire to prevent these complications and superior 
early results in stented patients has led to the increasing use of the technique of 
primary stenting in which the intention is to deploy a stent in every patient before 
dilation (but after pre-dilatation to allow the atraumatic passage of the stent) of the 
artery [245]. Primary stenting is now accepted as best practice and has become the 
radiological technique of choice for carotid stenosis, replacing balloon angioplasty. 
Advantages of carotid stenting 
The majority of major strokes after carotid PTA are the result of dissection of the 
carotid artery at the time of balloon inflation with subsequent thrombosis. It is believed 
that stenting is safer than simple balloon angioplasty because embolisation, dissection 
and closure of the carotid artery are less likely to occur [246] [247]. The subgroup 
analysis of stented patients in CAVATAS is consistent with this suggestion. The 
adverse consequences of dissection are minimised, because the stent maintains 
laminar flow across the stenosis and seals the site of dissection, preventing a free 
intimal flap. In addition, the stent mesh limits the size of any thrombus or atheromatous 
debris that may be dislodged from the plaque at the time of dilation of the artery. 
Superior dilation achieved by stenting compared with balloon angioplasty may also 
reduce the rate of stroke in the early post-treatment period. In the coronary circulation, 
stenting has been shown to produce superior outcomes compared with balloon 
angioplasty [248] [249]. Individual case series suggest that carotid stenting has a 
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similar rate of procedural stroke to that of carotid surgery [246] [247], while a recent 
registry reported a total of 2048 patients from 24 centres undergoing carotid stenting 
with a complication rate of stroke and death within 30 days of treatment of 5.8% [250]. 
Disadvantages of carotid stenting 
Although acceptable safety at the time of stenting has been suggested by the case 
series and registry data, stenting has not been subjected to a randomised trial in 
comparison to conventional surgical treatment and has not been demonstrated to 
prevent stroke, which is the aim of treatment. Stenting does not remove atheromatous 
plaque and stents may stimulate neo-intimal hyperplasia. In the long term it is likely that 
the rate of restenosis will be greater after stenting than after carotid surgery, which 
could well result in an unacceptable rate of long-term stroke recurrence. There is an 
important need to establish the efficacy of carotid stenting in comparison to surgery 
before the technique is widely introduced without adequate trial based evidence.        
Antiplatelet therapy 
In cardiological practice, ischaemic complications during coronary stenting have been 
shown to be significantly reduced by using a combination of two antiplatelet agents, 
ticlopidine and aspirin. In one coronary trial, stent thrombosis was reduced from 3.6% 
in patients assigned aspirin alone down to 0.5% in patients assigned aspirin and 
ticlopidine [251]. A recently completed trial has shown that similar results with less risk 
of side effects can be achieved during coronary stenting by using the combination of 
clopidogrel with aspirin [252]. It is likely that this combination would also reduce the 
risks of stroke during carotid stenting. A pilot study is currently being carried out at one 
of the centres to establish the safety of the combination of clopidogrel and aspirin given 
before and for 30 days after carotid stenting. It is likely that this will become standard 
therapy. Most surgeons currently believe that combination antiplatelet therapy during 
surgery is hazardous because of excess bleeding. 
Economic and quality of life considerations 
Quality of life and general health status were assessed in CAVATAS using the SF36 
and EuroQol EQ-5D questionnaires. These showed a similar quality of life for patients 
randomised to either treatment. Operating and radiology suite costs were similar in a 
sample of patients at two UK centres, but surgery was associated with a longer hospital 
stay and greater use of ITU beds. Surgery was therefore considerably more expensive 
than angioplasty (mean difference £946). However, the mean cost of an angioplasty 
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increased from £1086 to £1864 if a stent was used. The use of stents in every case is 
therefore likely to increase the costs of stenting close to that of surgery, but this might 
be counterbalanced by performing carotid stenting as a day case procedure. Surgical 
length of stay is also declining. Follow up costs might be very different if restenosis is 
more frequent in one arm. Economic analysis will therefore be an important component 
of ICSS. 
25.2.2 Aims of ICSS 
To compare the risks, benefits and cost effectiveness of a treatment policy of referral 
for carotid stenting compared with referral for carotid surgery. 
 Trial design  25.3
ICSS is an international, multicentre, randomised, controlled, open, prospective clinical 
trial comparing carotid surgery with carotid stenting. 
25.3.1 Participating centre requirements 
Each centre must have a neurologist or physician with an interest in stroke who will see 
patients prior to randomisation and for follow up. Carotid endarterectomy must be 
carried out by designated surgeons with expertise in the operation. Carotid stenting will 
be carried out by designated consultant interventionists with expertise in carotid 
angiography and the techniques of angioplasty and stenting. Good collaboration 
between the neurologists, surgeons and interventionists is essential and centres should 
have regular neurovascular meetings. Attendance at training sessions in carotid 
stenting provided by credentialing centres will be required for all interventionists prior to 
participation. Participating centres will be required to submit curriculum vitae for all 
participating clinicians and an audit of recent carotid surgery and PTA / stenting results. 
An accreditation committee will decide if they have appropriate experience and 
expertise to join the study. As a guide, surgeons and interventionists will be expected 
to show a stroke and death rate within 30 days of treatment, consistent with the centres 
in ECST who had an average rate of 7.0% with a 95% confidence interval of 5.8 to 
8.3% [36]. Surgeons will be expected to have performed a minimum of 50 carotid 
operations with a minimum annual rate of at least 10 cases per year. Interventionists 
will similarly be expected to have performed a minimum of 50 stenting procedures, of 
which at least 10 should be in the carotid territory. Centres where there is little or no 
experience of carotid stenting may join ICSS for a probationary period in order to gain 
the minimum experience of ten carotid stenting procedures required to join the trial 
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fully. The results in patients randomised during the probationary period will be analysed 
separately. 
All centres will have to provide proof of ethical committee approval for the study before 
commencing randomisation.  
25.3.2 Probationary centres  
Probationary centres will be required to fulfil all the other requirements for entry, but will 
not have to provide audited data on ten carotid stenting procedures initially. 
Probationary centres will randomise patients within the ICSS protocol between surgery 
and stenting. Individual interventionists who are not able to satisfy the credentialing 
requirements will be identified as probationary investigators. Stenting procedures 
carried out during the probationary period must be proctored by an experienced carotid 
interventionist, until the proctor is satisfied that the interventionist(s) at the centre can 
satisfactorily carry out procedures unproctored. Probationary interventionists will 
become fully enrolled in ICSS when both the proctor is satisfied that the interventionist 
can perform procedures unsupervised and the interventionist has 10 or more 
successfully completed cases in the trial, with an acceptable complication rate. When 
an investigator has done sufficient successful procedures, the trial office will get 
comments from the relevant proctor, and then have any decision to promote the 
investigator or centre signed off by the chair of steering committee. 
25.3.3 Proctoring  
Proctors for probationary centres will be approved by the accreditation committee in 
consultation with the probationary centre via the central ICSS office. Probationary 
centres may suggest an appropriate proctor, but he or she will require prior approval 
from the accreditation committee, based on review of the proctor’s experience of 
carotid stenting. It is the responsibility of the probationary interventionist to make 
contact with an approved ICSS proctor and to ensure a convenient date is organised 
for the stenting procedure at which the proctor can be present.  Copies of the relevant 
radiology should be available for the proctor for review prior to starting the stenting 
procedure. This should be done prior to randomisation if there was any doubt about the 
suitability of the patient for stenting. In the event of a centre requiring proctoring for 
surgery the same procedure will apply. 
It is the responsibility of the probationary interventionist and the proctor in discussion to 
ensure the lesion is appropriate for treatment (e.g. sufficiently severe), that the patient 
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has received appropriate premedication (e.g. a combination of clopidogrel and aspirin) 
and that the lesion is suitable for stenting. They should agree the type, range and sizes 
of equipment required and the probationary interventionist should ensure that this 
equipment is available to complete the procedure. If any of these conditions are not 
met, the procedure should be abandoned and if appropriate rescheduled for another 
occasion. 
Catheter or arch angiography is not required in ICSS prior to randomisation if the 
centre does not routinely perform angiography prior to treatment.  However, the centre 
interventionist, the proctor and the patient should be aware that if preliminary 
angiography at the time of planned stenting shows a lesion which is not suitable for 
stenting, the procedure should be abandoned and the patient referred for surgery, or 
continued medical management.  This type of cross over is envisaged in the trial 
design.  
Where a centre has an adequately qualified surgeon and interventionist they may 
supervise surgeons and interventionists at the same centre whose experience would 
not initially qualify them for the trial until they have gained sufficient experience.  These 
new investigators must enrol with the central ICSS office (see participating centre 
requirements). 
25.3.4 Inclusion criteria  
 Symptomatic extracranial, internal or bifurcation atheromatous carotid artery 
stenosis that is suitable for both stenting and surgery and is deemed by the 
randomising clinician to require treatment 
 The severity of the stenosis of the randomised artery should be at least 50% (as 
measured by NASCET method or non-invasive equivalent) 
 Symptoms must have occurred in the 12 months before randomisation. It is 
recommended that the time between symptoms and randomisation should be 
less than 6 months, but patients with symptoms occurring between 6 and 12 
months may be included if the randomising physician considers treatment 
indicated 
 The patient must be clinically stable following their most recent symptoms 
attributable to the stenotic vessel 
 Patients must be willing to have either treatment, be able to provide informed 
consent, and be willing to participate in follow up 
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 Patients must be able to undergo their allocated treatment as soon as possible 
after randomisation 
 Any age greater than 40 may be included. There is no upper age limit 
 Patients should only be randomised if the investigator is uncertain which of the 
two treatments is best for that patient at that time 
25.3.5 Exclusion criteria 
 Patients refusing either treatment 
 Patients unable or unwilling to give informed consent 
 Patients unwilling or unable to participate in follow up for whatever reason 
 Patients who have had a major stroke with no useful recovery of function within 
the territory of the treatable artery 
 Patients with a stenosis that is known to be unsuitable for stenting prior to 
randomisation because of one or more of: 
o Tortuous anatomy proximal or distal to the stenosis 
o Presence of visible thrombus 
o Proximal common carotid artery stenotic disease 
o Pseudoocclusion (‘string sign’) 
o Patients not suitable for surgery due to anatomical factors e.g. high 
stenosis, rigid neck 
 Patients in whom it is planned to carry out coronary artery bypass grafting or 
other major surgery within 1 month of carotid stenting or endarterectomy 
 Carotid stenosis caused by non-atherosclerotic disease e.g. dissection, 
fibromuscular disease or neck radiotherapy. 
 Previous carotid endarterectomy or stenting in the randomised artery 
 Patients in whom common carotid artery surgery is planned 
 Patients medically not fit for surgery 
 Patients who have a life expectancy of less than two years due to a pre-existing 
condition, e.g. cancer 
25.3.6 Non-randomised patients 
An anonymised log will be kept of patients undergoing treatment for carotid stenosis by 
the trial investigators but not randomised at the participating centres. Patients 
undergoing stenting but not randomised should also be included on a suitable registry, 
such as EUROCAST. 
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25.3.7 Consent 
Written witnessed, informed consent will be obtained from all patients and a copy must 
be retained by the randomising centre. All patients will be provided with a written 
explanation of the study. 
25.3.8 Randomisation 
Randomisation will be by a telephone call or fax to a computerised service provided by 
the Oxford Clinical Trials Service Unit. Randomisation will be stratified by centre with 
minimisation of the main risk factors and balanced between the arms. Patients who 
need treatment of both carotid arteries will only be randomised for the carotid artery to 
be treated first. Patients can only be randomised once. 
25.3.9 Investigations before randomisation 
The following investigations are required: Routine haematology (FBC, platelets), blood 
biochemistry (renal function, blood sugar, cholesterol), chest x-ray, ECG, brain CT or 
MRI scans. The brain scan is required to exclude other pathology, to identify existing 
infarcts and to provide a baseline reference against which any subsequent infarction or 
haemorrhage can be assessed. Copies of the CT or MRI scans should be sent to the 
ICSS office. 
25.3.10 Carotid imaging 
Mandatory investigation is required for entry into the study to confirm the presence and 
severity of the ipsilateral stenosis and to assess contralateral carotid disease. The 
following are acceptable: 
 Arch arteriogram showing both carotid bifurcations 
 Selective catheter carotid angiography showing the randomised carotid artery 
with non-invasive investigation of the contralateral carotid bifurcation 
 Bilateral magnetic resonance carotid angiograms together with a concordant 
ultrasound scan 
 Bilateral spiral CT angiograms together with a concordant ultrasound scan 
 Bilateral duplex and Doppler ultrasound scan, only if this is standard practice to 
treat on the basis of ultrasound alone in individual centres and the centre has 
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been able to provide proof of the reliability of their ultrasonographic imaging 
through clinical audit 
The following data from the pre-randomisation imaging will be sent to the Central Office 
for review: 
 A copy of the written reports of the studies 
 A film copy of the view of the vessel to be treated showing the stenosis at its 
most severe 
 A film copy of the view of the contralateral vessel showing any stenosis at its 
most severe 
 Velocity data from the ultrasound examination 
Patients who are randomised to stenting after ultrasound or other non-invasive 
investigation, in which subsequent angiography, prior to stenting, reveals one or more 
exclusion criteria should be treated by surgery, if appropriate, or medical care only if 
surgery is not appropriate (e.g. because the stenosis is less than 50%). These patients 
will continue follow up in the trial and will be analysed on an intention to treat basis. A 
similar approach should be taken to patients randomised to surgery in whom 
contraindications to surgery emerge after randomisation. 
25.3.11 Ultrasound 
Ultrasound study of the carotid artery to be treated will be performed at or before 
randomisation, at one month after treatment and then annually after randomisation in 
all patients. The following information is required for each study: Peak systolic velocity 
of internal carotid artery (PSV ICA), end diastolic velocity of internal carotid artery (EDV 
ICA), peak systolic velocity of common carotid artery (PSV CCA). The accuracy of 
individual ultrasound laboratories will be audited by comparing the pretreatment 
ultrasound examination against catheter angiography films, which will be available in 
patients randomised after angiography and in all the patients treated by stenting. 
 
25.3.12 Baseline data 
Baseline data collected at randomisation will include demographic data; existing 
medical risk factors; neurological symptoms including an assessment of disability using 
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the Modified Rankin Scale; current antiplatelet therapy and blood pressure. Films 
and/or reports of pre-randomisation imaging as detailed above and in all cases the 
results of Doppler ultrasound as detailed below are required to allow assessment of 
any subsequent stenosis. 
25.3.13 Baseline assessment  
Patients will be seen by the study neurologist or physician interested in stroke prior to 
randomisation to confirm suitability for the study. 
25.3.14 Stenting protocol 
Stenting will be carried out as soon as possible after randomisation using percutaneous 
transluminal interventional techniques from the femoral, brachial or common carotid 
artery by a designated interventional consultant using an appropriate stent. A cerebral 
protection system should be used whenever the operator thinks one can be safely 
deployed. Stents and other devices used in the trial must be CE marked and approved 
by the Steering Committee. Pre-medication will be discretionary. The combination of 
aspirin and clopidogrel is recommended as the antiplatelet regime of choice to cover 
the period of stenting and for a minimum of 4 weeks afterwards. Intra-procedural 
heparin is mandatory at a dose determined by the operator, post-procedural heparin 
may be given according to clinical requirements. Patients should be monitored for 
changes in their neurological status and heart rate throughout the procedure. If femoral 
or brachial access is being used a long sheath introducer or a guiding catheter is 
placed in the common carotid artery allowing pre-dilation and stent placement under 
direct arteriographic imaging. Atropine, or a similar agent, must be administered prior to 
stent deployment to counteract any effects on the carotid artery baroreceptors, which 
could lead to severe bradycardia and/or asystole. Virtually all patients will require pre-
dilatation of the stenosis by balloon angioplasty prior to stent deployment. This will 
minimise the embolic load caused by passage of the endoluminal stent through the 
stenosis. The size of the pre-dilatation balloon will be determined by the size of the 
delivery system being used. Further balloon dilation of the stent will usually be required 
to ensure apposition of the stent against the arterial wall.  Angiographic images 
showing the stenosis at its most severe prior to stenting and the same view and any 
other view that demonstrates the maximum residual stenosis after stenting must be 
sent to the Central Office. Details of the procedure, including all peri-procedural 
complications, drug therapy and devices used in the procedure, must be reported and 
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the stenting and cerebral protection technical data sheet returned to the trial Central 
Office. 
25.3.15 Endarterectomy protocol 
Endarterectomy is to be done as soon as possible after randomisation by a designated 
consultant surgeon who has been approved by the Credentials Committee. It is to be 
carried out using whichever procedures are standard at the individual centre, including 
the use of local or general anaesthesia, shunts or patches as required by the operating 
surgeon. Standard or eversion endarterectomy may be performed. 
25.3.16 Reporting of suspected problems with surgical or stenting 
techniques at individual centres 
If the local investigator or other member of the team at a trial centre has concern about 
the outcome of their trial procedures they should inform the ICSS trial office which will 
organise a blinded assessment of the relevant outcome events. This will be submitted 
by the central office to the chairman of the data monitoring committee who may 
recommend further action, such as suspending randomisation at the centre. Similarly, 
the database manager at the trial office will monitor outcome events and if there are 
two consecutive deaths or three consecutive major events at a single centre within 30 
days of treatment in the same arm of the study, then assessment of the events will be 
triggered. A cumulative major event or death rate of more than 10% over 20 cases 
would also trigger careful assessment of the relevant outcome events.  
25.3.17 Medical treatment  
All patients will receive best medical care including antiplatelet therapy or 
anticoagulation (when appropriate) and control of medical risk factors such as 
hypertension, smoking and hyperlipidaemia before treatment and throughout the period 
of follow up. 
25.3.18 Prevention of thrombosis 
Therapy to prevent thrombosis during or soon after surgery or stenting will be 
prescribed according to standard practice in each centre. This may include heparin, 
dextran, aspirin, dipyridamole, ticlopidine, clopidogrel, or a combination of aspirin and 
another antiplatelet agent. Glycoprotein IIb/IIIa antiplatelet receptor antagonists will not 
be used routinely. 
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25.3.19 Follow-up 
Patients will be followed up by a neurologist or a physician interested in stroke at the 
participating centres at 30 days after treatment, 6 months after randomisation and then 
annually after randomisation. All post-procedural complications occurring within thirty 
days after the procedure will be reported to the central office at the 30 day follow up. At 
each visit, levels of stroke-related disability will be assessed using the modified Rankin 
Scale and any relevant outcome events will be notified to the Central Office. A Doppler 
ultrasound will be used to measure carotid arterial diameter to assess patency at one 
month after treatment and then annually after randomisation. In addition, ultrasound re-
examination and CT or MRI scan should be performed in patients who have any 
transient ischaemic events and/or stroke during follow up. The duration of follow up will 
be a minimum of 5 years (or until termination of the trial if earlier). At the 5 year follow 
up, patients will be asked if they are willing to continue follow up, in which case annual 
follow up will continue up to a maximum of 10 years from randomisation. 
25.3.20 Sample size calculations and recruitment 
The planned sample size is 1500. We do not anticipate any large difference in the 
principal outcome between surgery and stenting. We propose to estimate this 
difference and present a confidence interval for difference in 30-day death, stroke or 
myocardial infarction and for three-year survival free of disabling stroke or death. For 
1500 patients, the 95% confidence interval will be the observed difference ±3.0% for 
the outcome measure of 30 day stroke, myocardial infarction and death rate and ±3.3% 
for the outcome measure of death or disabling stroke over three years follow up. 
However, the trial will have the power to detect major differences in the risks of the two 
procedures, for example if stenting proves to be much riskier than surgery or 
associated with more symptomatic restenosis. The differences detectable with power 
80% are 4.7% for 30 day outcome and 5.1% for survival free of disabling stroke. 
Similar differences are detectable for secondary outcomes. We expect to achieve this 
recruitment within 6 years. 
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 Principal research questions to be addressed 25.4
25.4.1 Primary analysis 
 What is the difference in the long-term rate of fatal or disabling stroke in any 
territory of patients with severe symptomatic stenosis after randomisation to a 
policy of carotid stenting compared to surgery? 
25.4.2 Secondary analysis 
 What are the differences in mortality and morbidity within 30 days of carotid 
stenting compared to surgery? 
 What is the rate of symptomatic and asymptomatic restenosis after carotid 
stenting compared to surgery? 
 What are the differences in the rate of ipsilateral stroke during follow-up after 
carotid stenting compared to surgery? 
 What is the cost-effectiveness of carotid stenting compared to surgery? 
 What are the risk factors for stroke within 30 days and during long term follow 
up (including those related to age, gender, symptoms, imaging, centre and 
technique)? 
25.4.3 Outcome events  
 Any stroke or death 
 Transient ischaemic attack 
 Myocardial infarction within 30 days of treatment 
 Cranial nerve palsy within 30 days of treatment 
 Haematoma caused by treatment requiring surgery or transfusion or prolonging 
hospital stay 
 Stenosis greater than 70% or occlusion during follow-up 
 Further treatment of the randomised artery by interventional radiology 
techniques or surgery after the initial attempt 
 Quality of life, health status and health service costs (see paragraph below) 
25.4.4 Outcome event reporting  
Outcome events will be documented in detail by the investigating centre, censored 
after receipt at the central office to remove clues as to the treatment received, and then 
 223 
adjudicated by an independent neurologist. Patients suffering stroke should have a CT 
or MRI brain scan as soon as possible after the event. A film copy of this, together with 
a film copy of the pre-randomisation scan (if done) should be submitted together with a 
report of the event. The event report should include copies of discharge summaries, 
death certificates and post mortem results if relevant. Deaths of UK patients will be 
tracked by flagging patients against the UK Registry of Births and Deaths. Disability 
after stroke and cranial nerve palsy will be assessed 30 days and six months after 
treatment or onset, using the modified Rankin Scale. Duration of symptoms will be 
recorded and outcome events will be classified as disabling if the Rankin score is 3 or 
more at six months. 
 Learning curve 25.5
Carotid stenting is a new procedure, while the techniques of carotid surgery are well 
established. It is likely that there will be a learning curve for carotid stenting and the 
results may improve with experience during the trial. However, we believe it is better 
that carotid stenting should be performed as part of a randomised clinical trial at this 
stage of its development, because this will ensure careful assessment and follow up of 
all patients treated in the trial and supervision from the Data Monitoring and Ethics 
Committee ensures that continuing treatment with the new technique remains ethical. 
The influence of the early part of the learning curve for carotid stenting will be limited by 
careful training of individual interventionists. The total experience of carotid PTA and 
stenting of individual interventionists will be recorded prior to entry into the trial. This 
will allow the average duration of the learning curve to be analysed, taking into account 
the current experience of the individual interventionists. This information may have 
implications for interpretation of the results of the trial and for the future training and 
supervision of the procedure. Similarly, there may be improvements in individual 
surgical or anaesthetic techniques during the trial. 
 Effect of changes in technology during the course of the study 25.6
The field of carotid stenting is an area of fast changing technology. The protocol does 
not at present specify the type or manufacturer of the stents or protection devices to be 
used, but devices to be used in the trial will be CE marked and approved by the 
Steering Committee who will expect a peer reviewed report of device safety. More than 
one device may be recommended to allow the interventionist to tailor the choice of 
stent to the individual stenosis and to use new designs of stent or protection devices if 
appropriate. The protocol will not specify the technique to be used during carotid 
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surgery. Decisions about the use of shunts or specific suture materials will be left to the 
individual surgeon. Local or general anaesthesia will be allowed in both arms. 
Technical details of surgical and stenting technique, including the manufacturer and 
type of stent used, the use of local or general anaesthesia, and the use of 
antithrombotic agents, will be recorded. The analysis will include a subgroup 
comparison of different techniques in both arms and the data will be presented to the 
DMC meetings to ensure that no one technique is significantly inferior to another. 
Randomisation will use a computer program to minimise variation between centres and 
over time, so that equal numbers of patients will be entered into the stenting and 
surgery arms before and after any change in practice. 
 Health service research issues 25.7
If the trial confirms the hypothesis that carotid stenting and surgery are equivalent in 
terms of the major risks of stroke and death, then the choice between the two 
procedures will be determined primarily by differences between the two procedures in 
other outcomes e.g. the disadvantage of a scar or cranial nerve palsy, or the effects of 
surgery on health related quality of life. If these differences are minor, the choice 
between the procedures will be made primarily on economic grounds. The effects of 
cranial nerve palsy may be detected by a minor increase in the disability score, but it is 
not easy to assess the effect of these outcomes during follow-up on clinical 
examination alone. Quality of life and health status will therefore be assessed using the 
EuroQol (EQ5D) questionnaire to compare patients’ feeling of well-being, health and 
quality of life before and after stenting or surgery at one month, six months and annual 
follow-up. The results will be analysed blind to treatment arm. The first questionnaire 
will be completed at the time of randomisation and subsequent questionnaires at each 
follow-up visit. The investigator performing randomisation or follow-up should ensure 
the patient completes the EQ5D at the same time. The English language version of the 
EQ5D has been modified to record the date on which it is completed and the patient’s 
trial number. Those centres using versions in other languages should also record the 
date and trial number on each completed form.  If patients are too disabled to complete 
the questionnaires themselves, the patient’s carer may complete them. The EQ5D 
should be returned to the central office with the other trial forms. 
Information on hospital resource use during the treatment and follow up, including the 
type and manufacturer of the devices employed in carotid stenting procedures, will be 
collected to measure treatment costs and estimate the costs of stroke and any 
consequences of restenosis (e.g. re-treatment) during follow up. Unit costs will be 
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obtained from a sample of representative centres.  The costs of stroke caused by 
treatment are a major component of the total cost of treatment, and therefore have a 
major influence on cost effectiveness. As the additional length of stay in hospital 
resulting from stroke largely drives these costs, the prospective collection of length of 
stay data will be designed to capture the stroke-related data in addition to direct 
operative stay. The economic evaluation will address cost-effectiveness and cost-utility 
(cost per QALY). The latter will be estimated from patients’ responses to the EuroQol 
(EQ-5D) questionnaires using the York MVH tariff. Uncertainty regarding specific 
parameters within the analysis will be subjected to a sensitivity analysis, and 
uncertainty around the point estimate of the cost utility ratio will be represented using 
cost-effectiveness acceptability curves. To inform the economic analyses, the 
preferences of potential patients and clinicians between carotid endarterectomy and 
carotid stenting given various differences in outcomes will be explored using the 
technique of conjoint analysis (discrete choice experiments).  A sample of members of 
the general population (matched to the ICSS patients) and clinicians will be asked to 
complete a questionnaire after completion of randomisation, informed by the 
preliminary safety results.  Preliminary work, structuring and piloting the conjoint 
analyses, will be undertaken earlier. 
 Stenosis after treatment 25.8
Patency of the carotid artery will be monitored by Doppler ultrasound at a minimum of 
30 days after treatment and then annually after randomisation. Restenosis should only 
be treated by further angioplasty or surgery if the patient has relevant new symptoms. 
Restenosis is usually the result of smooth muscle hypertrophy or neo-intimal 
hyperplasia, rather than recurrence of atherosclerosis and hence may not cause 
embolic stroke. Asymptomatic restenosis will not be an indication to retreat the lesion 
because the risk of disabling symptoms after restenosis is not known. 
 Crossovers 25.9
Crossovers before any attempt to treat the randomised artery by the allocated 
treatment will be avoided unless clinically essential, because the trial data will be 
analysed by intention to treat. Patients who are randomised to stenting after ultrasound 
or other non-invasive investigation, in whom subsequent angiography prior to stenting 
reveals one or more exclusion criteria, should be treated by surgery, if appropriate, or 
medical care only if surgery is not appropriate (e.g. because the stenosis is less than 
50%). These patients will continue follow up in the trial and will be analysed on an 
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intention-to-treat basis. A similar approach should be taken to patients randomised to 
surgery in whom contraindications to surgery emerge after randomisation. Patient 
refusal of the treatment to which they are randomised can be minimised by careful 
consent. Patients requiring re-treatment because of further symptoms should be re-
treated with whichever treatment is most appropriate. This is also the case if the non-
randomised carotid artery requires treatment. Patients in whom an attempt at stenting 
fails may proceed to early surgery if appropriate and vice versa. 
 Data analysis 25.10
The data will be analysed by intention to treat using standard statistical tests by the trial 
statistician. The analyses will compare the treatment groups with respect to the length 
of time before treatment failure (i.e. occurrence of an outcome event) by means of the 
Mantel-Haenszel chi-squared test and Kaplan-Meier survival curves. Secondary 
analysis will compare the proportions of outcome events within 30 days of treatment. 
All analyses will be adjusted for centre and predetermined risk factors. Subgroup 
analyses will examine risk factors for outcome events and will examine the influence of 
different devices, surgical techniques and experience within the trial. Results at 
probationary centres will be analysed separately.  The results of any interim data 
analysis will remain confidential to the trial statistician and Data Monitoring Committee 
until after completion or early discontinuation of the trial. Investigators and the Steering 
Committee will remain blind until such point. 
 Publication 25.11
Publication of the results of ICSS will be prepared by the Central Office and circulated 
to participating centres for comment prior to submission of the manuscript for 
publication on behalf of all the ICSS collaborators. 
 Ethical Committee approval 25.12
Multicentre Research Ethics Committee approval will be sought in the UK. In addition, 
individual centres are expected to obtain local ethical committee approval for the study.  
 Data Monitoring Committee 25.13
The safety aspects of the trial will be overseen by a Data Monitoring Committee 
consisting of an independent neurologist, medical statistician, surgeon and 
interventionist. The progress of the study will be assessed at regular intervals 
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determined by the Data Monitoring Committee. During the period of intake to the study, 
interim analyses of mortality and of any other information that is available on major 
endpoints (including serious adverse events believed to be due to treatment) will be 
supplied, in strict confidence, to the chairman of the Data Monitoring Committee, along 
with any other analyses that the Committee may request. In the light of these analyses, 
the Data Monitoring Committee will advise the chairman of the Steering Committee if, 
in their view, the randomised comparisons in ICSS have provided both (i) "proof 
beyond reasonable doubt" that for all, or for some, specific types of patients, one 
particular treatment is clearly indicated or clearly contraindicated in terms of a net 
difference in outcome, and (ii) evidence that might reasonably be expected to influence 
materially patient management. Appropriate criteria of proof beyond reasonable doubt 
cannot be specified precisely, but a difference of at least 3 standard deviations in an 
interim analysis of a major endpoint may be needed to justify halting, or modifying, the 
study prematurely. This criterion has the practical advantage that the number of interim 
analyses is of little importance.  
 Steering Committee 25.14
A Steering Committee, consisting of individuals participating in and independent of the 
trial with experience in stroke medicine, neurology, vascular surgery, vascular 
radiology, interventional neuroradiology, health economics, clinical trials and statistics 
will oversee the management of the trial. 
 Trial organisation 25.15
The study will be organised on behalf of the collaborators by the central office, located 
at the UCL Institute of Neurology in London. The office will be responsible for protocol 
design, data collection and management, and analysis of the results in consultation 
with the Steering and Data Monitoring Committees, but will consult with the 
collaborators at an annual meeting and at other times as necessary. Communication 
with investigators will also take place via a regular newsletter and the trial website. 
25.15.1 Payments to centres 
While funding is available, the Lead Institution (UCL Institute of Neurology, London) will 
pay the participating centres a one-off payment of £100 for each patient randomised 
patient for whom correctly filled-out randomisation, technical data and one month 
follow-up forms have been received. Participating centres must invoice to the Lead 
Institution within 6 months of receipt of this revised protocol and thereafter 6-monthly in 
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arrears. The Lead Centre may vary or terminate such payments in the future in 
accordance with budgetary needs and will inform the participating centre of such 
changes as they occur. 
25.15.2 Indemnity 
ICSS is an academic trial performed as a collaborative effort for the benefit of patients, 
and is not performed for, or on behalf of, an industry sponsor. The trial compares two 
existing forms of treatment currently used in many hospitals. The various devices 
approved for use in the trial are not investigational devices and are required by the 
protocol to be marketed and already in use in the carotid artery as recognised by the 
CE mark. Hence, the trial is not an industry sponsored test of a new treatment with 
unknown hazards. The trial protocol anticipates that some patients may be harmed 
inadvertently as a result of treatment in the trial. Indeed, the determination of the rate of 
these adverse outcome events is a major aim of the trial. However, we believe that the 
risks of these adverse events will be outweighed by the benefits of treatment in either 
arm of the trial. The trial protocol does not subject patients to hazards that the patient 
would not have encountered if they had received the trial treatments outside the 
context of the trial in routine practice. Hence, the organisers of the trial cannot take 
responsibility for any harm occurring to patients as a result of partaking in the trial. 
Individual investigators and hospitals are required to take responsibility for the 
occurrence of any adverse events in the same way as they would do if the treatments 
were performed outside the trial. 
25.15.3 Website  
The trial website contains updated information about the trial together with 
downloadable copies of the protocol, trial data collection forms, newsletters and contact 
information. The names of the collaborating centres will be included on the website. 
The website address is http://www.cavatas.com and all the pages are accessible to the 
public, patients and collaborators alike without a password. At present, the data 
collection forms cannot be completed on line. 
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26. Appendix V – ICSS-MRI Substudy protocol 
Symptomatic and asymptomatic ischaemic and haemorrhagic brain injury following 
protected and unprotected stenting versus endarterectomy in the International Carotid 
Stenting Study – the ICSS-MRI Substudy. 
 Summary 26.1
26.1.1 Background and aim 
Diffusion weighted imaging (DWI) – a modern magnetic resonance imaging (MRI) 
technique – may detect ischaemic brain lesions after carotid interventions in patients 
who do not experience symptoms. Previous studies showed that DWI lesions are found 
more frequently after endarterectomy than after stenting of carotid stenosis, and more 
frequently after stenting without the use of cerebral protection devices than after 
protected stenting. However, methodological shortcomings of those non-randomised 
studies may account for the observed differences. Moreover, it is not clear how 
ischaemic lesions on DWI relate to the risk of clinically apparent cerebrovascular 
events (stroke or TIA) associated with the intervention. About one in ten strokes 
occurring as a complication of carotid interventions is caused by intracerebral 
haemorrhage (ICH), but asymptomatic ICH after carotid interventions has never been 
assessed. We therefore aim to study the frequency and significance of symptomatic 
and asymptomatic ischaemic and haemorrhagic brain injury in protected and 
unprotected stenting and endarterectomy in a randomised trial. 
26.1.2 Primary objective 
 To compare the rate of ischaemic brain injury detectable on MRI after treatment 
of symptomatic carotid stenosis by stenting or endarterectomy 
26.1.3 Secondary objectives 
 To test for an interaction between the use of cerebral protection devices and 
ischaemic brain injury associated with stenting 
 To compare the rate of haemorrhagic brain injury detectable on MRI after 
treatment of symptomatic carotid stenosis by stenting or endarterectomy 
 To evaluate the usefulness of ischaemic and haemorrhagic brain lesions visible 
on MRI as surrogate markers of the procedural risk of carotid interventions 
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 Methods  26.2
Multicentre prospective MRI substudy of the International Carotid Stenting Study 
(ICSS). Multimodal MRI to detect ischaemic and haemorrhagic brain injury will be 
performed at 3 time points in patients with symptomatic carotid stenosis randomised to 
stenting or endarterectomy in ICSS: 1-3 days before, 1-3 days after and again 30±3 
days after intervention. 
 Background and aim 26.3
Carotid stenting has emerged as a treatment alternative to endarterectomy in patients 
with symptomatic carotid stenosis. Cerebral protection devices are used in stenting 
with the aim of reducing the risk of plaque embolisation during the procedure. Recently 
completed randomised trials comparing the safety of stenting and endarterectomy 
yielded conflicting results [79] [77]. Concern that stenting without cerebral protection 
may be associated with an increased risk of stroke led to the abandonment of 
unprotected procedures in one trial [63] but in another trial, there was no difference in 
the risk of stenting with and without protection [77]. Although clear evidence that 
cerebral protection enhances treatment safety is lacking [253], protection devices are 
widely used today, significantly contributing to the cost of carotid stenting. 
Until clinical trials investigating the benefit of cerebral protection devices can be 
realised, surrogate markers of brain injury may provide further insights into the risk of 
protected and unprotected stenting in comparison to endarterectomy. Diffusion 
weighted imaging (DWI), a modern magnetic resonance imaging (MRI) technique, may 
show ischaemic lesions after carotid interventions even in patients who do not 
experience symptoms [214]. In previous studies new ischaemic lesions on DWI were 
detected more frequently after stenting than after endarterectomy [254] [255] [256] 
[257] [258] [259] [260]. DWI lesions were also more frequent after unprotected stenting 
than after protected stenting [215] [261]. However, selection bias and the use of 
historical controls may be accountable for the observed differences in these non-
randomised comparisons. Moreover, it is not clear how ischaemic lesions on DWI 
relate to the risk of clinically apparent cerebrovascular events (stroke or TIA) 
associated with the intervention. Larger studies with randomised treatment allocation 
are needed to gain further insight into the significance of asymptomatic DWI lesions 
and their potential role as surrogate markers of treatment risk.  
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About one in ten strokes occurring as a complication of carotid interventions is caused 
by intracerebral haemorrhage (ICH). A special MRI technique (so-called gradient echo 
imaging) allows the detection of small intracerebral bleedings, but has never been 
applied to detect ICH after carotid interventions. Asymptomatic ICH may be an 
expression of subclinical reperfusion damage following carotid revascularisation. 
Thus, there is a clear need to study symptomatic and asymptomatic ischaemic and 
haemorrhagic brain injury in protected and unprotected stenting and endarterectomy in 
a randomised trial. 
 Objectives 26.4
The primary objective of this substudy is to compare the risk of ischaemic brain injury 
assessed on MRI in patients with symptomatic carotid artery stenosis undergoing 
stenting in comparison to those undergoing endarterectomy.  
Secondary objectives are: to assess the effect of protection devices on the risk of 
ischaemic brain injury associated with stenting, to compare the risk of haemorrhagic 
brain injury assessed on MRI in stenting compared to endarterectomy, and to gain 
further insight into the usefulness of ischaemic and haemorrhagic brain lesions on MRI 
as surrogate markers of the risk of carotid interventions.  
 Study design 26.5
This project is an MRI-based substudy of a multicentre randomised trial known as the 
International Carotid Stenting Study [81], which is comparing the risks and benefits of 
stenting and endarterectomy of symptomatic carotid stenosis using clinical endpoints, 
e.g. stroke and death. 
The ICSS-MRI Substudy allows a randomised comparison of the procedural risk of 
symptomatic and asymptomatic ischaemic and haemorrhagic brain injury visible on 
MRI between stenting and endarterectomy. The use of cerebral protection devices in 
patients undergoing stenting is not subject to randomisation in ICSS. However, the 
participating centres systematically use either protected or unprotected stenting. The 
risk of brain injury associated with either stenting technique can therefore be compared 
to a randomised control group of patients undergoing endarterectomy. 
Outcome measures and analyses are defined as follows: 
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26.5.1 Primary outcome measure 
 Rate of symptomatic and asymptomatic ischaemic brain injury detectable on 
MRI after endarterectomy and stenting 
26.5.2 Secondary analyses 
 Interaction between the use of protection devices and ischaemic brain injury in 
patients undergoing stenting  
 Rate of symptomatic and asymptomatic haemorrhagic brain injury detectable on 
MRI after endarterectomy and stenting 
 Relation of brain injury on MRI to risk of stroke during procedure and follow-up 
26.5.3 Subject selection 
Inclusion criteria 
Patients are eligible to participate in the ICSS-MRI Substudy if they are enrolled in the 
ICSS trial and separately provide written informed consent to undergo three MRI 
exams. Detailed inclusion and exclusion criteria for ICSS are provided elsewhere [81]. 
In short, patients with recently symptomatic ≥50% carotid stenosis who are equally 
suitable for endarterectomy and stenting are eligible for enrolment in ICSS. 
Exclusion criteria  
Patients with contraindications to MRI, e.g. pacemakers, metallic implants, and 
claustrophobia, are excluded from the ICSS-MRI Substudy. 
26.5.4 MRI protocol 
Patients enrolled in the ICSS-MRI Substudy will undergo three MRI investigations, 1-3 
days before, 1-3 days after and 30±3 days after the intervention. The following 
sequences will be performed in all three investigations: 
 Diffusion weighted imaging (DWI) to detect acute ischaemic brain injury 
associated with the procedure 
 Gradient echo T2*-weighted sequences to detect haemorrhagic brain injury 
associated with the procedure 
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 T1-weighted, T2-weighted and fluid-attenuated inversion recovery (FLAIR) 
sequences will be used to assess whether acute brain lesions detected on DWI 
after the procedure lead to permanent scarring at 1 month 
26.5.5 Data acquisition 
Baseline data (such as age, gender, medical risk factors, degree of carotid stenosis, 
etc.) will be collected as part of ICSS.  
Two researchers will independently score the presence, size and location (vascular 
territory) of ischaemic and haemorrhagic lesions on the MRI scans.  A third researcher 
will review the scans in case of disagreement.  The scans will be reported and scored 
blind to patient identifiers, treatment, date and time of the scans.  
Patients will be clinically examined by a neurologist at the time of MRI examination and 
will be followed up after treatment as part of ICSS to determine outcome events 
including transient ischaemic attack, stroke, myocardial infarction and death. 
26.5.6 Statistical considerations 
Statistical analysis 
The rates of ischaemic and haemorrhagic brain lesions will be compared between 
patients undergoing endarterectomy and stenting using chi-squared and Fisher’s exact 
tests. Significance will be declared at p<0.05. 
Sample size calculation 
Power calculations are based on the primary outcome measure. The two largest series 
reported new ischaemic lesions on DWI after carotid endarterectomy in 17% and 34% 
of patients respectively [262]. If a rate of new DWI lesions after endarterectomy of 25% 
is assumed, a total sample size of 200 patients would have a 90% power to detect a 
twofold increase in the DWI lesion rate associated with carotid stenting. Testing the 
interaction between the use of cerebral protection devices and the rate of DWI lesions 
after stenting would have less power. 126 patients have been enrolled in the ICSS-MRI 
Substudy from its initiation in 2004 until July 2007 in two participating centres (Utrecht 
and Basel). The projected number of enrolled patients at the end of the ICSS 
randomisation period in those centres is 170. The target population of 200 could be 
reached with a contribution of 30 patients enrolled in ICSS centres in the UK. 
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26.5.7 Withdrawal of consent 
Subjects enrolled in the ICSS-MRI Substudy can withdraw their consent at any time 
during the substudy. This will not affect their enrolment in ICSS or the standard of care 
they receive. 
